title,url,date,category
U.S. FDA Approves Pfizer’s BRAFTOVI® Combination Regimen as First-Line Treatment of BRAF V600E-Mutant Metastatic Colorectal Cancer,https://www.pfizer.com/news/press-release/press-release-detail/us-fda-approves-pfizers-braftovir-combination-regimen-first,2024-12-20,prescription medicines
Pfizer Invites Public to View and Listen to Webcast of February 4 Conference Call with Analysts,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-invites-public-view-and-listen-webcast-february-4,2024-12-19,financial news
Pfizer Provides Full-Year 2025 Guidance and Reaffirms Full-Year 2024 Guidance,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-provides-full-year-2025-guidance-and-reaffirms-full,2024-12-17,financial news
Pfizer Declares First-Quarter 2025 Dividend,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-declares-first-quarter-2025-dividend,2024-12-12,financial news
"Pfizer’s IBRANCE® in Combination with Standard-of-Care Therapies Extends Median Progression-Free Survival by Over 15 Months in Phase 3 PATINA Study in Patients with HR+, HER2+ Metastatic Breast Cancer",https://www.pfizer.com/news/press-release/press-release-detail/pfizers-ibrancer-combination-standard-care-therapies,2024-12-12,prescription medicines
Pfizer Invites Public to View and Listen to Webcast of December 17 Conference Call with Analysts to Provide Full-Year 2025 Financial Guidance,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-invites-public-view-and-listen-webcast-december-17,2024-12-10,financial news
Arvinas and Pfizer Announce Initial Phase 1b Data from the TACTIVE-U Sub-Study of Vepdegestrant in Combination with Abemaciclib at 2024 San Antonio Breast Cancer Symposium,https://www.pfizer.com/news/press-release/press-release-detail/arvinas-and-pfizer-announce-initial-phase-1b-data-tactive-u,2024-12-10,clinical trial update
Pfizer Showcases Scientific Leadership in Breast Cancer and Blood Disorders Across More than 100 Presentations at ASH and SABCS,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-showcases-scientific-leadership-breast-cancer-and,2024-12-05,research and pipeline
"Pfizer Announces New Chief Scientific Officer and President, Research & Development",https://www.pfizer.com/news/press-release/press-release-detail/pfizer-announces-new-chief-scientific-officer-and-president,2024-11-20,management update
European Commission Approves Pfizer’s HYMPAVZI™ (marstacimab) for the Treatment of Adults and Adolescents with Severe Hemophilia A or B Without Inhibitors,https://www.pfizer.com/news/press-release/press-release-detail/european-commission-approves-pfizers-hympavzitm-marstacimab,2024-11-20,prescription medicines
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-invites-public-view-and-listen-webcast-pfizer-23,2024-11-14,financial news
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-invites-public-view-and-listen-webcast-pfizer-22,2024-11-04,financial news
Pfizer Reports Strong Third-Quarter 2024 Results And Raises 2024 Guidance,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-reports-strong-third-quarter-2024-results-and-raises,2024-10-29,financial news
Advisory Committee on Immunization Practices Recommends PREVNAR 20® (20-Valent Pneumococcal Conjugate Vaccine) for Adults Aged 50 and Older,https://www.pfizer.com/news/press-release/press-release-detail/advisory-committee-immunization-practices-recommends,2024-10-23,vaccines
U.S. FDA Approves Pfizer’s RSV Vaccine ABRYSVO® for Adults Aged 18 to 59 at Increased Risk for Disease,https://www.pfizer.com/news/press-release/press-release-detail/us-fda-approves-pfizers-rsv-vaccine-abrysvor-adults-aged-18,2024-10-22,vaccines
"Pfizer Supplies One Billionth Pneumococcal Conjugated Vaccine Dose for Vaccination of Children in Lower- Income Countries Through Gavi, the Vaccine Alliance",https://www.pfizer.com/news/press-release/press-release-detail/pfizer-supplies-one-billionth-pneumococcal-conjugated,2024-10-22,vaccines
Tim Buckley Elected to Pfizer’s Board of Directors,https://www.pfizer.com/news/press-release/press-release-detail/tim-buckley-elected-pfizers-board-directors,2024-10-15,management update
U.S. FDA Approves Pfizer’s HYMPAVZI™ (marstacimab-hncq) for the Treatment of Adults and Adolescents with Hemophilia A or B Without Inhibitors,https://www.pfizer.com/news/press-release/press-release-detail/us-fda-approves-pfizers-hympavzitm-marstacimab-hncq,2024-10-11,prescription medicines
Pfizer’s TALZENNA® in Combination with XTANDI® Prolongs Overall Survival in Phase 3 TALAPRO-2 Trial,https://www.pfizer.com/news/press-release/press-release-detail/pfizers-talzennar-combination-xtandir-prolongs-overall,2024-10-10,prescription medicines
Pfizer Declares Fourth-Quarter 2024 Dividend,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-declares-fourth-quarter-2024-dividend,2024-10-09,financial news
Pfizer to Showcase Scientific Advancements in Respiratory and Other Infectious Diseases at IDWeek 2024,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-showcase-scientific-advancements-respiratory-and,2024-10-08,research and pipeline
Pfizer Voluntarily Withdraws All Lots of Sickle Cell Disease Treatment OXBRYTA® (voxelotor) From Worldwide Markets,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-voluntarily-withdraws-all-lots-sickle-cell-disease,2024-09-25,prescription medicines
Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron KP.2-adapted COVID-19 Vaccine in the European Union,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-receive-positive-chmp-opinion-omicron-4,2024-09-20,vaccines
Pfizer Invites Public to View and Listen to Webcast of October 29 Conference Call with Analysts,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-invites-public-view-and-listen-webcast-october-29,2024-09-17,financial news
Pfizer Presents Positive Data from Phase 2 Study of Ponsegromab in Patients with Cancer Cachexia,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-presents-positive-data-phase-2-study-ponsegromab,2024-09-14,clinical trial update
Pfizer’s BRAFTOVI® + MEKTOVI® Shows Long-Term Clinically Meaningful Response in Patients with BRAF V600E-Mutant Metastatic Non-Small Cell Lung Cancer,https://www.pfizer.com/news/press-release/press-release-detail/pfizers-braftovir-mektovir-shows-long-term-clinically,2024-09-14,prescription medicines
Pfizer Highlights Diverse Oncology Portfolio and Combination Approaches at ESMO 2024,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-highlights-diverse-oncology-portfolio-and,2024-09-11,research and pipeline
Valneva and Pfizer Report Further Positive Phase 2 Booster Results for Lyme Disease Vaccine Candidate,https://www.pfizer.com/news/press-release/press-release-detail/valneva-and-pfizer-report-further-positive-phase-2-booster,2024-09-03,clinical trial update
"Pfizer to Launch Process to Identify a Successor for Dr. Mikael Dolsten, Chief Scientific Officer and President, Pfizer Research & Development",https://www.pfizer.com/news/press-release/press-release-detail/pfizer-launch-process-identify-successor-dr-mikael-dolsten,2024-07-09,management update
Cyrus Taraporevala Elected to Pfizer’s Board of Directors,https://www.pfizer.com/news/press-release/press-release-detail/cyrus-taraporevala-elected-pfizers-board-directors,2024-07-01,management update
Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron JN.1-adapted COVID-19 Vaccine in the European Union,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-receive-positive-chmp-opinion-omicron-3,2024-06-27,vaccines
Pfizer Declares Third-Quarter 2024 Dividend,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-declares-third-quarter-2024-dividend,2024-06-26,financial news
Pfizer Invites Public to View and Listen to Webcast of July 30 Conference Call with Analysts,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-invites-public-view-and-listen-webcast-july-30,2024-06-18,financial news
ELREXFIO™ Shows Median Overall Survival of More Than Two Years in People with Relapsed or Refractory Multiple Myeloma,https://www.pfizer.com/news/press-release/press-release-detail/elrexfiotm-shows-median-overall-survival-more-two-years,2024-06-14,prescription medicines
Pfizer Provides Update on Phase 3 Study of Investigational Gene Therapy for Ambulatory Boys with Duchenne Muscular Dystrophy,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-provides-update-phase-3-study-investigational-gene,2024-06-12,clinical trial update
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-invites-public-listen-webcast-pfizer-discussion-18,2024-06-03,financial news
Pfizer’s ADCETRIS® Regimen Produces Clinically Meaningful Improvement in Overall Survival in Patients with Relapsed/​Refractory Diffuse Large B-cell Lymphoma (DLBCL),https://www.pfizer.com/news/press-release/press-release-detail/pfizers-adcetrisr-regimen-produces-clinically-meaningful,2024-06-01,prescription medicines
Takeda and Pfizer Announce Four-Year Results from Positive Phase 3 HD21 Trial of Additional ADCETRIS® (brentuximab vedotin) Combination in Frontline Hodgkin Lymphoma,https://www.pfizer.com/news/press-release/press-release-detail/takeda-and-pfizer-announce-four-year-results-positive-phase,2024-06-01,clinical trial update
Pfizer Reports Strong Second-Quarter 2024 Results And Raises 2024 Guidance,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-reports-strong-second-quarter-2024-results-and,2024-07-30,financial news
"European Commission Approves Pfizer’s DURVEQTIX® (fidanacogene elaparvovec), a One-Time Gene Therapy for Adults with Hemophilia B",https://www.pfizer.com/news/press-release/press-release-detail/european-commission-approves-pfizers-durveqtixr,2024-07-25,prescription medicines
Pfizer Announces Positive Topline Results From Phase 3 Study of Hemophilia A Gene Therapy Candidate,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-announces-positive-topline-results-phase-3-study,2024-07-24,clinical trial update
Phase 3 VALOR Lyme Disease Trial: Valneva and Pfizer Announce Primary Vaccination Series Completion,https://www.pfizer.com/news/press-release/press-release-detail/phase-3-valor-lyme-disease-trial-valneva-and-pfizer,2024-07-17,clinical trial update
Pfizer Advances Development of Once-Daily Formulation of Oral GLP-1 Receptor Agonist Danuglipron,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-advances-development-once-daily-formulation-oral-glp,2024-07-11,research and pipeline
Pfizer and BioNTech Provide Update on mRNA-based Combination Vaccine Program Against Influenza and COVID-19 in Individuals 18-64 Years of Age,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-provide-update-mrna-based-combination,2024-08-16,vaccines
Pfizer Announces Top-Line Results of ABRYSVO® for RSV in Immunocompromised Adults,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-announces-top-line-results-abrysvor-rsv,2024-08-12,clinical trial update
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-invites-public-view-and-listen-webcast-pfizer-21,2024-08-28,financial news
"Pfizer Launches PfizerForAll™, a Digital Platform that Helps Simplify Access to Healthcare",https://www.pfizer.com/news/press-release/press-release-detail/pfizer-launches-pfizerforalltm-digital-platform-helps,2024-08-27,corporate
Pfizer’s LORBRENA® CROWN Study Shows Majority of Patients with ALK-Positive Advanced Lung Cancer Living Beyond Five Years Without Disease Progression,https://www.pfizer.com/news/press-release/press-release-detail/pfizers-lorbrenar-crown-study-shows-majority-patients-alk,2024-05-31,clinical trial update
"Malawi Ministry of Health, bioMérieux, and Pfizer Form Country’s First Multisectoral Collaboration to Help Address Antimicrobial Resistance",https://www.pfizer.com/news/press-release/press-release-detail/malawi-ministry-health-biomerieux-and-pfizer-form-countrys,2024-05-23,partnerships
Arvinas and Pfizer Announce Updated Clinical Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE®),https://www.pfizer.com/news/press-release/press-release-detail/arvinas-and-pfizer-announce-updated-clinical-data-phase-1b,2024-05-16,clinical trial update
Pfizer Announces New Chief Strategy and Innovation Officer,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-announces-new-chief-strategy-and-innovation-officer,2024-05-06,management update
Pfizer Reports First-Quarter 2024 Results,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-reports-first-quarter-2024-results,2024-05-01,financial news
FDA Grants Full Approval for TIVDAK® to Treat Recurrent or Metastatic Cervical Cancer,https://www.pfizer.com/news/press-release/press-release-detail/fda-grants-full-approval-tivdakr-treat-recurrent-or,2024-04-29,regulatory approval
Pfizer Highlights Progress in Accelerating Breakthrough Cancer Medicines at ASCO 2024 Annual Meeting,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-highlights-progress-accelerating-breakthrough-cancer,2024-04-29,clinical trial update
"U.S. FDA Approves Pfizer’s BEQVEZ™ (fidanacogene elaparvovec-dzkt), a One-Time Gene Therapy for Adults with Hemophilia B",https://www.pfizer.com/news/press-release/press-release-detail/us-fda-approves-pfizers-beqveztm-fidanacogene-elaparvovec,2024-04-26,regulatory approval
Pfizer Announces 2024 Shareholder Meeting Preliminary Results,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-announces-2024-shareholder-meeting-preliminary,2024-04-25,financial news
Pfizer Declares Second-Quarter 2024 Dividend,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-declares-second-quarter-2024-dividend,2024-04-24,financial news
European Commission Approves Pfizer’s EMBLAVEO® for Patients with Multidrug-Resistant Infections and Limited Treatment Options,https://www.pfizer.com/news/press-release/press-release-detail/european-commission-approves-pfizers-emblaveor-patients,2024-04-22,regulatory approval
Pfizer Invites Shareholders to Attend Virtual-Only 2024 Annual Meeting of Shareholders on April 25,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-invites-shareholders-attend-virtual-only-2024-annual,2024-04-11,financial news
Pfizer Announces Positive Top-Line Results from Phase 3 Study of ABRYSVO® in Adults Aged 18 to 59 at Increased Risk for RSV Disease,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-announces-positive-top-line-results-phase-3-study-1,2024-04-09,clinical trial update
Pfizer Invites Public to View and Listen to Webcast of May 1 Conference Call with Analysts,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-invites-public-view-and-listen-webcast-may-1,2024-03-20,financial news
European Commission Approves Pfizer’s PREVENAR 20® to Help Protect Infants and Children Against Pneumococcal Disease,https://www.pfizer.com/news/press-release/press-release-detail/european-commission-approves-pfizers-prevenar-20r-help,2024-03-13,regulatory approval
Pfizer Announces Positive Overall Survival in Phase 3 Trial of ADCETRIS® Regimen in Patients with Relapsed/​Refractory Diffuse Large B-cell Lymphoma (DLBCL),https://www.pfizer.com/news/press-release/press-release-detail/pfizer-announces-positive-overall-survival-phase-3-trial,2024-03-12,clinical trial update
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-invites-public-listen-webcast-pfizer-discussion-17,2024-03-05,financial news
"Pfizer Oncology Hosts Innovation Day, Highlighting Fully Integrated Organization, Robust Portfolio, and Strategic Priorities to Drive Long-Term Sustainable Growth",https://www.pfizer.com/news/press-release/press-release-detail/pfizer-oncology-hosts-innovation-day-highlighting-fully,2024-02-29,management update
Pfizer Announces Positive Top-Line Data for Full Season Two Efficacy of ABRYSVO® for RSV in Older Adults,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-announces-positive-top-line-data-full-season-two,2024-02-29,clinical trial update
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-invites-public-listen-webcast-pfizer-discussion-16,2024-02-26,financial news
European Commission Approves Pfizer’s VELSIPITY® for Patients with Moderately to Severely Active Ulcerative Colitis,https://www.pfizer.com/news/press-release/press-release-detail/european-commission-approves-pfizers-velsipityr-patients,2024-02-19,regulatory approval
Pfizer Invites Public to Register for Webcast of Pfizer Oncology Innovation Day,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-invites-public-register-webcast-pfizer-oncology,2024-02-15,financial news
UT Southwestern collaborates with Pfizer  to develop improved RNA Delivery Technologies,https://www.pfizer.com/news/press-release/press-release-detail/ut-southwestern-collaborates-pfizer-develop-improved-rna,2024-02-12,partnerships
"Breaking Barriers in Cancer Care: The American Cancer Society and Pfizer Announce a $15 Million, Three-Year Initiative to Bridge the Gap in Cancer Care Disparities",https://www.pfizer.com/news/press-release/press-release-detail/breaking-barriers-cancer-care-american-cancer-society-and,2024-02-05,partnerships
Pfizer Reports Full-Year 2023 Results and Reaffirms Full-Year 2024 Financial Guidance,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-reports-full-year-2023-results-and-reaffirms-full,2024-01-30,financial news
European Medicines Agency Validates Type II Variation Application for PADCEV® (enfortumab vedotin) with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer,https://www.pfizer.com/news/press-release/press-release-detail/european-medicines-agency-validates-type-ii-variation,2024-01-26,regulatory approval
Pfizer Recommends Shareholders Reject the Below-Market Mini-Tender Offer by TRC Capital Investment Corporation,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-recommends-shareholders-reject-below-market-mini,2024-01-10,financial news
TIVDAK® Supplemental Biologics License Application Accepted for Priority Review by FDA for Patients with Recurrent or Metastatic Cervical Cancer,https://www.pfizer.com/news/press-release/press-release-detail/tivdakr-supplemental-biologics-license-application-accepted,2024-01-09,regulatory approval
European Commission Approves Pfizer’s TALZENNA® in Combination with XTANDI® for Adult Patients with Metastatic Castration-Resistant Prostate Cancer,https://www.pfizer.com/news/press-release/press-release-detail/european-commission-approves-pfizers-talzennar-combination,2024-01-08,regulatory approval
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-invites-public-listen-webcast-pfizer-discussion-15,2024-01-02,financial news
Pfizer Invites Public to View and Listen to Webcast of January 30 Conference Call with Analysts,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-invites-public-view-and-listen-webcast-january-30,2023-12-19,financial news
PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) Approved by FDA as the First and Only ADC Plus PD-1 to Treat Advanced Bladder Cancer,https://www.pfizer.com/news/press-release/press-release-detail/padcevr-enfortumab-vedotin-ejfv-keytrudar-pembrolizumab,2023-12-15,regulatory approval
Pfizer Declares First-Quarter 2024 Dividend,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-declares-first-quarter-2024-dividend,2023-12-14,financial news
Pfizer Completes Acquisition of Seagen,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-completes-acquisition-seagen,2023-12-14,management update
Pfizer Provides Full-Year 2024 Guidance,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-provides-full-year-2024-guidance,2023-12-13,financial news
FDA and EMA Accept Marstacimab Regulatory Submissions for the Treatment of Hemophilia A and B,https://www.pfizer.com/news/press-release/press-release-detail/fda-and-ema-accept-marstacimab-regulatory-submissions,2023-12-11,regulatory approval
Marstacimab Phase 3 Data Presented at ASH 2023 Demonstrate Significant Bleed Reduction in Hemophilia A and B,https://www.pfizer.com/news/press-release/press-release-detail/marstacimab-phase-3-data-presented-ash-2023-demonstrate,2023-12-09,clinical trial update
European Commission Approves Pfizer’s ELREXFIO® for Relapsed and Refractory Multiple Myeloma,https://www.pfizer.com/news/press-release/press-release-detail/european-commission-approves-pfizers-elrexfior-relapsed-and,2023-12-08,regulatory approval
Arvinas and Pfizer Announce Interim Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE®) and Plans to Expand Vepdegestrant Development Program,https://www.pfizer.com/news/press-release/press-release-detail/arvinas-and-pfizer-announce-interim-data-phase-1b-trial,2023-12-05,clinical trial update
"Pfizer and Valneva Complete Recruitment for Phase 3 VALOR Trial for Lyme Disease Vaccine Candidate, VLA15",https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-valneva-complete-recruitment-phase-3-valor-trial,2023-12-04,clinical trial update
"Pfizer Announces Topline Phase 2b Results of Oral GLP-1R Agonist, Danuglipron, in Adults with Obesity",https://www.pfizer.com/news/press-release/press-release-detail/pfizer-announces-topline-phase-2b-results-oral-glp-1r,2023-12-01,clinical trial update
Arvinas and Pfizer Announce Updated Vepdegestrant (ARV-471) Data to be Presented at the 2023 San Antonio Breast Cancer Symposium,https://www.pfizer.com/news/press-release/press-release-detail/arvinas-and-pfizer-announce-updated-vepdegestrant-arv-471,2023-11-28,clinical trial update
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-invites-public-view-and-listen-webcast-pfizer-20,2023-11-21,financial news
Pfizer and Astellas' XTANDI® Approved by U.S. FDA in Earlier Prostate Cancer Treatment Setting,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-astellas-xtandir-approved-us-fda-earlier,2023-11-16,regulatory approval
Pfizer Highlights Scientific Advances from Growing Hematology Portfolio at American Society of Hematology Annual Meeting,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-highlights-scientific-advances-growing-hematology,2023-11-02,clinical trial update
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-invites-public-view-and-listen-webcast-pfizer-19,2023-11-02,financial news
Stanford Medicine Launches New Global Health Scholars Program for African Physicians,https://www.pfizer.com/news/press-release/press-release-detail/stanford-medicine-launches-new-global-health-scholars,2023-11-01,partnerships
Pfizer Reports Third-Quarter 2023 Results,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-reports-third-quarter-2023-results,2023-10-31,financial news
Pfizer and BioNTech Announce Positive Topline Data for mRNA-based Combination Vaccine Program Against Influenza and COVID-19,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-announce-positive-topline-data-mrna,2023-10-26,clinical trial update
"FDA Approves PENBRAYA™, the First and Only Vaccine for the Prevention of the Five Most Common Serogroups Causing Meningococcal Disease in Adolescents",https://www.pfizer.com/news/press-release/press-release-detail/fda-approves-penbrayatm-first-and-only-vaccine-prevention,2023-10-20,regulatory approval
Arvinas and Pfizer Announce Upcoming Vepdegestrant (ARV-0) Poster Presentation at ESMO Congress 2023,https://www.pfizer.com/news/press-release/press-release-detail/arvinas-and-pfizer-announce-upcoming-vepdegestrant-arv-0,2023-10-15,clinical trial update
Pfizer Amends U.S. Government Paxlovid Supply Agreement and Updates Full-Year 2023 Guidance,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-amends-us-government-paxlovid-supply-agreement-and,2023-10-13,commercialized drug update
U.S. FDA Approves Pfizer’s VELSIPITY™ for Adults with Moderately to Severely Active Ulcerative Colitis (UC),https://www.pfizer.com/news/press-release/press-release-detail/us-fda-approves-pfizers-velsipitytm-adults-moderately,2023-10-13,regulatory approval
Pfizer Presents New Data at IDWeek 2023 Highlighting Advances in Prevention and Treatment of Certain Respiratory Illnesses and Other Infectious Diseases,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-presents-new-data-idweek-2023-highlighting-advances,2023-10-05,clinical trial update
Pfizer Declares Fourth-Quarter 2023 Dividend,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-declares-fourth-quarter-2023-dividend,2023-10-04,financial news
Pfizer Broadens Portfolio of Respiratory Vaccines Recommended by CDC Advisory Committee with ABRYSVO™ for RSV,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-broadens-portfolio-respiratory-vaccines-recommended,2023-09-22,regulatory approval
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-invites-public-view-and-listen-webcast-pfizer-18,2023-09-19,management update
European Commission Approves Pfizer’s LITFULO™ for Adolescents and Adults With Severe Alopecia Areata,https://www.pfizer.com/news/press-release/press-release-detail/european-commission-approves-pfizers-litfulotm-adolescents,2023-09-19,regulatory approval
Pfizer Invites Public to View and Listen to Webcast of October 31 Conference Call with Analysts,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-invites-public-view-and-listen-webcast-october-31,2023-09-18,management update
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-invites-public-view-and-listen-webcast-pfizer-17,2023-09-12,management update
Pfizer and BioNTech Receive U.S. FDA Approval for 2023-2024 COVID-19 Vaccine,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-receive-us-fda-approval-2023-2024-covid,2023-09-11,regulatory approval
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-invites-public-view-and-listen-webcast-pfizer-16,2023-09-05,management update
Pfizer Invites Public to View and Listen to Two Webcasts of Pfizer Discussions at Healthcare Conferences,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-invites-public-view-and-listen-two-webcasts-pfizer-0,2023-08-30,management update
Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron XBB.1.5-adapted COVID-19 Vaccine in the European Union,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-receive-positive-chmp-opinion-omicron-2,2023-08-30,regulatory approval
European Commission Approves Pfizer’s ABRYSVO™ to Help Protect Infants through Maternal Immunization and Older Adults from RSV,https://www.pfizer.com/news/press-release/press-release-detail/european-commission-approves-pfizers-abrysvotm-help-protect,2023-08-24,regulatory approval
FDA Grants Priority Review for XTANDI® in Non-Metastatic Castration-Sensitive Prostate Cancer with High-Risk Biochemical Recurrence,https://www.pfizer.com/news/press-release/press-release-detail/fda-grants-priority-review-xtandir-non-metastatic,2023-08-23,regulatory approval
"U.S. FDA Approves ABRYSVO™, Pfizer’s Vaccine for the Prevention of Respiratory Syncytial Virus (RSV) in Infants Through Active Immunization of Pregnant Individuals 32-36 Weeks of Gestational Age",https://www.pfizer.com/news/press-release/press-release-detail/us-fda-approves-abrysvotm-pfizers-vaccine-prevention-0,2023-08-21,regulatory approval
Pfizer’s ELREXFIO™ Receives U.S. FDA Accelerated Approval for Relapsed or Refractory Multiple Myeloma,https://www.pfizer.com/news/press-release/press-release-detail/pfizers-elrexfiotm-receives-us-fda-accelerated-approval,2023-08-14,regulatory approval
"Bill & Melinda Gates Foundation, Children’s Investment Fund Foundation, Pfizer and Becton, Dickinson & Company Expand Partnership for Greater Access to Injectable Contraceptive for Women in Low- and Lower-Middle-Income Countries",https://www.pfizer.com/news/press-release/press-release-detail/bill-melinda-gates-foundation-childrens-investment-fund,2023-08-03,management update
Pfizer Reports Second-Quarter 2023 Results,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-reports-second-quarter-2023-results,2023-08-01,financial news
"Arvinas and Pfizer Awarded Innovation Passport Designation by the U.K. Innovative Licensing and Access Pathway Steering Group for Vepdegestrant, an Investigational PROTAC® ER degrader being developed in ER+/HER2- Breast Cancer",https://www.pfizer.com/news/press-release/press-release-detail/arvinas-and-pfizer-awarded-innovation-passport-designation,2023-07-31,management update
Pfizer Announces Executive Leadership to Advance Oncology Research and Development Strategy,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-announces-executive-leadership-advance-oncology,2023-07-27,management update
Pfizer Announces Post-Tornado Relief Plans for Rocky Mount Community and Manufacturing Facility,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-announces-post-tornado-relief-plans-rocky-mount,2023-07-21,management update
Pfizer Announces New England Journal of Medicine Publication on Group B Streptococcus (GBS) Maternal Vaccine Candidate,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-announces-new-england-journal-medicine-publication,2023-07-19,clinical trial update
Flagship Pioneering and Pfizer Partner to Accelerate Development of Innovative Medicines Targeting Unmet Needs,https://www.pfizer.com/news/press-release/press-release-detail/flagship-pioneering-and-pfizer-partner-accelerate,2023-07-18,management update
"FDA Approves Pfizer’s NGENLA™, a Long-Acting Once-Weekly Treatment for Pediatric Growth Hormone Deficiency",https://www.pfizer.com/news/press-release/press-release-detail/fda-approves-pfizers-ngenlatm-long-acting-once-weekly,2023-06-28,regulatory approval
FDA Accepts Pfizer’s Application for Hemophilia B Gene Therapy Fidanacogene Elaparvovec,https://www.pfizer.com/news/press-release/press-release-detail/fda-accepts-pfizers-application-hemophilia-b-gene-therapy,2023-06-27,regulatory approval
Pfizer Provides Update on GLP-1-RA Clinical Development Program for Adults with Obesity and Type 2 Diabetes Mellitus,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-provides-update-glp-1-ra-clinical-development,2023-06-26,clinical trial update
FDA Approves Pfizer’s LITFULO™ (Ritlecitinib) for Adults and Adolescents With Severe Alopecia Areata,https://www.pfizer.com/news/press-release/press-release-detail/fda-approves-pfizers-litfulotm-ritlecitinib-adults-and,2023-06-23,regulatory approval
Pfizer Declares Third-Quarter 2023 Dividend,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-declares-third-quarter-2023-dividend,2023-06-22,financial news
Pfizer’s TALZENNA® in Combination with XTANDI® Receives U.S. FDA Approval,https://www.pfizer.com/news/press-release/press-release-detail/pfizers-talzennar-combination-xtandir-receives-us-fda,2023-06-20,regulatory approval
Pfizer Invites Public to View and Listen to Webcast of August 1 Conference Call with Analysts,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-invites-public-view-and-listen-webcast-august-1,2023-06-20,management update
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-invites-public-view-and-listen-webcast-pfizer-15,2023-06-06,management update
Phase 3 Studies of Pfizer’s Novel Antibiotic Combination Offer New Treatment Hope for Patients with Multidrug-Resistant Infections and Limited Treatment Options,https://www.pfizer.com/news/press-release/press-release-detail/phase-3-studies-pfizers-novel-antibiotic-combination-offer,2023-06-01,clinical trial update
"U.S. FDA Approves ABRYSVO™, Pfizer’s Vaccine for the Prevention of Respiratory Syncytial Virus (RSV) in Older Adults",https://www.pfizer.com/news/press-release/press-release-detail/us-fda-approves-abrysvotm-pfizers-vaccine-prevention,2023-05-31,regulatory approval
Pfizer Announces Positive Marstacimab Results from Pivotal Phase 3 Hemophilia A and B Trial,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-announces-positive-marstacimab-results-pivotal-phase,2023-05-30,clinical trial update
Pfizer Presents Scientific Advancements from its Leading Oncology Portfolio at ASCO 2023 Annual Meeting,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-presents-scientific-advancements-its-leading,2023-05-25,clinical trial update
Pfizer’s PAXLOVID™ Receives FDA Approval for Adult Patients at High Risk of Progression to Severe COVID-19,https://www.pfizer.com/news/press-release/press-release-detail/pfizers-paxlovidtm-receives-fda-approval-adult-patients,2023-05-25,regulatory approval
FDA Advisory Committee Votes in Support of Approval for Pfizer’s Vaccine Candidate to Help Prevent RSV in Infants Through Maternal Immunization,https://www.pfizer.com/news/press-release/press-release-detail/fda-advisory-committee-votes-support-approval-pfizers,2023-05-18,regulatory approval
"Pfizer Prices $31,000,000,000 Debt Offering",https://www.pfizer.com/news/press-release/press-release-detail/pfizer-prices-31000000000-debt-offering,2023-05-16,financial news
Pfizer Announces Proposed Notes Offering,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-announces-proposed-notes-offering,2023-05-15,financial news
Thermo Fisher Scientific & Pfizer Partner to Expand Localized Access to Next Generation Sequencing-Based Testing for Cancer Patients in International Markets,https://www.pfizer.com/news/press-release/press-release-detail/thermo-fisher-scientific-pfizer-partner-expand-localized,2023-05-09,management update
Arvinas and Pfizer Announce Upcoming Vepdegestrant (ARV-471) Poster Presentations at the 2023 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress,https://www.pfizer.com/news/press-release/press-release-detail/arvinas-and-pfizer-announce-upcoming-vepdegestrant-arv-471,2023-05-08,clinical trial update
Pfizer Reports First-Quarter 2023 Results,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-reports-first-quarter-2023-results,2023-05-02,financial news
XTANDI® (enzalutamide) plus Leuprolide Reduced the Risk of Metastasis by 58% in Non-Metastatic Hormone-Sensitive Prostate Cancer versus Placebo plus Leuprolide,https://www.pfizer.com/news/press-release/press-release-detail/xtandir-enzalutamide-plus-leuprolide-reduced-risk,2023-04-29,clinical trial update
"U.S. FDA Approves PREVNAR 20®, Pfizer’s 20-valent Pneumococcal Conjugate Vaccine for Infants and Children",https://www.pfizer.com/news/press-release/press-release-detail/us-fda-approves-prevnar-20r-pfizers-20-valent-pneumococcal,2023-04-27,regulatory approval
Pfizer Announces 2023 Shareholder Meeting Preliminary Results,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-announces-2023-shareholder-meeting-preliminary,2023-04-27,financial news
Pfizer Declares Second-Quarter 2023 Dividend,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-declares-second-quarter-2023-dividend,2023-04-26,financial news
Pfizer Invites Shareholders to Attend Virtual-Only 2023 Annual Meeting of Shareholders on April 27,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-invites-shareholders-attend-virtual-only-2023-annual,2023-04-13,management update
FDA Accepts Pfizer’s Supplemental New Drug Applications for BRAFTOVI + MEKTOVI,https://www.pfizer.com/news/press-release/press-release-detail/fda-accepts-pfizers-supplemental-new-drug-applications,2023-04-04,regulatory approval
Pfizer Invites Public to View and Listen to Webcast of May 2 Conference Call with Analysts,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-invites-public-view-and-listen-webcast-may-2,2023-03-21,financial news
Phase 3 Study Shows XTANDI® (enzalutamide) plus Leuprolide Significantly Improves Metastasis-Free Survival in Men with Non-Metastatic Prostate Cancer,https://www.pfizer.com/news/press-release/press-release-detail/phase-3-study-shows-xtandir-enzalutamide-plus-leuprolide,2023-03-16,clinical trial update
FDA Advisory Committee Votes in Support of Favorable Benefit-Risk Profile for Pfizer’s PAXLOVID™,https://www.pfizer.com/news/press-release/press-release-detail/fda-advisory-committee-votes-support-favorable-benefit-risk,2023-03-16,regulatory approval
Pfizer and BioNTech Receive U.S. Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Booster in Children Under 5 Years,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-receive-us-emergency-use-authorization,2023-03-14,regulatory approval
Pfizer Invests $43 Billion to Battle Cancer,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-invests-43-billion-battle-cancer,2023-03-13,commercialized drug update
Pfizer’s ZAVZPRET™ (zavegepant) Migraine Nasal Spray Receives FDA Approval,https://www.pfizer.com/news/press-release/press-release-detail/pfizers-zavzprettm-zavegepant-migraine-nasal-spray,2023-03-10,regulatory approval
Pfizer and BioNTech Submit for U.S. Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Booster in Children Under 5 Years,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-submit-us-emergency-use-authorization-0,2023-03-01,regulatory approval
Pfizer Receives Positive FDA Advisory Committee Votes Supporting Potential Approval for Vaccine Candidate to Help Combat RSV in Older Adults,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-receives-positive-fda-advisory-committee-votes,2023-02-28,regulatory approval
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-invites-public-view-and-listen-webcast-pfizer-14,2023-02-27,financial news
Pfizer and BioNTech Submit Supplemental Biologics License Application for U.S. FDA Approval of Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine for Ages 12 Years and Older as Primary Series or Booster,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-submit-supplemental-biologics-license-1,2023-02-24,regulatory approval
Pfizer’s Elranatamab Receives FDA and EMA Filing Acceptance,https://www.pfizer.com/news/press-release/press-release-detail/pfizers-elranatamab-receives-fda-and-ema-filing-acceptance,2023-02-22,regulatory approval
U.S. FDA Accepts Biologics License Application for Pfizer’s Respiratory Syncytial Virus Maternal Vaccine Candidate for Priority Review,https://www.pfizer.com/news/press-release/press-release-detail/us-fda-accepts-biologics-license-application-pfizers,2023-02-21,regulatory approval
Pfizer Announces Positive TALZENNA® and XTANDI® Combination Data from Phase 3 TALAPRO-2 Study,https://www.pfizer.com/news/press-release/press-release-detail/pfizers-announces-positive-talzennar-and-xtandir-combination,2023-02-16,clinical trial update
Pfizer Announces The Lancet Neurology Has Published Phase 3 Data for Zavegepant for the Acute Treatment of Migraine in Adults,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-announces-lancet-neurology-has-published-phase-3,2023-02-16,clinical trial update
FDA Approves Pfizer's Supplemental New Drug Application for CIBINQO® (abrocitinib),https://www.pfizer.com/news/press-release/press-release-detail/fda-approves-pfizers-supplemental-new-drug-application,2023-02-10,regulatory approval
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-invites-public-listen-webcast-pfizer-discussion-14,2023-02-09,financial news
PFIZER REPORTS RECORD FULL-YEAR 2022 RESULTS AND PROVIDES FULL-YEAR 2023 FINANCIAL GUIDANCE,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-reports-record-full-year-2022-results-and-provides,2023-01-31,financial news
Pfizer Expands ‘An Accord for a Healthier World’ Product Offering to Include Full Portfolio for Greater Benefit to 1.2 Billion People in 45 Lower-Income Countries,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-expands-accord-healthier-world-product-offering,2023-01-17,commercialized drug update
U.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for Pfizer’s 20-Valent Pneumococcal Conjugate Vaccine in Infants and Children,https://www.pfizer.com/news/press-release/press-release-detail/us-fda-accepts-priority-review-supplemental-biologics,2023-01-06,regulatory approval
Longevity Biotech Gero Entered a Research Collaboration with Pfizer to Discover Potential Targets for Fibrotic Diseases,https://www.pfizer.com/news/press-release/press-release-detail/longevity-biotech-gero-entered-research-collaboration,2023-01-06,management update
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-invites-public-listen-webcast-pfizer-discussion-13,2023-01-03,financial news
Pfizer Announces Positive Top-Line Results from Phase 3 Study of Hemophilia B Gene Therapy Candidate,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-announces-positive-top-line-results-phase-3-study,2022-12-29,clinical trial update
U.S. FDA Accepts for Review the Biologics License Application for Pfizer’s Investigational Pentavalent Meningococcal Vaccine Candidate (MenABCWY) in Adolescents,https://www.pfizer.com/news/press-release/press-release-detail/us-fda-accepts-review-biologics-license-application-pfizers,2022-12-28,regulatory approval
Pfizer Announces FDA and EMA Acceptance of Etrasimod Regulatory Submissions for Ulcerative Colitis,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-announces-fda-and-ema-acceptance-etrasimod,2022-12-21,regulatory approval
Pfizer Invites Public to View and Listen to Webcast of January 31 Conference Call with Analysts,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-invites-public-view-and-listen-webcast-january-31,2022-12-20,financial news
Pfizer Presents Updated Favorable Elranatamab Data from Pivotal Phase 2 MagnetisMM-3 Trial,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-presents-updated-favorable-elranatamab-data-pivotal,2022-12-10,clinical trial update
Pfizer Declares First-Quarter 2023 Dividend,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-declares-first-quarter-2023-dividend,2022-12-09,financial news
Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine in Children Under 5 Years,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-receive-us-fda-emergency-use-2,2022-12-08,regulatory approval
U.S. FDA Accepts for Priority Review the Biologics License Application for Pfizer’s Respiratory Syncytial Virus Vaccine Candidate for the Prevention of RSV Disease in Older Adults,https://www.pfizer.com/news/press-release/press-release-detail/us-fda-accepts-priority-review-biologics-license-0,2022-12-07,regulatory approval
Pfizer and Clear Creek Bio to Collaborate on a Research Program Targeting SARS-CoV-2 Papain-Like Protease,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-clear-creek-bio-collaborate-research-program,2022-12-06,management update
Pfizer and BioNTech Submit Application to U.S. FDA for Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine in Children Under 5 Years,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-submit-application-us-fda-emergency-1,2022-12-05,regulatory approval
Pfizer Invites Public to Register for Webcast of Pfizer Near-Term Launches + High-Value Pipeline Day,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-invites-public-register-webcast-pfizer-near-term,2022-12-01,financial news
Roivant and Pfizer Form New Vant Company Focused on Developing TL1A Drug Candidate for Inflammatory and Fibrotic Diseases,https://www.pfizer.com/news/press-release/press-release-detail/roivant-and-pfizer-form-new-vant-company-focused-developing,2022-12-01,management update
Valneva and Pfizer Report Six-Month Antibody Persistence Data in Children and Adults for Lyme Disease Vaccine Candidate,https://www.pfizer.com/news/press-release/press-release-detail/valneva-and-pfizer-report-six-month-antibody-persistence,2022-12-01,clinical trial update
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-invites-public-view-and-listen-webcast-pfizer-13,2022-11-28,financial news
Pfizer and BioNTech Report New Data on Omicron BA.4/BA.5-Adapted Bivalent Booster Demonstrating Improved Immune Response Against Emerging Omicron Sublineages,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-report-new-data-omicron-ba4ba5-adapted,2022-11-18,clinical trial update
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-invites-public-view-and-listen-webcast-pfizer-12,2022-11-11,financial news
Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster for Children 5 Through 11 Years of Age in European Union,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-receive-positive-chmp-opinion-omicron-1,2022-11-10,regulatory approval
Fox Chase Cancer Center and Sylvester Comprehensive Cancer Center Collaborate with Pfizer’s Institute of Translational Equitable Medicine to Identify Novel Genetic Drivers of Cancer Disparities in African Ancestry Populations,https://www.pfizer.com/news/press-release/press-release-detail/fox-chase-cancer-center-and-sylvester-comprehensive-cancer,2022-11-10,management update
Pfizer and BioNTech Announce Updated Clinical Data for Omicron BA.4/BA.5-Adapted Bivalent Booster Demonstrating Substantially Higher Immune Response in Adults Compared to the Original COVID-19 Vaccine,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-announce-updated-clinical-data-omicron,2022-11-04,clinical trial update
Pfizer’s Elranatamab Granted FDA Breakthrough Therapy Designation for Relapsed or Refractory Multiple Myeloma,https://www.pfizer.com/news/press-release/press-release-detail/pfizers-elranatamab-granted-fda-breakthrough-therapy,2022-11-03,regulatory approval
PFIZER REPORTS STRONG THIRD-QUARTER 2022 RESULTS AND RAISES 2022 OUTLOOK,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-reports-strong-third-quarter-2022-results-and-raises,2022-11-01,financial news
Pfizer Announces Positive Top-Line Data of Phase 3 Global Maternal Immunization Trial for its Bivalent Respiratory Syncytial Virus (RSV) Vaccine Candidate,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-announces-positive-top-line-data-phase-3-global,2022-11-01,clinical trial update
Pfizer Presents Scientific Advancements in Infectious Disease Prevention and Treatments at IDWeek 2022,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-presents-scientific-advancements-infectious-disease,2022-10-18,clinical trial update
Pfizer and BioNTech Announce Positive Early Data From Clinical Trial of Omicron BA.4/BA.5-Adapted Bivalent Booster in Individuals 18 Years and Older,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-announce-positive-early-data-clinical,2022-10-13,clinical trial update
Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster in Children 5 Through 11 Years of Age,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-receive-us-fda-emergency-use-1,2022-10-12,regulatory approval
Pfizer Completes Acquisition of Global Blood Therapeutics,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-completes-acquisition-global-blood-therapeutics,2022-10-05,management update
Voyager Therapeutics Announces Pfizer License of  Next-Generation AAV Capsid for Rare Neurologic Disease Target,https://www.pfizer.com/news/press-release/press-release-detail/voyager-therapeutics-announces-pfizer-license-next,2022-10-04,management update
Pfizer Announces Positive Topline Results from Phase 3 TALAPRO-2 Trial,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-announces-positive-topline-results-phase-3-talapro-2,2022-10-04,clinical trial update
Pfizer Completes Acquisition of Biohaven Pharmaceuticals,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-completes-acquisition-biohaven-pharmaceuticals,2022-10-03,management update
Pfizer and BioNTech Submit Application to U.S. FDA for Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent Vaccine Booster in Children 5 Through 11 Years of Age,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-submit-application-us-fda-emergency-0,2022-09-26,regulatory approval
Pfizer Declares Fourth-Quarter 2022 Dividend,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-declares-fourth-quarter-2022-dividend,2022-09-22,financial news
Pfizer to Supply Global Fund Up to 6 Million PAXLOVID™ Treatment Courses for Low-and-Middle-Income Countries,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-supply-global-fund-6-million-paxlovidtm-treatment,2022-09-22,commercialized drug update
Pfizer Invites Public to View and Listen to Webcast of November 1 Conference Call with Analysts,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-invites-public-view-and-listen-webcast-november-1,2022-09-20,financial news
CytoReason Announces Expanded Collaboration Deal with Pfizer to Deliver AI for Drug Discovery and Development,https://www.pfizer.com/news/press-release/press-release-detail/cytoreason-announces-expanded-collaboration-deal-pfizer,2022-09-20,management update
Pfizer Announces Positive Top-Line Results from Phase 3 Study in 20-Valent Pneumococcal Conjugate Vaccine in Infants in the European Union,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-announces-positive-topline-results-phase-3-study-0,2022-09-19,clinical trial update
Pfizer Announces Positive Top-Line Results from Phase 3 Trial of Pentavalent Meningococcal Vaccine Candidate (MenABCWY) in Adolescents,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-announces-positive-top-line-results-phase-3-trial-0,2022-09-15,clinical trial update
Pfizer Invites Public to View and Listen to Webcast of Analyst and Investor Call to Review Oral GLP-1 Data Presented at European Association for the Study of Diabetes (EASD) 2022,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-invites-public-view-and-listen-webcast-analyst-and,2022-09-14,financial news
Pfizer Initiates Phase 3 Study of mRNA-Based Influenza Vaccine,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-initiates-phase-3-study-mrna-based-influenza-vaccine,2022-09-14,clinical trial update
Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster in European Union,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-receive-positive-chmp-opinion-omicron-0,2022-09-12,regulatory approval
FDA and EMA Accept Regulatory Submission for Pfizer’s Ritlecitinib for Individuals 12 Years and Older with Alopecia Areata,https://www.pfizer.com/news/press-release/press-release-detail/fda-and-ema-accept-regulatory-submission-pfizers,2022-09-09,regulatory approval
FDA Grants Breakthrough Therapy Designation to Pfizer’s Group B Streptococcus Vaccine Candidate to Help Prevent Infection in Infants Via Immunization of Pregnant Women,https://www.pfizer.com/news/press-release/press-release-detail/fda-grants-breakthrough-therapy-designation-pfizers-group-b,2022-09-07,regulatory approval
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-invites-public-view-and-listen-webcast-pfizer-11,2022-09-06,financial news
Pfizer Invites Public to View and Listen to a Webcast of Pfizer Discussion on Climate Action,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-invites-public-view-and-listen-webcast-pfizer-10,2022-09-06,management update
Pfizer Invites Public to View and Listen to Two Webcasts of Pfizer Discussions at Healthcare Conferences,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-invites-public-view-and-listen-two-webcasts-pfizer,2022-09-01,financial news
Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron BA.1-Adapted Bivalent COVID-19 Vaccine Booster in European Union,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-receive-positive-chmp-opinion-omicron,2022-09-01,regulatory approval
Pfizer and BioNTech Granted FDA Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster for Ages 12 Years and Older,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-granted-fda-emergency-use-authorization,2022-08-31,regulatory approval
Pfizer and BioNTech Complete Submission to European Medicines Agency for Omicron BA.4/BA.5 Adapted Bivalent Vaccine,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-complete-submission-european-medicines,2022-08-26,regulatory approval
Pfizer Announces Positive Top-Line Data from Phase 3 Trial of Older Adults for its Bivalent Respiratory Syncytial Virus (RSV) Vaccine Candidate,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-announces-positive-top-line-data-phase-3-trial-older,2022-08-25,clinical trial update
Pfizer and BioNTech Announce Updated COVID-19 Vaccine Data Supporting Efficacy in Children 6 Months through 4 Years of Age,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-announce-updated-covid-19-vaccine-data,2022-08-23,clinical trial update
Pfizer and BioNTech Submit Application to U.S. FDA for Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-submit-application-us-fda-emergency-use,2022-08-22,regulatory approval
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-invites-public-view-and-listen-webcast-pfizer-9,2022-08-19,financial news
Pfizer Announces Positive Top-Line Results from Phase 3 Study of 20-Valent Pneumococcal Conjugate Vaccine in Infants,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-announces-positive-top-line-results-phase-3-study-20,2022-08-12,clinical trial update
Pfizer and Valneva Initiate Phase 3 Study of Lyme Disease Vaccine Candidate VLA15,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-valneva-initiate-phase-3-study-lyme-disease,2022-08-08,clinical trial update
Pfizer to Acquire Global Blood Therapeutics for $5.4 Billion to Enhance Presence in Rare Hematology,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-acquire-global-blood-therapeutics-54-billion-enhance,2022-08-08,management update
"Myovant Sciences and Pfizer Receive U.S. FDA Approval of MYFEMBREE®, a Once-Daily Treatment for the Management of Moderate to Severe Pain Associated With Endometriosis",https://www.pfizer.com/news/press-release/press-release-detail/myovant-sciences-and-pfizer-receive-us-fda-approval,2022-08-05,regulatory approval
PFIZER REPORTS SECOND-QUARTER 2022 RESULTS,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-reports-second-quarter-2022-results,2022-07-28,financial news
Pfizer Announces Submission of New Drug Application to the U.S. FDA for PAXLOVID™,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-announces-submission-new-drug-application-us-fda,2022-06-30,regulatory approval
Pfizer and BioNTech Announce New Agreement with U.S. Government to Provide Additional Doses of COVID-19 Vaccine,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-announce-new-agreement-us-government,2022-06-29,commercialized drug update
Roivant and Pfizer Unveil Priovant Therapeutics and Ongoing Registrational Studies for Oral Brepocitinib in Dermatomyositis and Lupus,https://www.pfizer.com/news/press-release/press-release-detail/roivant-and-pfizer-unveil-priovant-therapeutics-and-ongoing,2022-06-28,clinical trial update
Pfizer and BioNTech Announce Omicron-Adapted COVID-19 Vaccine Candidates Demonstrate High Immune Response Against Omicron,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-announce-omicron-adapted-covid-19,2022-06-25,clinical trial update
Pfizer Invites Public to View and Listen to Webcast of July 28 Conference Call with Analysts,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-invites-public-view-and-listen-webcast-july-28-0,2022-06-24,financial news
Valneva and Pfizer Announce Closing of Equity Investment,https://www.pfizer.com/news/press-release/press-release-detail/valneva-and-pfizer-announce-closing-equity-investment,2022-06-23,financial news
Pfizer Declares Third-Quarter 2022 Dividend,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-declares-third-quarter-2022-dividend,2022-06-23,financial news
Truveta Announces Strategic Collaboration with Pfizer to Accelerate Safety Insights in Real Time,https://www.pfizer.com/news/press-release/press-release-detail/truveta-announces-strategic-collaboration-pfizer-accelerate,2022-06-21,management update
Valneva and Pfizer Enter into an Equity Subscription Agreement and Update Terms of Collaboration Agreement for Lyme Disease Vaccine Candidate VLA15,https://www.pfizer.com/news/press-release/press-release-detail/valneva-and-pfizer-enter-equity-subscription-agreement-and,2022-06-20,management update
Pfizer-BioNTech COVID-19 Vaccine Receives FDA Emergency Use Authorization for Children 6 Months through 4 Years of Age,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-biontech-covid-19-vaccine-receives-fda-emergency-use,2022-06-17,regulatory approval
Myovant Sciences and Pfizer Announce Publication in The Lancet of Phase 3 SPIRIT 1 and SPIRIT 2 Studies of Once-Daily Relugolix Combination Therapy in Women With Endometriosis-Associated Pain,https://www.pfizer.com/news/press-release/press-release-detail/myovant-sciences-and-pfizer-announce-publication-lancet,2022-06-17,clinical trial update
Pfizer Reports Additional Data on PAXLOVID™ Supporting Upcoming New Drug Application Submission to U.S. FDA,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-reports-additional-data-paxlovidtm-supporting,2022-06-14,regulatory approval
Pfizer Completes Acquisition of ReViral,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-completes-acquisition-reviral,2022-06-09,management update
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-invites-public-view-and-listen-webcast-pfizer-8,2022-06-09,financial news
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-invites-public-view-and-listen-webcast-pfizer-7,2022-06-08,financial news
Pfizer to Invest $120 Million to Produce COVID-19 Oral Treatment in the U.S.,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-invest-120-million-produce-covid-19-oral-treatment,2022-06-06,commercialized drug update
Pfizer Presents First Data from Planned Interim Analysis of Pivotal Phase 2 MagnetisMM-3 Trial of BCMA-CD3 Bispecific Antibody Elranatamab Under Investigation for Relapsed/Refractory           Multiple Myeloma,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-presents-first-data-planned-interim-analysis-pivotal,2022-06-05,clinical trial update
"Pfizer Announces Overall Survival Results from Phase 3 PALOMA-2 Trial of IBRANCE® (palbociclib) for the First-Line Treatment of ER+, HER2- Metastatic Breast Cancer",https://www.pfizer.com/news/press-release/press-release-detail/pfizer-announces-overall-survival-results-phase-3-paloma-2,2022-06-04,clinical trial update
Myovant Sciences and Pfizer Announce FDA Acceptance of Supplemental New Drug Application for MYFEMBREE®,https://www.pfizer.com/news/press-release/press-release-detail/myovant-sciences-and-pfizer-announce-fda-acceptance-1,2022-06-02,regulatory approval
"Annaliesa Anderson, Ph.D., Will Lead Pfizer’s Vaccine Research & Development",https://www.pfizer.com/news/press-release/press-release-detail/annaliesa-anderson-phd-will-lead-pfizers-vaccine-research,2022-06-01,management update
Pfizer Provides Update on Ownership Interest in Haleon,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-provides-update-ownership-interest-haleon,2022-06-01,financial news
Pfizer Invites Public to View and Listen to a Webcast of Pfizer Discussion on Expanding Access & Affordability,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-invites-public-view-and-listen-webcast-pfizer-6,2022-05-31,financial news
Pfizer Granted FDA Fast Track Designation for Ervogastat/Clesacostat Combination for the Treatment of Non-Alcoholic Steatohepatitis (NASH),https://www.pfizer.com/news/press-release/press-release-detail/pfizer-granted-fda-fast-track-designation,2022-05-26,regulatory approval
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-invites-public-view-and-listen-webcast-pfizer-5,2022-05-25,financial news
Pfizer Launches ‘An Accord for a Healthier World’ to Improve Health Equity for 1.2 Billion People Living in 45 Lower-Income Countries,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-launches-accord-healthier-world-improve-health,2022-05-25,social responsibility
Pfizer Presents ELEVATE Pivotal Findings Demonstrating Etrasimod’s Potentially Best-in-Class Profile in Ulcerative Colitis,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-presents-elevate-pivotal-findings-demonstrating,2022-05-24,clinical trial update
"Pfizer-BioNTech COVID-19 Vaccine Demonstrates Strong Immune Response, High Efficacy and Favorable Safety in Children 6 Months to Under 5 Years of Age Following Third Dose",https://www.pfizer.com/news/press-release/press-release-detail/pfizer-biontech-covid-19-vaccine-demonstrates-strong-immune,2022-05-23,clinical trial update
NetVation DL Medicine Announces Research Collaboration with Pfizer Inc.,https://www.pfizer.com/news/press-release/press-release-detail/netvation-dl-medicine-announces-research-collaboration,2022-05-20,partnership
Pfizer and BioNTech Granted U.S. Emergency Use Authorization for Booster Dose of Their COVID-19 Vaccine in Children 5 Through 11 Years of Age,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-granted-us-emergency-use-authorization,2022-05-17,regulatory approval
Pfizer and BioNTech Provide Update on COVID-19 Vaccine Supply Agreement with European Commission,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-provide-update-covid-19-vaccine-supply,2022-05-13,commercialized drug update
Pfizer to Acquire Biohaven Pharmaceuticals,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-acquire-biohaven-pharmaceuticals,2022-05-10,partnership
Myovant Sciences and Pfizer Provide Update on Supplemental New Drug Application (sNDA) for MYFEMBREE® for the Management of Moderate to Severe Pain Associated with Endometriosis,https://www.pfizer.com/news/press-release/press-release-detail/myovant-sciences-and-pfizer-provide-update-supplemental-0,2022-05-06,regulatory approval
"Pfizer Presents Positive Real-World Evidence for First-Line IBRANCE® (palbociclib) Combination Therapy in HR+, HER2- Metastatic Breast Cancer at ESMO Breast Cancer 2022",https://www.pfizer.com/news/press-release/press-release-detail/pfizer-presents-positive-real-world-evidence-first-line,2022-05-04,clinical trial update
Pfizer Reports First-Quarter 2022 Results,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-reports-first-quarter-2022-results,2022-05-03,financial news
Pfizer Shares Top-Line Results from Phase 2/3 EPIC-PEP Study of PAXLOVID™ for Post-Exposure Prophylactic Use,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-shares-top-line-results-phase-23-epic-pep-study,2022-04-29,clinical trial update
Pfizer Announces 2022 Shareholder Meeting Preliminary Results,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-announces-2022-shareholder-meeting-preliminary,2022-04-28,financial news
Pfizer Declares Second-Quarter 2022 Dividend,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-declares-second-quarter-2022-dividend,2022-04-28,financial news
Pfizer to Open First U.S. Sites in Phase 3 Trial of Investigational Gene Therapy for Ambulatory Patients with Duchenne Muscular Dystrophy,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-open-first-us-sites-phase-3-trial-investigational,2022-04-28,clinical trial update
Zentalis Pharmaceuticals Announces $25 Million Equity Investment from Pfizer,https://www.pfizer.com/news/press-release/press-release-detail/zentalis-pharmaceuticals-announces-25-million-equity,2022-04-27,partnership
Pfizer and Biohaven’s VYDURA® (Rimegepant) Granted First Ever Marketing Authorization by European Commission for Both Acute Treatment of Migraine and Prophylaxis of Episodic Migraine,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biohavens-vydurar-rimegepant-granted-first-ever,2022-04-27,regulatory approval
Pfizer and BioNTech Submit Application for U.S. Emergency Use Authorization for a COVID-19 Vaccine Booster Dose in Children 5 Through 11 Years of Age,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-submit-application-us-emergency-use,2022-04-26,regulatory approval
Valneva and Pfizer Report Positive Phase 2 Pediatric Data for Lyme Disease Vaccine Candidate,https://www.pfizer.com/news/press-release/press-release-detail/valneva-and-pfizer-report-positive-phase-2-pediatric-data,2022-04-26,clinical trial update
Pfizer Voluntary Nationwide Recall of Lots of ACCUPRIL® (Quinapril HCl) Due to N-Nitroso-Quinapril Content,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-voluntary-nationwide-recall-lots-accuprilr-quinapril,2022-04-22,commercialized drug update
Pfizer Invites Shareholders to Attend Virtual-Only 2022 Annual Meeting of Shareholders on April 28,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-invites-shareholders-attend-virtual-only-2022-annual,2022-04-19,financial news
Pfizer and BioNTech Announce Data Demonstrating High Immune Response Following a Booster Dose of their COVID-19 Vaccine in Children 5 Through 11 Years of Age,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-announce-data-demonstrating-high-immune,2022-04-14,clinical trial update
Myovant Sciences and Pfizer Provide Update on Supplemental New Drug Application for MYFEMBREE® for the Management of Moderate to Severe Pain Associated with Endometriosis,https://www.pfizer.com/news/press-release/press-release-detail/myovant-sciences-and-pfizer-provide-update-supplemental-new,2022-04-12,regulatory approval
Pfizer Names David M. Denton Chief Financial Officer,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-names-david-m-denton-chief-financial-officer,2022-04-11,management update
Three Year Follow-Up Data from Phase 3 CROWN Trial of Pfizer’s LORBRENA® (lorlatinib) Confirm Prolonged Progression-Free Survival in First-Line ALK-Positive Advanced Lung Cancer,https://www.pfizer.com/news/press-release/press-release-detail/three-year-follow-data-phase-3-crown-trial-pfizers,2022-04-08,clinical trial update
Pfizer to Acquire ReViral and Its Respiratory Syncytial Virus Therapeutic Candidates,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-acquire-reviral-and-its-respiratory-syncytial-virus,2022-04-07,partnership
Pfizer and BioNTech Receive Expanded U.S. Emergency Use Authorization for an Additional COVID-19 Vaccine Booster in Individuals Aged 50 Years and Older,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-receive-expanded-us-emergency-use,2022-03-29,regulatory approval
"Pfizer Announces Positive Top-line Results from Yearlong Phase 3 Trial of Etrasimod in Ulcerative Colitis, Underscoring Best-in-Class Potential",https://www.pfizer.com/news/press-release/press-release-detail/pfizer-announces-positive-top-line-results-yearlong-phase-3,2022-03-29,clinical trial update
Pfizer Granted FDA Breakthrough Therapy Designation for Respiratory Syncytial Virus Vaccine Candidate for the Prevention of RSV in Older Adults,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-granted-fda-breakthrough-therapy-designation-0,2022-03-24,regulatory approval
Pfizer Announces Positive Top-Line Results for Phase 3 Trial of Etrasimod in Ulcerative Colitis Patients,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-announces-positive-top-line-results-phase-3-trial,2022-03-23,clinical trial update
Pfizer Invites Public to View and Listen to Webcast of May 3 Conference Call with Analysts,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-invites-public-view-and-listen-webcast-may-3,2022-03-22,financial news
Pfizer to Supply UNICEF up to 4 Million Treatment Courses of Novel COVID-19 Oral Treatment for Low- and Middle-Income Countries,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-supply-unicef-4-million-treatment-courses-novel,2022-03-22,commercialized drug update
"Pfizer Voluntary Nationwide Recall of Lots of ACCURETIC™ (quinapril HCl/hydrochlorothiazide), quinapril and hydrochlorothiazide Tablets, and quinapril HCl/hydrochlorothiazide Tablets Due to N-Nitroso- Quinapril Content",https://www.pfizer.com/news/press-release/press-release-detail/pfizer-voluntary-nationwide-recall-lots-accuretictm,2022-03-21,commercialized drug update
Pfizer and BioNTech Submit for U.S. Emergency Use Authorization of an Additional Booster Dose of their COVID-19 Vaccine for Older Adults,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-submit-us-emergency-use-authorization,2022-03-15,regulatory approval
Pfizer Updates Company Position in Russia,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-updates-company-position-russia,2022-03-14,corporate
Pfizer Completes Acquisition of Arena Pharmaceuticals,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-completes-acquisition-arena-pharmaceuticals,2022-03-11,partnership
Pfizer Initiates Phase 2/3 Study of Novel COVID-19 Oral Treatment in Pediatric Participants,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-initiates-phase-23-study-novel-covid-19-oral,2022-03-09,clinical trial update
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-invites-public-view-and-listen-webcast-pfizer-4,2022-03-08,financial news
Pfizer Granted FDA Breakthrough Therapy Designation for Respiratory Syncytial Virus (RSV) Vaccine Candidate for the Prevention of RSV in Infants from Birth up to Six Months of Age by Active Immunization of Pregnant Women,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-granted-fda-breakthrough-therapy-designation,2022-03-02,clinical trial update
Phase 3 CLOVER Trial for Pfizer’s Investigational Clostridioides Difficile Vaccine Indicates Strong Potential Effect in Reducing Duration and Severity of Disease Based on Secondary Endpoints,https://www.pfizer.com/news/press-release/press-release-detail/phase-3-clover-trial-pfizers-investigational-clostridioides,2022-03-01,clinical trial update
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-invites-public-view-and-listen-webcast-pfizer-3,2022-02-28,financial news
FDA Accepts for Review Pfizer’s Supplemental Application for ABRILADA™ (adalimumab-afzb) Interchangeability,https://www.pfizer.com/news/press-release/press-release-detail/fda-accepts-review-pfizers-supplemental-application,2022-02-25,regulatory approval
Biohaven and Pfizer Receive Positive CHMP Opinion for Migraine Treatment,https://www.pfizer.com/news/press-release/press-release-detail/biohaven-and-pfizer-receive-positive-chmp-opinion-migraine,2022-02-25,commercialized drug update
Pfizer and BioNTech Receive Positive CHMP Opinion for COVID-19 Vaccine Booster in Adolescents 12 through 17 Years of Age in the European Union,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-receive-positive-chmp-opinion-covid-19,2022-02-24,clinical trial update
"CDC Advisory Committee on Immunization Practices Votes to Recommend TicoVac™, Pfizer’s Tick-Borne Encephalitis (TBE) Vaccine, For Those at Risk of Virus Exposure",https://www.pfizer.com/news/press-release/press-release-detail/cdc-advisory-committee-immunization-practices-votes,2022-02-23,regulatory approval
Pfizer Statement on Results of Third Annual Pay Equity Study Among Colleagues Worldwide,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-statement-results-third-annual-pay-equity-study,2022-02-22,management update
Pfizer Invites Public to View and Listen to Webcast of Pfizer Keynote Presentation at Healthcare Conference,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-invites-public-view-and-listen-webcast-pfizer-2,2022-02-22,financial news
Pfizer and OPKO’s Once-Weekly NGENLA™ (somatrogon) Injection Receives Marketing Authorization in European Union for Treatment of Pediatric Growth Hormone Deficiency,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-opkos-once-weekly-ngenlatm-somatrogon-injection,2022-02-15,regulatory approval
European Medicines Agency Approves Pfizer’s 20-Valent Pneumococcal Conjugate Vaccine Against Invasive Pneumococcal Disease and Pneumonia in Adults,https://www.pfizer.com/news/press-release/press-release-detail/european-medicines-agency-approves-pfizers-20-valent,2022-02-15,regulatory approval
Pfizer joins the Open Targets consortium,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-joins-open-targets-consortium,2022-02-14,partnership
Biohaven and Pfizer Announce Positive Top-Line Results of Pivotal Trial of Rimegepant for the Acute Treatment of Migraine in China and South Korea,https://www.pfizer.com/news/press-release/press-release-detail/biohaven-and-pfizer-announce-positive-top-line-results,2022-02-14,clinical trial update
Pfizer and BioNTech Provide Update on Rolling Submission for Emergency Use Authorization of Their COVID-19 Vaccine in Children 6 Months Through 4 Years of Age,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-provide-update-rolling-submission,2022-02-11,regulatory approval
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-invites-public-listen-webcast-pfizer-discussion-11,2022-02-09,financial news
Pfizer Reports Fourth-Quarter and Full-Year 2021 Results,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-reports-fourth-quarter-and-full-year-2021-results,2022-02-08,financial news
Valneva and Pfizer Report Further Positive Phase 2 Data for Lyme Disease Vaccine Candidate,https://www.pfizer.com/news/press-release/press-release-detail/valneva-and-pfizer-report-further-positive-phase-2-data,2022-02-04,clinical trial update
Pfizer and BioNTech Initiate Rolling Submission for Emergency Use Authorization of Their COVID-19 Vaccine in Children 6 Months Through 4 Years of Age Following Request From U.S. FDA,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-initiate-rolling-submission-emergency,2022-02-01,regulatory approval
Pfizer Announces New Chief Development Officer,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-announces-new-chief-development-officer,2022-02-01,management update
Pfizer Invites Public to View and Listen to a Webcast with Pfizer Director Joseph Echevarria to Discuss Board Oversight of ESG,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-invites-public-view-and-listen-webcast-pfizer-0,2022-02-01,management update
Pfizer and Ionis Announce Discontinuation of Vupanorsen Clinical Development Program,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-ionis-announce-discontinuation-vupanorsen,2022-01-31,clinical trial update
European Commission Approves LORVIQUA® (lorlatinib) as a First-Line Treatment for ALK-Positive Advanced Lung Cancer,https://www.pfizer.com/news/press-release/press-release-detail/european-commission-approves-lorviquar-lorlatinib-first,2022-01-28,regulatory approval
Pfizer Receives CHMP Positive Opinion for Novel COVID-19 Oral Treatment,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-receives-chmp-positive-opinion-novel-covid-19-oral,2022-01-27,regulatory approval
Pfizer and BioNTech Initiate Study to Evaluate Omicron-Based COVID-19 Vaccine in Adults 18 to 55 Years of Age,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-initiate-study-evaluate-omicron-based,2022-01-25,clinical trial update
Pfizer and BioNTech Publish Data from Two Laboratory Studies on COVID-19 Vaccine-induced Antibodies Ability to Neutralize SARS-CoV-2 Omicron Variant,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-publish-data-two-laboratory-studies,2022-01-24,clinical trial update
Pfizer and OPKO Provide Update on the Biologics License Application for Somatrogon for Pediatric Growth Hormone Deficiency,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-opko-provide-update-biologics-license,2022-01-21,regulatory approval
Dren Bio Announces Research Collaboration and License Agreement with Pfizer to Discover and Advance Multiple Therapeutic Antibodies Using its Targeted Myeloid Engager and Phagocytosis Platform for the Treatment of Cancer,https://www.pfizer.com/news/press-release/press-release-detail/dren-bio-announces-research-collaboration-and-license,2022-01-18,partnership
Pfizer Shares In Vitro Efficacy of Novel COVID-19 Oral Treatment Against Omicron Variant,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-shares-vitro-efficacy-novel-covid-19-oral-treatment,2022-01-18,clinical trial update
U.S. FDA Approves Pfizer’s CIBINQO® (abrocitinib) for Adults with Moderate-to-Severe Atopic Dermatitis,https://www.pfizer.com/news/press-release/press-release-detail/us-fda-approves-pfizers-cibinqor-abrocitinib-adults,2022-01-14,regulatory approval
Positive Top-Line Results of Pfizer’s Phase 3 Study Exploring Coadministration of PREVNAR 20™ With Pfizer-BioNTech COVID-19 Vaccine in Older Adults Released,https://www.pfizer.com/news/press-release/press-release-detail/positive-top-line-results-pfizers-phase-3-study-exploring-0,2022-01-12,clinical trial update
Dren Bio Announces Research Collaboration and License Agreement with Pfizer to Discover and Advance Multiple Therapeutic Antibodies Using its Targeted Myeloid Engager and Phagocytosis Platform for the Treatment of Cancer,https://www.pfizer.com/news/press-release/press-release-detail/dren-bio-announces-research-collaboration-and-license,2022-01-11,partnership
Pfizer Enters into Agreement with Acuitas Therapeutics for Lipid Nanoparticle Delivery System for Use in mRNA Vaccines and Therapeutics,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-enters-agreement-acuitas-therapeutics-lipid,2022-01-10,partnership
Biohaven and Pfizer Complete Collaboration Transaction for Commercialization of Rimegepant and Zavegepant Outside United States,https://www.pfizer.com/news/press-release/press-release-detail/biohaven-and-pfizer-complete-collaboration-transaction,2022-01-05,partnership
Pfizer and BioNTech Sign New Global Collaboration Agreement to Develop First mRNA-based Shingles Vaccine,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-sign-new-global-collaboration-agreement,2022-01-05,partnership
Pfizer to Provide U.S. Government with an Additional 10 Million Treatment Courses of its Oral Therapy to Help Combat COVID-19,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-provide-us-government-additional-10-million,2022-01-04,commercialized drug update
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-invites-public-listen-webcast-pfizer-discussion-10,2022-01-04,financial news
Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization of COVID-19 Vaccine Booster for Individuals 12 Years of Age and Older,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-receive-us-fda-emergency-use-0,2022-01-03,regulatory approval
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-invites-public-listen-webcast-pfizer-discussion-9,2021-12-30,financial news
Pfizer Invites Public to View and Listen to Webcast of February 8 Conference Call with Analysts,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-invites-public-view-and-listen-webcast-february-8,2021-12-28,financial news
Pfizer and BioNTech Submit Updated Longer-Term Follow-Up Data of COMIRNATY® in Adolescents 12 Through 15 Years of Age to EMA,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-submit-updated-longer-term-follow-data,2021-12-23,clinical trial update
Pfizer Receives U.S. FDA Emergency Use Authorization for Novel COVID-19 Oral Antiviral Treatment,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-receives-us-fda-emergency-use-authorization-novel,2021-12-22,regulatory approval
Pfizer to Provide the United Kingdom an Additional 2.5 Million Treatment Courses of Investigational Oral Antiviral Candidate to Help Combat COVID-19,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-provide-united-kingdom-additional-25-million,2021-12-22,commercialized drug update
"Pfizer’s VYNDAQEL®/VYNDAMAX® Reduced the Risk of All-Cause Mortality by 41% Among Patients with Transthyretin Amyloid Cardiomyopathy, Five-Year Follow-Up Data Demonstrate",https://www.pfizer.com/news/press-release/press-release-detail/pfizers-vyndaqelrvyndamaxr-reduced-risk-all-cause-mortality,2021-12-20,clinical trial update
Pfizer and BioNTech to Provide European Union More Than 200 Million Additional Doses of COMIRNATY® to Help Meet Continued Need for Vaccine Supply,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-provide-european-union-more-200-million,2021-12-20,commercialized drug update
Pfizer and BioNTech Provide Update on Ongoing Studies of COVID-19 Vaccine,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-provide-update-ongoing-studies-covid-19,2021-12-17,clinical trial update
"EMA Adopts a Positive CHMP Opinion for Pfizer’s and OPKO’s Somatrogon, a Long-Acting Treatment for Pediatric Growth Hormone Deficiency",https://www.pfizer.com/news/press-release/press-release-detail/ema-adopts-positive-chmp-opinion-pfizers-and-opkos,2021-12-17,regulatory approval
CHMP Issues Positive Opinion for Pfizer’s 20-Valent Pneumococcal Conjugate Vaccine for the Prevention of Vaccine-Type Pneumococcal Pneumonia in Adults,https://www.pfizer.com/news/press-release/press-release-detail/chmp-issues-positive-opinion-pfizers-20-valent-pneumococcal,2021-12-17,regulatory approval
Pfizer Receives Positive CHMP Opinion for LORVIQUA® (lorlatinib) as First-Line Treatment for ALK-Positive Advanced Lung Cancer,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-receives-positive-chmp-opinion-lorviquar-lorlatinib,2021-12-17,regulatory approval
Pfizer and BioNTech Submit Supplemental Biologics License Application for U.S. FDA Approval of COMIRNATY® in Adolescents 12 Through 15 Years of Age,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-submit-supplemental-biologics-license,2021-12-16,regulatory approval
EMA Issues Advice for Potential Early Use of Pfizer’s Novel COVID-19 Oral Antiviral Candidate,https://www.pfizer.com/news/press-release/press-release-detail/ema-issues-advice-potential-early-use-pfizers-novel-covid,2021-12-16,clinical trial update
Anaveon to raise CHF 110 million in oversubscribed Series B financing,https://www.pfizer.com/news/press-release/press-release-detail/anaveon-raise-chf-110-million-oversubscribed-series-b,2021-12-16,financial news
"Pfizer Invests $68.5 Million in New State-of-the-Art Facility in Durham, North Carolina to Further Advance Gene Therapy Capabilities",https://www.pfizer.com/news/press-release/press-release-detail/pfizer-invests-685-million-new-state-art-facility-durham,2021-12-15,management update
U.S. FDA Approves Pfizer’s XELJANZ® (tofacitinib) for the Treatment of Active Ankylosing Spondylitis,https://www.pfizer.com/news/press-release/press-release-detail/us-fda-approves-pfizers-xeljanzr-tofacitinib-treatment-0,2021-12-14,regulatory approval
Pfizer Announces Additional Phase 2/3 Study Results Confirming Robust Efficacy of Novel COVID-19 Oral Antiviral Treatment Candidate in Reducing Risk of Hospitalization or Death,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-announces-additional-phase-23-study-results,2021-12-14,clinical trial update
Pfizer to Acquire Arena Pharmaceuticals,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-acquire-arena-pharmaceuticals,2021-12-13,financial news
Pfizer and Sangamo Announce Updated Phase 1/2 Results Showing Sustained Bleeding Control in Highest Dose Cohort Through Two Years Following Hemophilia A Gene Therapy,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-sangamo-announce-updated-phase-12-results-1,2021-12-12,clinical trial update
Pfizer Declares First-Quarter 2022 Dividend,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-declares-first-quarter-2022-dividend,2021-12-10,financial news
European Commission Approves Pfizer’s Cibinqo® (abrocitinib) for the Treatment of Adults with Moderate-to-Severe Atopic Dermatitis,https://www.pfizer.com/news/press-release/press-release-detail/european-commission-approves-pfizers-cibinqor-abrocitinib,2021-12-10,regulatory approval
Arvinas and Pfizer Announce PROTAC® Protein Degrader ARV-471 Continues to Demonstrate Encouraging Clinical Benefit Rate in Patients with Locally Advanced or Metastatic ER+/HER2- Breast Cancer,https://www.pfizer.com/news/press-release/press-release-detail/arvinas-and-pfizer-announce-protacr-protein-degrader-arv,2021-12-10,clinical trial update
Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization of COVID-19 Vaccine Booster for Individuals 16 Years and Older,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-receive-us-fda-emergency-use,2021-12-09,regulatory approval
Pfizer and BioNTech Provide Update on Omicron Variant,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-provide-update-omicron-variant,2021-12-08,clinical trial update
Pfizer Invites Public to Register for Webcast of Analyst and Investor Call to Discuss Pfizer-BioNTech COVID-19 Vaccine and Pfizer’s Novel COVID-19 Oral Antiviral Treatment Candidate,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-invites-public-register-webcast-analyst-and-0,2021-12-07,financial news
FDA Issues Update to XELJANZ® Prescribing Information in the United States,https://www.pfizer.com/news/press-release/press-release-detail/fda-issues-update-xeljanzr-prescribing-information-united,2021-12-03,regulatory approval
AWS Helps Pfizer Accelerate Drug Development And Clinical Manufacturing,https://www.pfizer.com/news/press-release/press-release-detail/aws-helps-pfizer-accelerate-drug-development-and-clinical,2021-12-02,management update
Ranok Therapeutics Announces Agreement with Pfizer on Targeted Protein Degradation,https://www.pfizer.com/news/press-release/press-release-detail/ranok-therapeutics-announces-agreement-pfizer-targeted,2021-11-29,management update
Pfizer and BioNTech Receive Positive CHMP Opinion for COMIRNATY® in Children 5 to under 12 Years of Age in the European Union,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-receive-positive-chmp-opinion,2021-11-25,regulatory approval
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-invites-public-view-and-listen-webcast-pfizer,2021-11-24,financial news
Pfizer Announces Topline Results from Phase 2b Trial of Vupanorsen in Statin-treated Participants with Dyslipidemia,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-announces-topline-results-phase-2b-trial-vupanorsen,2021-11-24,clinical trial update
"Important Update on EpiPen® (epinephrine injection, USP) 0.3 mg  Auto-Injectors",https://www.pfizer.com/news/press-release/press-release-detail/important-update-epipenr-epinephrine-injection-usp-03-mg,2021-11-23,regulatory approval
Follow-Up Data From Phase 3 Trial of Pfizer-BioNTech COVID-19 Vaccine Support Safety and High Efficacy in Adolescents 12 Through 15 Years of Age,https://www.pfizer.com/news/press-release/press-release-detail/follow-data-phase-3-trial-pfizer-biontech-covid-19-vaccine,2021-11-22,clinical trial update
Arvinas And Pfizer Announce Updated Phase 1 Dose Escalation Data For ARV-471 To Be Presented In Spotlight Poster Session At 2021 San Antonio Breast Cancer Symposium,https://www.pfizer.com/news/press-release/press-release-detail/arvinas-and-pfizer-announce-updated-phase-1-dose-escalation,2021-11-19,clinical trial update
Pfizer and BioNTech Receive Expanded U.S. FDA Emergency Use Authorization of COVID-19 Vaccine Booster to Include Individuals 18 and Older,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-receive-expanded-us-fda-emergency,2021-11-19,regulatory approval
Pfizer’s XELJANZ® (tofacitinib) Receives Marketing Authorization in the European Union for the Treatment of Active Ankylosing Spondylitis,https://www.pfizer.com/news/press-release/press-release-detail/pfizers-xeljanzr-tofacitinib-receives-marketing,2021-11-18,regulatory approval
Cardiff Oncology Announces $15 Million Equity Investment from Pfizer through its Pfizer Breakthrough Growth Initiative,https://www.pfizer.com/news/press-release/press-release-detail/cardiff-oncology-announces-15-million-equity-investment,2021-11-18,financial news
Pfizer to Provide U.S. Government with 10 Million Treatment Courses of Investigational Oral Antiviral Candidate to Help Combat COVID-19,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-provide-us-government-10-million-treatment-courses,2021-11-18,commercialized drug update
Pfizer Completes Acquisition of Trillium Therapeutics,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-completes-acquisition-trillium-therapeutics,2021-11-17,financial news
Pfizer Announces Retirement of Chief Financial Officer Frank D’Amelio,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-announces-retirement-chief-financial-officer-frank,2021-11-17,management update
Pfizer Seeks Emergency Use Authorization for Novel COVID-19 Oral Antiviral Candidate,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-seeks-emergency-use-authorization-novel-covid-19,2021-11-16,regulatory approval
Pfizer and The Medicines Patent Pool (MPP) Sign Licensing Agreement for COVID-19 Oral Antiviral Treatment Candidate to Expand Access in Low- and Middle-Income Countries,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-medicines-patent-pool-mpp-sign-licensing,2021-11-16,commercialized drug update
"Pfizer Names Bill Sessa, Ph.D., Chief Scientific Officer to Lead Internal Medicine Research",https://www.pfizer.com/news/press-release/press-release-detail/pfizer-names-bill-sessa-phd-chief-scientific-officer-lead,2021-11-12,management update
"Zipline, Pfizer and BioNTech Collaboration Paves the Way for Automated, On-Demand Delivery of First mRNA COVID-19 Vaccines in Ghana",https://www.pfizer.com/news/press-release/press-release-detail/zipline-pfizer-and-biontech-collaboration-paves-way,2021-11-11,commercialized drug update
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-invites-public-listen-webcast-pfizer-discussion-8,2021-11-10,financial news
Pfizer and BioNTech Submit Request to Amend U.S. FDA Emergency Use Authorization of Their COVID-19 Vaccine Booster to Include All Individuals 18 and Older,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-submit-request-amend-us-fda-emergency,2021-11-09,regulatory approval
Biohaven and Pfizer Enter Strategic Collaboration for the Commercialization of Rimegepant Outside the United States,https://www.pfizer.com/news/press-release/press-release-detail/biohaven-and-pfizer-enter-strategic-collaboration,2021-11-09,management update
Pfizer’s Novel COVID-19 Oral Antiviral Treatment Candidate Reduced Risk of Hospitalization or Death by 89% in Interim Analysis of Phase 2/3 EPIC-HR Study,https://www.pfizer.com/news/press-release/press-release-detail/pfizers-novel-covid-19-oral-antiviral-treatment-candidate,2021-11-05,clinical trial update
PFIZER REPORTS THIRD-QUARTER 2021 RESULTS,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-reports-third-quarter-2021-results,2021-11-02,financial news
Pfizer and BioNTech Receive First U.S. FDA Emergency Use Authorization of a COVID-19 Vaccine in Children Ages 5 Through 11 Years,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-receive-first-us-fda-emergency-use,2021-10-29,regulatory approval
Pfizer and BioNTech to Provide U.S. Government an Additional 50 Million Pediatric Doses of COVID-19 Vaccine to Support Further Preparedness for Future Needs,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-provide-us-government-additional-50,2021-10-28,commercialized drug update
FDA Advisory Committee Votes in Favor of Granting Emergency Use Authorization for the Pfizer-BioNTech COVID-19 Vaccine in Children 5 to <12 Years,https://www.pfizer.com/news/press-release/press-release-detail/fda-advisory-committee-votes-favor-granting-emergency-use,2021-10-26,regulatory approval
Pfizer and BioNTech Announce Phase 3 Trial Data Showing High Efficacy of a Booster Dose of Their COVID-19 Vaccine,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-announce-phase-3-trial-data-showing,2021-10-21,clinical trial update
Advisory Committee on Immunization Practices Votes to Recommend Routine Use of Pfizer’s PREVNAR 20™ (Pneumococcal 20-valent Conjugate Vaccine) in Adults,https://www.pfizer.com/news/press-release/press-release-detail/advisory-committee-immunization-practices-votes-recommend,2021-10-20,regulatory approval
Myovant Sciences and Pfizer Present Data on Relugolix Combination Therapy from Studies in Uterine Fibroids and Endometriosis at the American Society for Reproductive Medicine Congress,https://www.pfizer.com/news/press-release/press-release-detail/myovant-sciences-and-pfizer-present-data-relugolix,2021-10-19,clinical trial update
New Formulation of COMIRNATY® Receives Positive Opinion from CHMP,https://www.pfizer.com/news/press-release/press-release-detail/new-formulation-comirnatyr-receives-positive-opinion-chmp,2021-10-18,regulatory approval
Pfizer and BioNTech Submit Data to EMA for the Vaccination of Children 5 to <12 Years of Age with COMIRNATY®,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-submit-data-ema-vaccination-children-5,2021-10-15,regulatory approval
Pfizer’s Abrocitinib Receives Positive CHMP Opinion for the Treatment of Adults with Moderate to Severe Atopic Dermatitis,https://www.pfizer.com/news/press-release/press-release-detail/pfizers-abrocitinib-receives-positive-chmp-opinion,2021-10-15,regulatory approval
"AION Labs, Biotech Innovation Lab Launched by Top Pharma, Tech and Investment Leaders",https://www.pfizer.com/news/press-release/press-release-detail/aion-labs-biotech-innovation-lab-launched-top-pharma-tech,2021-10-13,partnerships
Pfizer and BioNTech Receive CHMP Positive Opinion for COVID-19 Vaccine Booster in the European Union,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-receive-chmp-positive-opinion-covid-19,2021-10-04,"covid-19, vaccines"
Japan’s MHLW Approves Pfizer’s CIBINQO® (abrocitinib) for Adults and Adolescents with Moderate to Severe Atopic Dermatitis,https://www.pfizer.com/news/press-release/press-release-detail/japans-mhlw-approves-pfizers-cibinqor-abrocitinib-adults,2021-09-30,medicines
Positive Top-line Results of Pfizer’s Phase 3 Study Exploring Coadministration of Prevnar 20™ With Seasonal Flu Vaccine in Older Adults Released,https://www.pfizer.com/news/press-release/press-release-detail/positive-top-line-results-pfizers-phase-3-study-exploring,2021-09-29,"research, vaccines"
"Valneva and Pfizer Report Further Positive Phase 2 Results, Including Booster Response, for Lyme Disease Vaccine Candidate",https://www.pfizer.com/news/press-release/press-release-detail/valneva-and-pfizer-report-further-positive-phase-2-results,2021-09-28,"research, vaccines"
Pfizer and BioNTech Submit Initial Data to U.S. FDA From Pivotal Trial of COVID-19 Vaccine in Children 5 to <12 Years of Age,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-submit-initial-data-us-fda-pivotal,2021-09-28,"covid-19, research, vaccines"
Pfizer Starts Study of mRNA-Based Next Generation Flu Vaccine Program,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-starts-study-mrna-based-next-generation-flu-vaccine,2021-09-27,"research, vaccines"
Pfizer Starts Global Phase 2/3 EPIC-PEP Study of Novel COVID-19 Oral Antiviral Candidate for Post-Exposure Prophylaxis in Adults,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-starts-global-phase-23-epic-pep-study-novel-covid-19,2021-09-27,"covid-19, research"
Pfizer and OPKO Announce Extension of U.S. FDA Review of Biologics License Application of Somatrogon for Pediatric Growth Hormone Deficiency,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-opko-announce-extension-us-fda-review-biologics,2021-09-24,medicines
Pfizer Declares Fourth-Quarter 2021 Dividend,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-declares-fourth-quarter-2021-dividend,2021-09-23,finance
Pfizer and BioNTech Expand Collaboration with U.S. to Provide 500 Million Additional COVID-19 Vaccine Doses at Not-for-Profit Price for Donation to Poorest Countries,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-expand-collaboration-us-provide-500,2021-09-22,"covid-19, partnerships, vaccines"
Pfizer and BioNTech Announce Positive Topline Results From Pivotal Trial of COVID-19 Vaccine in Children 5 to 11 Years,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-announce-positive-topline-results,2021-09-20,"covid-19, research, vaccines"
FDA Advisory Committee Votes Unanimously in Favor Of COMIRNATY® Booster for Emergency Use in People 65 and Older and Certain High-risk Populations,https://www.pfizer.com/news/press-release/press-release-detail/fda-advisory-committee-votes-unanimously-favor-comirnatyr,2021-09-17,"covid-19, vaccines"
Astellas’ and Pfizer’s XTANDI® (enzalutamide) Reduced Risk of Death by 34% in Men with Metastatic Hormone-Sensitive Prostate Cancer in Phase 3 ARCHES Study,https://www.pfizer.com/news/press-release/press-release-detail/astellas-and-pfizers-xtandir-enzalutamide-reduced-risk,2021-09-17,research
Pfizer Expands Voluntary Nationwide Recall to include All Lots of CHANTIX® (varenicline) Tablets Due to N-Nitroso Varenicline Content,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-expands-voluntary-nationwide-recall-include-all-lots,2021-09-17,medicines
Anjarium Biosciences Raises CHF 55.5M ($61M) Series A Financing to Develop Next-Generation Non-viral Gene Therapies,https://www.pfizer.com/news/press-release/press-release-detail/anjarium-biosciences-raises-chf-555m-61m-series-financing,2021-09-16,partnerships
Myovant Sciences and Pfizer Announce FDA Acceptance of Supplemental New Drug Application for MYFEMBREE® for the Management of Moderate to Severe Pain Associated With Endometriosis,https://www.pfizer.com/news/press-release/press-release-detail/myovant-sciences-and-pfizer-announce-fda-acceptance,2021-09-09,"medicines, research"
UK’s MHRA Grants Marketing Authorisation for Pfizer’s CIBINQO® (abrocitinib) for Adults and Adolescents With Moderate to Severe Atopic Dermatitis,https://www.pfizer.com/news/press-release/press-release-detail/uks-mhra-grants-marketing-authorisation-pfizers-cibinqor,2021-09-09,medicines
Pfizer Invites Public to Listen to Two Webcasts of Pfizer Discussions at Upcoming Healthcare Conferences,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-invites-public-listen-two-webcasts-pfizer-0,2021-09-07,finance
Pfizer and BioNTech Submit a Variation to EMA with the Data in  Support of a Booster Dose of COMIRNATY®,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-submit-variation-ema-data-support,2021-09-06,"covid-19, vaccines"
The Bristol-Myers Squibb-Pfizer Alliance is pleased with the decision by the U.S.  Court of Appeals for the Federal Circuit upholding the Eliquis®Patents,https://www.pfizer.com/news/press-release/press-release-detail/bristol-myers-squibb-pfizer-alliance-pleased-decision-us,2021-09-03,medicines
Pfizer Announces Start of Phase 3 Clinical Trial in Adults for Its Investigational Vaccine Against Respiratory Syncytial Virus (RSV),https://www.pfizer.com/news/press-release/press-release-detail/pfizer-announces-start-phase-3-clinical-trial-adults-its,2021-09-02,"research, vaccines"
FDA Issues Drug Safety Communication Related to Current XELJANZ® Label,https://www.pfizer.com/news/press-release/press-release-detail/fda-issues-drug-safety-communication-related-current,2021-09-01,medicines
First Participant Dosed in Phase 2/3 Study of Oral Antiviral Candidate  in Non-Hospitalized Adults with COVID-19 Who Are at Low Risk of  Severe Illness,https://www.pfizer.com/news/press-release/press-release-detail/first-participant-dosed-phase-23-study-oral-antiviral,2021-09-01,research
Positive Top-Line Results From Pfizer’s Phase 3 JADE DARE Trial Comparing the Efficacy of Abrocitinib and Dupilumab for Moderate to Severe Atopic Dermatitis,https://www.pfizer.com/news/press-release/press-release-detail/positive-top-line-results-pfizers-phase-3-jade-dare-trial,2021-08-30,"medicines, research"
Pfizer Announces New Chief Business Innovation Officer,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-announces-new-chief-business-innovation-officer,2021-08-26,management update
Pfizer and BioNTech Announce Collaboration With Brazil’s Eurofarma to Manufacture COVID-19 Vaccine Doses for Latin America,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-announce-collaboration-brazils,2021-08-26,"covid-19, partnerships, vaccines"
Pfizer and BioNTech Initiate Rolling Submission of Supplemental Biologics License Application to U.S. FDA for Booster Dose of COMIRNATY® in Individuals 16 and Older,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-initiate-rolling-submission,2021-08-25,"covid-19, vaccines"
Pfizer-BioNTech COVID-19 Vaccine COMIRNATY® Receives Full U.S. FDA Approval for Individuals 16 Years and Older,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-biontech-covid-19-vaccine-comirnatyr-receives-full,2021-08-23,vaccines
Pfizer to Acquire Trillium Therapeutics Inc.,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-acquire-trillium-therapeutics-inc,2021-08-23,"finance, investments"
XELJANZ® (tofacitinib citrate) Receives Marketing Authorization in the European Union for the Treatment of Active Polyarticular Juvenile Idiopathic Arthritis and Juvenile Psoriatic Arthritis,https://www.pfizer.com/news/press-release/press-release-detail/xeljanzr-tofacitinib-citrate-receives-marketing,2021-08-20,medicines
Pfizer Prices $1.0 Billion Sustainability Bond,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-prices-10-billion-sustainability-bond,2021-08-16,finance
Pfizer and BioNTech Announce Submission of Initial Data to U.S. FDA to Support Booster Dose of COVID-19 Vaccine,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-announce-submission-initial-data-us-fda,2021-08-16,"covid-19, vaccines"
"U.S. FDA Approves TICOVAC™, Pfizer’s Tick-Borne Encephalitis (TBE) Vaccine",https://www.pfizer.com/news/press-release/press-release-detail/us-fda-approves-ticovactm-pfizers-tick-borne-encephalitis,2021-08-13,vaccines
Pfizer Expands Voluntary Nationwide Recall to include Four  Additional Lots of CHANTIX® (varenicline) Tablets Due to N-Nitroso Varenicline Content,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-expands-voluntary-nationwide-recall-include-four,2021-08-13,medicines
VTX-801 Receives U.S. FDA Fast Track Designation for the Treatment of Wilson Disease,https://www.pfizer.com/news/press-release/press-release-detail/vtx-801-receives-us-fda-fast-track-designation-treatment,2021-08-12,vaccines
Pfizer Announces Positive Top-Line Results from Phase 2b/3 Trial of Ritlecitinib in Alopecia Areata,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-announces-positive-top-line-results-phase-2b3-trial,2021-08-04,"medicines, research"
Pfizer and BioNTech Share Detailed Update to the Results from 6 Month Safety and  Efficacy Data Analysis of Landmark COVID-19 Vaccine Study,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-share-detailed-update-results-6-month,2021-07-28,"research, vaccines"
PFIZER REPORTS SECOND-QUARTER 2021 RESULTS,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-reports-second-quarter-2021-results,2021-07-28,finance
Pfizer and BioNTech to Provide U.S. Government with an Additional 200 Million Doses of COVID-19 Vaccine to Help Meet Continued Need for Vaccine Supply in the U.S.,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-provide-us-government-additional-200,2021-07-23,"covid-19, vaccines"
Arvinas And Pfizer Announce Global Collaboration To Develop And Commercialize Protac® Protein Degrader Arv-471,https://www.pfizer.com/news/press-release/press-release-detail/arvinas-and-pfizer-announce-global-collaboration-develop-1,2021-07-22,partnerships
Arvinas and Pfizer Announce Global Collaboration to Develop and Commercialize PROTAC® Protein Degrader ARV-471,https://www.pfizer.com/news/press-release/press-release-detail/arvinas-and-pfizer-announce-global-collaboration-develop,2021-07-22,"partnerships, medicines"
Pfizer Provides Update on U.S. FDA Review of Abrocitinib and XELJANZ® Filings,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-provides-update-us-fda-review-abrocitinib-and,2021-07-21,medicines
Pfizer and BioNTech Announce Collaboration With Biovac to Manufacture and Distribute COVID-19 Vaccine Doses Within Africa,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-announce-collaboration-biovac,2021-07-21,"partnerships, vaccines"
Valneva and Pfizer Complete Recruitment for Phase 2 Trial of Lyme Disease Vaccine Candidate,https://www.pfizer.com/news/press-release/press-release-detail/valneva-and-pfizer-complete-recruitment-phase-2-trial-lyme,2021-07-19,"research, vaccines"
Pfizer Announces New Investor Relations Leader,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-announces-new-investor-relations-leader,2021-07-19,finance
Pfizer Issues A Voluntary Nationwide Recall for Twelve Lots of  CHANTIX® (varenicline) Tablets Due to N-Nitroso Varenicline  Content,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-issues-voluntary-nationwide-recall-twelve-lots,2021-07-16,medicines
U.S. FDA Grants Priority Review for the Biologics License Application for Pfizer-BioNTech COVID-19 Vaccine,https://www.pfizer.com/news/press-release/press-release-detail/us-fda-grants-priority-review-biologics-license-application,2021-07-16,"covid-19, vaccines"
Pfizer and BioNTech Provide Update on Booster Program in Light of the Delta-Variant,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-provide-update-booster-program-light,2021-07-08,vaccine update
Newly Published Expert Opinion Article Details Evidence for Classifying Aging Immune System as a High-Risk Condition for Pneumococcal Vaccine Policy,https://www.pfizer.com/news/press-release/press-release-detail/newly-published-expert-opinion-article-details-evidence,2021-07-08,vaccine update
"Collaboration Between Abbvie, Biogen And Pfizer Creates World's Largest Browsable Resource Linking Rare Protein-Coding Genetic Variants To Human Health And Disease.",https://www.pfizer.com/news/press-release/press-release-detail/collaboration-between-abbvie-biogen-and-pfizer-creates-1,2021-07-08,partnership
"Collaboration Between Abbvie, Biogen and Pfizer Creates World's Largest Browsable Resource Linking Rare Protein-Coding Genetic Variants to Human Health and Disease",https://www.pfizer.com/news/press-release/press-release-detail/collaboration-between-abbvie-biogen-and-pfizer-creates-0,2021-07-08,partnership
Spero Therapeutics Announces $40 Million Equity Investment from Pfizer Inc. and Licensing Agreement for SPR206,https://www.pfizer.com/news/press-release/press-release-detail/spero-therapeutics-announces-40-million-equity-investment,2021-06-30,investment
Pfizer Declares Third-Quarter 2021 Dividend,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-declares-third-quarter-2021-dividend,2021-06-24,financial news
First Participant Dosed in Pfizer’s Pivotal Phase 3 TALAPRO-3 Combination Study of Talazoparib and Enzalutamide in Metastatic Castration-Sensitive Prostate Cancer (mCSPC),https://www.pfizer.com/news/press-release/press-release-detail/first-participant-dosed-pfizers-pivotal-phase-3-talapro-3,2021-06-23,clinical trial update
SVI announces collaboration with Pfizer,https://www.pfizer.com/news/press-release/press-release-detail/svi-announces-collaboration-pfizer,2021-06-22,partnership
Data Published in New England Journal of Medicine Shows Pfizer’s Tofacitinib Meets Primary Endpoint in Brazilian Study in Patients Hospitalized with COVID-19 Pneumonia,https://www.pfizer.com/news/press-release/press-release-detail/data-published-new-england-journal-medicine-shows-pfizers,2021-06-16,clinical trial update
Pfizer Invites Public to View and Listen to Webcast of Pfizer July 28 Conference Call with Analysts,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-invites-public-view-and-listen-webcast-pfizer-july,2021-06-16,financial news
XELJANZ® Safety Review Recommendation Issued in the European Union,https://www.pfizer.com/news/press-release/press-release-detail/xeljanzr-safety-review-recommendation-issued-european-union,2021-06-11,regulatory approval
Pfizer and BioNTech to Provide 500 Million Doses of COVID-19 Vaccine to U.S. Government for Donation to Poorest Nations,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-provide-500-million-doses-covid-19,2021-06-10,vaccine update
"U.S. FDA Approves PREVNAR 20™, Pfizer’s Pneumococcal 20-valent Conjugate Vaccine for Adults Ages 18 Years or Older",https://www.pfizer.com/news/press-release/press-release-detail/us-fda-approves-prevnar-20tm-pfizers-pneumococcal-20-valent,2021-06-08,regulatory approval
"IMI SOPHIA PARTNERS WITH MACCABI’S RESEARCH AND INNOVATION CENTER (KSM), PFIZER, AND LAUSANNE UNIVERSITY HOSPITAL TO IMPROVE OBESITY TREATMENT",https://www.pfizer.com/news/press-release/press-release-detail/imi-sophia-partners-maccabis-research-and-innovation-center,2021-06-01,partnership
Pfizer and BioNTech Receive First Authorization in European Union for COVID-19 Vaccine in Adolescents,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-receive-first-authorization-european,2021-05-28,regulatory approval
Pfizer Colleagues to Mentor Veterans in Transition to Civilian Life,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-colleagues-mentor-veterans-transition-civilian-life,2021-05-28,management update
RefleXion Announces New Additions to Board of Directors and Appoints Audit Committee Chair,https://www.pfizer.com/news/press-release/press-release-detail/reflexion-announces-new-additions-board-directors-and,2021-05-27,management update
"Myovant Sciences and Pfizer Receive FDA Approval for MYFEMBREE®, the First Once-Daily Treatment for Heavy Menstrual Bleeding Associated With Uterine Fibroids",https://www.pfizer.com/news/press-release/press-release-detail/myovant-sciences-and-pfizer-receive-fda-approval-myfembreer,2021-05-26,regulatory approval
The Foundation for the NIH Announces a New Research Initiative to Find Integrated Treatments Across Common Metabolic Diseases,https://www.pfizer.com/news/press-release/press-release-detail/foundation-nih-announces-new-research-initiative-find,2021-05-26,partnership
Pfizer Initiates Study Exploring Coadministration of Its 20-valent Pneumococcal Conjugate Vaccine Candidate Along With a Third Dose of the Pfizer-BioNTech COVID-19 Vaccine in Older Adults,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-initiates-study-exploring-coadministration-its-20,2021-05-24,clinical trial update
Pfizer and BioNTech to Supply the European Union With up to 1.8 Billion Additional Doses of COMIRNATY®,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-supply-european-union-18-billion,2021-05-20,vaccine update
Sosei Heptares announces that the third novel drug candidate from its multi-target drug discovery collaboration with Pfizer has started clinical trials,https://www.pfizer.com/news/press-release/press-release-detail/sosei-heptares-announces-third-novel-drug-candidate-its,2021-05-19,partnership
"Pfizer’s Novel Prediction Model, Derived from Machine Learning, Shows Robust Performance for Identifying Heart Failure Patients At-Risk for Wild-Type Transthyretin Amyloid Cardiomyopathy, a Rare and Life-Threatening Condition",https://www.pfizer.com/news/press-release/press-release-detail/pfizers-novel-prediction-model-derived-machine-learning,2021-05-11,clinical trial update
Pfizer and BioNTech Receive First U.S. Authorization for Emergency Use of COVID-19 Vaccine in Adolescents,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-receive-first-us-authorization,2021-05-10,regulatory approval
Pfizer and BioNTech Initiate Rolling Submission of Biologics License Application for U.S. FDA Approval of Their COVID 19 Vaccine,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-initiate-rolling-submission-biologics,2021-05-07,regulatory approval
Pfizer and BioNTech to Provide COVID-19 Vaccine Doses for Olympic Athletes at the 2020 Tokyo Games,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-provide-covid-19-vaccine-doses-olympic,2021-05-06,vaccine update
"Hospira Issues A Voluntary Nationwide Recall for One Lot of  0.5% Bupivacaine Hydrochloride Injection, USP and One Lot of 1%  Lidocaine HCl Injection, USP Due to Mislabeling",https://www.pfizer.com/news/press-release/press-release-detail/hospira-issues-voluntary-nationwide-recall-one-lot-05,2021-05-04,commercialized drug update
"Hospira Issues A Voluntary Nationwide Recall for One Lot of  Sterile Water for Injection, USP, Due to the Potential Presence of Visible Particulate",https://www.pfizer.com/news/press-release/press-release-detail/hospira-issues-voluntary-nationwide-recall-one-lot-sterile,2021-05-04,commercialized drug update
PFIZER REPORTS STRONG FIRST-QUARTER 2021 RESULTS,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-reports-strong-first-quarter-2021-results,2021-05-04,financial news
Pfizer Ventures' Barbara Dalton Appointed as AMRA Medical's Newest Board Member,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-ventures-barbara-dalton-appointed-amra-medicals,2021-04-29,management update
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-invites-public-listen-webcast-pfizer-discussion-7,2021-04-28,financial news
Pfizer Acquires Amplyx Pharmaceuticals,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-acquires-amplyx-pharmaceuticals-0,2021-04-28,investment
Pfizer Acquires Amplyx Pharmaceuticals,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-acquires-amplyx-pharmaceuticals,2021-04-28,investment
Pfizer Announces 2021 Shareholder Meeting Results,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-announces-2021-shareholder-meeting-results,2021-04-22,financial news
Pfizer Declares Second-Quarter 2021 Dividend,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-declares-second-quarter-2021-dividend,2021-04-22,financial news
Pfizer and BioNTech to Supply the European Union with 100 Million Additional Doses of COMIRNATY®,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-supply-european-union-100-million-0,2021-04-19,vaccine update
Pfizer Invites Shareholders to Attend Virtual-Only 2021 Annual Meeting of Shareholders on April 22,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-invites-shareholders-attend-virtual-only-2021-annual,2021-04-15,financial news
AMRA Medical Generates Largest Imaging Dataset on Body Composition Profiling,https://www.pfizer.com/news/press-release/press-release-detail/amra-medical-generates-largest-imaging-dataset-body,2021-04-14,partnership
Myovant Sciences and Pfizer Announce First Participant Dosed in Phase 3 SERENE Study Evaluating Contraceptive Efficacy of Once-Daily Relugolix Combination Tablet,https://www.pfizer.com/news/press-release/press-release-detail/myovant-sciences-and-pfizer-announce-first-participant,2021-04-12,clinical trial update
Pfizer and BioNTech Request Regulatory Agencies Expand  Emergency Use of Their COVID-19 Vaccine to Adolescents,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-request-regulatory-agencies-expand,2021-04-09,regulatory approval
Pfizer Announces Extension of Review of New Drug Application of Abrocitinib for the Treatment of Moderate to Severe Atopic Dermatitis,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-announces-extension-review-new-drug-application,2021-04-07,regulatory approval
"Pfizer Invites Public to Register for Webcast of Analyst and Investor Call to Review Oncology Business on April 9, 2021",https://www.pfizer.com/news/press-release/press-release-detail/pfizer-invites-public-register-webcast-analyst-and-investor,2021-04-02,financial news
Pfizer and BioNTech Confirm High Efficacy and No Serious Safety Concerns Through Up to Six Months Following Second Dose in Updated Topline Analysis of Landmark COVID-19 Vaccine Study,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-confirm-high-efficacy-and-no-serious,2021-04-01,vaccine update
Pfizer-BioNTech Announce Positive Topline Results of Pivotal COVID-19 Vaccine Study in Adolescents,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-biontech-announce-positive-topline-results-pivotal,2021-03-31,vaccine update
"EMA Approves New Storage Option for Pfizer-BioNTech Vaccine, Easing Distribution and Storage of Doses Across European Union",https://www.pfizer.com/news/press-release/press-release-detail/ema-approves-new-storage-option-pfizer-biontech-vaccine,2021-03-26,regulatory approval
Joint FDA Advisory Committee Votes on Application for Tanezumab for the Treatment of Osteoarthritis Pain,https://www.pfizer.com/news/press-release/press-release-detail/joint-fda-advisory-committee-votes-application-tanezumab,2021-03-25,regulatory approval
Results from Pfizer’s Phase 3 Jade Compare Study of Abrocitinib in Moderate to Severe Atopic Dermatitis Published in New England Journal of Medicine,https://www.pfizer.com/news/press-release/press-release-detail/results-pfizers-phase-3-jade-compare-study-abrocitinib,2021-03-25,clinical trial update
"Real-World Evidence Supports Effectiveness of First-line IBRANCE® (palbociclib) Combination Therapy in HR+, HER2- Metastatic Breast Cancer",https://www.pfizer.com/news/press-release/press-release-detail/real-world-evidence-supports-effectiveness-first-line,2021-03-25,clinical trial update
Myovant Sciences and Pfizer Announce Positive Data from Phase 3 LIBERTY Randomized Withdrawal Study of Once-Daily Relugolix Combination Therapy in Women with Uterine Fibroids,https://www.pfizer.com/news/press-release/press-release-detail/myovant-sciences-and-pfizer-announce-positive-data-phase-3,2021-03-24,clinical trial update
Pfizer Initiates Phase 1 Study of Novel Oral Antiviral Therapeutic Agent Against SARS-CoV-2,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-initiates-phase-1-study-novel-oral-antiviral,2021-03-23,clinical trial update
Pfizer Invites Public to View and Listen to Webcast of Pfizer May 4 Conference Call with Analysts,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-invites-public-view-and-listen-webcast-pfizer-may-4,2021-03-23,financial news
Mediar Therapeutics Adds New Investors As It Advances Anti-Fibrotic Treatments,https://www.pfizer.com/news/press-release/press-release-detail/mediar-therapeutics-adds-new-investors-it-advances-anti,2021-03-17,management update
Real-World Evidence Confirms High Effectiveness of Pfizer-BioNTech COVID-19 Vaccine and Profound Public Health Impact of Vaccination One Year After Pandemic Declared,https://www.pfizer.com/news/press-release/press-release-detail/real-world-evidence-confirms-high-effectiveness-pfizer,2021-03-11,clinical trial update
Valneva and Pfizer Announce Initiation of Phase 2 Study for Lyme Disease Vaccine Candidate,https://www.pfizer.com/news/press-release/press-release-detail/valneva-and-pfizer-announce-initiation-phase-2-study-lyme,2021-03-08,clinical trial update
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-invites-public-listen-webcast-pfizer-discussion-6,2021-03-04,financial news
U.S. FDA Expands Approval of Pfizer’s LORBRENA® as First-Line Treatment for ALK-Positive Metastatic Lung Cancer,https://www.pfizer.com/news/press-release/press-release-detail/us-fda-expands-approval-pfizers-lorbrenar-first-line,2021-03-03,regulatory approval
Pfizer-BioNTech’s COVID-19 Vaccine Arrives in Rwanda,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-biontechs-covid-19-vaccine-arrives-rwanda,2021-03-03,commercialized drug update
European Medicines Agency Accepts Pfizer’s Marketing Authorization Application for Its Investigational 20-valent Pneumococcal Conjugate Vaccine for Adults 18 Years of Age or Older,https://www.pfizer.com/news/press-release/press-release-detail/european-medicines-agency-accepts-pfizers-marketing,2021-02-26,regulatory approval
EMA Accepts Marketing Application for Somatrogon to Treat Pediatric Patients with Growth Hormone Deficiency,https://www.pfizer.com/news/press-release/press-release-detail/ema-accepts-marketing-application-somatrogon-treat,2021-02-26,regulatory approval
Pfizer Statement on Results of Second Annual Pay Equity Study  Among Colleagues Worldwide,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-statement-results-second-annual-pay-equity-study,2021-02-25,management update
Pfizer and BioNTech Initiate a Study as Part of Broad Development Plan to Evaluate COVID-19 Booster and New Vaccine Variants,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-initiate-study-part-broad-development,2021-02-25,clinical trial update
U.S. FDA Accepts for Priority Review Pfizer’s Application for TicoVac™ (Tick-borne Encephalitis Vaccine),https://www.pfizer.com/news/press-release/press-release-detail/us-fda-accepts-priority-review-pfizers-application,2021-02-23,regulatory approval
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-invites-public-listen-webcast-pfizer-discussion-5,2021-02-22,financial news
President Biden Visits Pfizer’s Kalamazoo Manufacturing Facility,https://www.pfizer.com/news/press-release/press-release-detail/president-biden-visits-pfizers-kalamazoo-manufacturing,2021-02-19,management update
Pfizer and BioNTech Submit COVID-19 Vaccine Stability Data at Standard Freezer Temperature to the U.S. FDA,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-submit-covid-19-vaccine-stability-data,2021-02-19,regulatory approval
Pfizer and BioNTech Commence Global Clinical Trial to Evaluate COVID-19 Vaccine in Pregnant Women,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-commence-global-clinical-trial-evaluate,2021-02-18,clinical trial update
Myovant Sciences and Pfizer Announce Publication in the New England Journal of Medicine of Phase 3 LIBERTY Studies of Once-Daily Relugolix Combination Therapy in Women with Uterine Fibroids,https://www.pfizer.com/news/press-release/press-release-detail/myovant-sciences-and-pfizer-announce-publication-new,2021-02-17,clinical trial update
Imcyse Raises Additional EUR 21.3 Million in Series B Financing Round - Pfizer Joins as Newest Shareholder,https://www.pfizer.com/news/press-release/press-release-detail/imcyse-raises-additional-eur-213-million-series-b-financing,2021-02-17,management update
Pfizer Initiates Pivotal Phase 2 MagnetisMM-3 Trial of BCMA-CD3 Bispecific Antibody Elranatamab (PF-06863135) in Multiple Myeloma,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-initiates-pivotal-phase-2-magnetismm-3-trial-bcma,2021-02-17,clinical trial update
Pfizer and BioNTech to Supply the European Union with 200 Million Additional Doses of COMIRNATY®,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-supply-european-union-200-million,2021-02-17,commercialized drug update
In Vitro Study Published in The New England Journal of Medicine Demonstrates Sera from Individuals Immunized with the Pfizer- BioNTech COVID-19 Vaccine Neutralize SARS-CoV-2 with South African Variant Spike Mutations,https://www.pfizer.com/news/press-release/press-release-detail/vitro-study-published-new-england-journal-medicine,2021-02-17,clinical trial update
U.S. FDA Approves PANZYGA® for the Treatment of Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP),https://www.pfizer.com/news/press-release/press-release-detail/us-fda-approves-panzygar-treatment-adults-chronic,2021-02-12,regulatory approval
Pfizer and BioNTech to Supply the United States with 100 Million Additional Doses of COVID-19 Vaccine,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-supply-united-states-100-million,2021-02-12,commercialized drug update
"Pfizer And Ida Foundation Partner To Expand Access To Essential Cancer Treatments In  70 Low-And Lower-Middle-Income Countries New Partnership Broadens Access To Oncology Treatments Across Latin America, Asia, Africa And The  Western Pacific.",https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-ida-foundation-partner-expand-access-essential-0,2021-02-09,management update
Pfizer and IDA Foundation Partner to Expand Access to Essential Cancer Treatments in 70 Low- and Lower-Middle-Income Countries,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-ida-foundation-partner-expand-access-essential,2021-02-09,management update
Palleon Pharmaceuticals Appoints Nikola Trbovic to its Board of Directors,https://www.pfizer.com/news/press-release/press-release-detail/palleon-pharmaceuticals-appoints-nikola-trbovic-its-board,2021-02-08,management update
Pfizer and BioNTech Publish Data from In Vitro Studies in Nature Medicine Demonstrating COVID-19 Vaccine Elicits Antibodies that Neutralize SARS-CoV-2 with Key Mutations Present in U.K. and South African Variants,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-publish-data-vitro-studies-nature,2021-02-08,clinical trial update
Pfizer Confirms U.S. Patent Term Extension for IBRANCE® (palbociclib) Until March 2027,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-confirms-us-patent-term-extension-ibrancer,2021-02-05,regulatory approval
PFIZER REPORTS FOURTH-QUARTER AND FULL-YEAR 2020 RESULTS AND RELEASES 5-YEAR PIPELINE METRICS,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-reports-fourth-quarter-and-full-year-2020-results,2021-02-02,financial news
Pfizer and BioNTech Publish Preclinical Data from Investigational COVID-19 Vaccine  Program in Nature,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-publish-preclinical-data,2021-02-01,clinical trial update
Pfizer and BioNTech Publish Data on COVID-19 Vaccine-Induced Antibodies’ Ability to Neutralize SARS-CoV-2 U.K. Strain Pseudovirus in Cell Culture in Science,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-publish-data-covid-19-vaccine-induced,2021-01-29,clinical trial update
Pfizer Shares Co-Primary Endpoint Results from Post-Marketing Required Safety Study of XELJANZ® (tofacitinib) in Subjects with Rheumatoid Arthritis (RA),https://www.pfizer.com/news/press-release/press-release-detail/pfizer-shares-co-primary-endpoint-results-post-marketing,2021-01-27,clinical trial update
In Vitro Studies Demonstrate Pfizer and BioNTech COVID-19 Vaccine Elicits Antibodies that Neutralize SARS-CoV-2 with Key Mutations Present in U.K. and South African Variants,https://www.pfizer.com/news/press-release/press-release-detail/vitro-studies-demonstrate-pfizer-and-biontech-covid-19,2021-01-27,clinical trial update
Myovant Sciences and Pfizer Announce Positive One-Year Data from Phase 3 SPIRIT Extension Study of Once-Daily Relugolix Combination Therapy in Women with Endometriosis,https://www.pfizer.com/news/press-release/press-release-detail/myovant-sciences-and-pfizer-announce-positive-one-year-data,2021-01-26,clinical trial update
Statement on ATMI Ranking,https://www.pfizer.com/news/press-release/press-release-detail/statement-atmi-ranking,2021-01-26,management update
European Commission Approves BAVENCIO® (avelumab) for First-Line Maintenance Treatment of Locally Advanced or Metastatic Urothelial Carcinoma,https://www.pfizer.com/news/press-release/press-release-detail/european-commission-approves-bavencior-avelumab-first-line,2021-01-25,regulatory approval
Pfizer and BioNTech Reach Agreement with COVAX for Advance Purchase of Vaccine to Help Combat COVID-19,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-reach-agreement-covax-advance-purchase,2021-01-22,commercialized drug update
Ten Leading BioPharma Companies Announce Formation of Accumulus Synergy to Develop Global Data Sharing Platform,https://www.pfizer.com/news/press-release/press-release-detail/ten-leading-biopharma-companies-announce-formation,2021-01-22,management update
Cerevel Therapeutics Announces the Appointments of Deval Patrick and Deborah Baron to its Board of Directors,https://www.pfizer.com/news/press-release/press-release-detail/cerevel-therapeutics-announces-appointments-deval-patrick,2021-01-21,management update
Pfizer and BioNTech Publish Results of Study Showing COVID-19  Vaccine Elicits Antibodies that Neutralize Pseudovirus Bearing the  SARS-CoV-2 U.K. Strain Spike Protein in Cell Culture,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-publish-results-study-showing-covid-19,2021-01-20,clinical trial update
Statement by Pfizer Chairman and CEO Albert Bourla,https://www.pfizer.com/news/press-release/press-release-detail/statement-pfizer-chairman-and-ceo-albert-bourla,2021-01-15,management update
Statement on European Upscaling as well as Impact on Deliveries,https://www.pfizer.com/news/press-release/press-release-detail/statement-european-upscaling-well-impact-deliveries,2021-01-15,commercialized drug update
Pfizer’s XALKORI® (crizotinib) Approved by FDA for ALK-positive Anaplastic Large Cell Lymphoma in Children and Young Adults,https://www.pfizer.com/news/press-release/press-release-detail/pfizers-xalkorir-crizotinib-approved-fda-alk-positive,2021-01-14,regulatory approval
Vedanta Biosciences Announces $25 Million Investment from Pfizer Inc.,https://www.pfizer.com/news/press-release/press-release-detail/vedanta-biosciences-announces-25-million-investment-pfizer,2021-01-12,management update
Pfizer Invests $120 Million in Biotechnology Innovation Through the Pfizer Breakthrough Growth Initiative,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-invests-120-million-biotechnology-innovation-through,2021-01-12,management update
Codex DNA Signs Early Access Collaboration and Licensing Agreement with Pfizer to FurtherDevelop CodexDNA’s Novel Enzymatic DNA Synthesis Technology for Pfizer’s use in its Research and  Development ofmRNA-based Vaccines and Biotherapies,https://www.pfizer.com/news/press-release/press-release-detail/codex-dna-signs-early-access-collaboration-and-licensing,2021-01-10,management update
An In Vitro Study Shows Pfizer-BioNTech COVID-19 Vaccine Elicits Antibodies that Neutralize SARS-CoV-2 with a Mutation Associated with Rapid Transmission,https://www.pfizer.com/news/press-release/press-release-detail/vitro-study-shows-pfizer-biontech-covid-19-vaccine-elicits,2021-01-08,clinical trial update
Pfizer Doses First Participant in Phase 3 Study for Duchenne Muscular Dystrophy Investigational Gene Therapy,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-doses-first-participant-phase-3-study-duchenne,2021-01-07,clinical trial update
Pfizer Invites Public to Listen to Two Webcasts of Pfizer Discussions at Healthcare Conference,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-invites-public-listen-two-webcasts-pfizer,2021-01-05,financial news
US FDA Accepts Regulatory Submission from Pfizer and OPKO for Review of Somatrogon to Treat Pediatric Patients with Growth Hormone Deficiency,https://www.pfizer.com/news/press-release/press-release-detail/us-fda-accepts-regulatory-submission-pfizer-and-opko-review,2021-01-04,regulatory approval
Pfizer and BioNTech to Supply the European Union with 100 Million Additional Doses of COMIRNATY®,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-supply-european-union-100-million,2020-12-29,commercialized drug update
LORBRENA® (lorlatinib) sNDA in Previously Untreated ALK-Positive Lung Cancer Accepted for Priority Review by U.S. FDA,https://www.pfizer.com/news/press-release/press-release-detail/lorbrenar-lorlatinib-snda-previously-untreated-alk-positive,2020-12-28,regulatory approval
Myovant Sciences and Pfizer Announce Collaboration to Develop and Commercialize Relugolix in Oncology and Women's Health,https://www.pfizer.com/news/press-release/press-release-detail/myovant-sciences-and-pfizer-announce-collaboration-develop,2020-12-28,management update
Pfizer and BioNTech to Supply the U.S. with 100 Million Additional Doses of COVID-19 Vaccine,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-supply-us-100-million-additional-doses,2020-12-23,commercialized drug update
Pfizer Invites Public to View and Listen to Webcast of February 2 Conference Call with Analysts,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-invites-public-view-and-listen-webcast-february-2,2020-12-22,financial news
Pfizer and BioNTech Receive Authorization in the European Union for COVID-19 Vaccine,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-receive-authorization-european-union,2020-12-21,regulatory approval
Pfizer and BioNTech Receive CHMP Positive Opinion for their COVID-19 Vaccine,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-receive-chmp-positive-opinion-their,2020-12-21,regulatory approval
Pfizer COVID-19 Vaccine Production and Distribution Working Well,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-covid-19-vaccine-production-and-distribution-working,2020-12-17,commercialized drug update
Pfizer Doses First Participants as Part of Global Achondroplasia Phase 2 Development Program,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-doses-first-participants-part-global-achondroplasia,2020-12-15,clinical trial update
Pfizer and BioNTech Provide Data from German Phase 1/2 Study Further Characterizing Immune Response Following Immunization with Lead COVID-19 Vaccine Candidate BNT162b2,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-provide-data-german-phase-12-study,2020-12-14,clinical trial update
U.S. CDC Committee of Independent Health Experts Recommends Vaccination with Pfizer and BioNTech COVID-19 Vaccine for Persons Ages 16 Years and Older,https://www.pfizer.com/news/press-release/press-release-detail/us-cdc-committee-independent-health-experts-recommends,2020-12-12,regulatory approval
Pfizer and BioNTech Celebrate Historic First Authorization in the U.S. of Vaccine to Prevent COVID-19,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-celebrate-historic-first-authorization,2020-12-11,regulatory approval
BAVENCIO® (avelumab) Receives Positive CHMP Opinion for First-Line Maintenance Treatment of Locally Advanced or Metastatic Urothelial Carcinoma,https://www.pfizer.com/news/press-release/press-release-detail/bavencior-avelumab-receives-positive-chmp-opinion-first-0,2020-12-11,regulatory approval
BAVENCIO® (avelumab) Receives Positive CHMP Opinion for First-Line Maintenance Treatment of Locally Advanced or Metastatic Urothelial Carcinoma,https://www.pfizer.com/news/press-release/press-release-detail/bavencior-avelumab-receives-positive-chmp-opinion-first,2020-12-11,regulatory approval
Pfizer Declares First-Quarter 2021 Dividend,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-declares-first-quarter-2021-dividend,2020-12-11,financial news
Pfizer and BioNTech Receive FDA Advisory Committee Vote Supporting Potential First Emergency Use Authorization for Vaccine to Combat COVID-19 in the U.S.,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-receive-fda-advisory-committee-vote,2020-12-10,regulatory approval
Pfizer and BioNTech Announce Publication of Results from Landmark Phase 3 Trial of BNT162b2 COVID-19 Vaccine Candidate in The New England Journal of Medicine,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-announce-publication-results-landmark,2020-12-10,clinical trial update
Statement on EMA Cyberattack,https://www.pfizer.com/news/press-release/press-release-detail/statement-ema-cyberattack,2020-12-09,management update
U.S. FDA Accepts for Priority Review the Biologics License Application for Pfizer’s Investigational 20-valent Pneumococcal Conjugate Vaccine for Adults 18 Years of Age and Older,https://www.pfizer.com/news/press-release/press-release-detail/us-fda-accepts-priority-review-biologics-license,2020-12-08,regulatory approval
PostEra enters a multi-year strategic partnership with Pfizer Inc. to advance machine  learning for Drug Discovery,https://www.pfizer.com/news/press-release/press-release-detail/postera-enters-multi-year-strategic-partnership-pfizer-inc,2020-12-07,management update
Pfizer Reports Positive Clinical Data for BCMA-CD3 Bispecific Antibody (PF-06863135) in Multiple Myeloma,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-reports-positive-clinical-data-bcma-cd3-bispecific,2020-12-07,clinical trial update
Pfizer and Sangamo Announce Updated Phase 1/2 Results Showing Sustained Factor VIII Activity Levels in 3x10¹³ VG/KG Cohort Through One Year Following Hemophilia A Gene Therapy,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-sangamo-announce-updated-phase-12-results-0,2020-12-07,clinical trial update
Pfizer and BioNTech Achieve First Authorization in the World for a Vaccine to Combat COVID-19,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-achieve-first-authorization-world,2020-12-02,regulatory approval
Pfizer and BioNTech Submitted Application for Conditional Marketing Authorization for COVID-19 Vaccine to the EMA,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-submitted-application-conditional-0,2020-12-01,regulatory approval
Pfizer and BioNTech Submitted Application for Conditional Marketing  Authorization for COVID-19 Vaccine to the EMA,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-submitted-application-conditional,2020-12-01,regulatory approval
"Pfizer Doses First Participant in Phase 3 Study Evaluating anti-TFPI Investigational Therapy, Marstacimab, for People With Severe Hemophilia A and B With or Without Inhibitors",https://www.pfizer.com/news/press-release/press-release-detail/pfizer-doses-first-participant-phase-3-study-evaluating,2020-11-23,clinical trial update
"Pfizer Receives European Approval for Oncology Supportive Care Biosimilar, NYVEPRIATM (pegfilgrastim)",https://www.pfizer.com/news/press-release/press-release-detail/pfizer-receives-european-approval-oncology-supportive-care,2020-11-20,regulatory approval
Pfizer and BioNTech to Submit Emergency Use Authorization Request Today to the U.S. FDA for COVID-19 Vaccine,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-submit-emergency-use-authorization,2020-11-20,regulatory approval
Pfizer and LianBio Announce Strategic Collaboration to Expand Development of Novel Therapeutics in Greater China,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-lianbio-announce-strategic-collaboration-expand,2020-11-19,management update
Results from Phase 3 CROWN Trial of Pfizer’s LORBRENA® (lorlatinib) in Previously Untreated ALK-Positive Lung Cancer Published in the New England Journal of Medicine,https://www.pfizer.com/news/press-release/press-release-detail/results-phase-3-crown-trial-pfizers-lorbrenar-lorlatinib,2020-11-19,clinical trial update
"Pfizer and BioNTech Conclude Phase 3 Study of COVID-19 Vaccine Candidate, Meeting All Primary Efficacy Endpoints",https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-conclude-phase-3-study-covid-19-vaccine,2020-11-18,clinical trial update
PFIZER UPDATE ON OUR U.S. COVID-19 VACCINE CANDIDATE  DISTRIBUTION PREPAREDNESS,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-update-our-us-covid-19-vaccine-candidate-0,2020-11-16,commercialized drug update
Pfizer Update On Our U.S. COVID-19 Vaccine Candidate Distribution Preparedness,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-update-our-us-covid-19-vaccine-candidate,2020-11-16,commercialized drug update
Pfizer Completes Transaction to Combine Its Upjohn Business with Mylan,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-completes-transaction-combine-its-upjohn-business,2020-11-16,management update
Analysis from Phase 3 ATTR-ACT and Its Long-Term Extension Study Demonstrates VYNDAQEL® 80 mg/VYNDAMAX® 61 mg Significantly Improved Survival in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Compared to VYNDAQEL 20 mg,https://www.pfizer.com/news/press-release/press-release-detail/analysis-phase-3-attr-act-and-its-long-term-extension-study,2020-11-12,clinical trial update
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-invites-public-listen-webcast-pfizer-discussion-4,2020-11-11,financial news
"Pfizer Announces Positive Results from Fifth Phase 3 Trial of Abrocitinib, Evaluating Safety and Efficacy Across Different Dosing Regimens",https://www.pfizer.com/news/press-release/press-release-detail/pfizer-announces-positive-results-fifth-phase-3-trial,2020-11-11,clinical trial update
Pfizer and BioNTech Reach an Agreement to Supply the EU With 200 Million Doses of Their BNT162b2 mRNA-Based Vaccine Candidate Against SARS-CoV-2,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-reach-agreement-supply-eu-200-million,2020-11-11,commercialized drug update
Pfizer Statement on Geodon (ziprasidone) Trial Closure in the  United States,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-statement-geodon-ziprasidone-trial-closure-united,2020-11-10,clinical trial update
Homology Medicines Announces $60 Million Equity Investment from Pfizer Inc.,https://www.pfizer.com/news/press-release/press-release-detail/homology-medicines-announces-60-million-equity-investment,2020-11-09,financial news
Pfizer and BioNTech Announce Vaccine Candidate Against COVID-19 Achieved Success in First Interim Analysis from Phase 3 Study,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-announce-vaccine-candidate-against,2020-11-09,clinical trial update
Pfizer Announces Positive Phase 3 Study Results for XELJANZ ® (tofacitinib) in Ankylosing Spondylitis (AS),https://www.pfizer.com/news/press-release/press-release-detail/pfizer-announces-positive-phase-3-study-results-xeljanz-r,2020-11-06,clinical trial update
Pfizer Announces Details for When-Issued and Ex-Distribution Trading of Viatris and Pfizer Common Stock,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-announces-details-when-issued-and-ex-distribution,2020-11-05,financial news
Mylan and Pfizer Receive Clearance from the U.S. Federal Trade Commission for Proposed Combination of Mylan and Upjohn,https://www.pfizer.com/news/press-release/press-release-detail/mylan-and-pfizer-receive-clearance-us-federal-trade,2020-10-30,management update
New Report Identifies Need for More Effective Policy Responses and Investment to Prevent Strokes in Europe,https://www.pfizer.com/news/press-release/press-release-detail/new-report-identifies-need-more-effective-policy-responses,2020-10-29,medicines
"FDA Grants Priority Review and EMA Accepts Regulatory Submission for Pfizer’s Abrocitinib, an Oral Once-Daily JAK1 Inhibitor, for Patients 12 and Up with Moderate to Severe Atopic Dermatitis",https://www.pfizer.com/news/press-release/press-release-detail/fda-grants-priority-review-and-ema-accepts-regulatory,2020-10-27,research
PFIZER REPORTS THIRD-QUARTER 2020 RESULTS,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-reports-third-quarter-2020-results,2020-10-27,finance
Data From Pfizer’s Adult and Pediatric Clinical Trial Programs for 20-Valent Pneumococcal Conjugate Vaccine Presented at IDWeek 2020,https://www.pfizer.com/news/press-release/press-release-detail/data-pfizers-adult-and-pediatric-clinical-trial-programs-20,2020-10-21,clinical trial update
Pfizer and BioNTech Announce New England Journal of Medicine Publication of Phase 1 Data on Lead mRNA Vaccine Candidate  BNT162b2 Against COVID-19,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-announce-new-england-journal-medicine,2020-10-14,clinical trial update
PENELOPE-B Trial of IBRANCE® (palbociclib) in Early Breast Cancer Did Not Meet Primary Endpoint,https://www.pfizer.com/news/press-release/press-release-detail/penelope-b-trial-ibrancer-palbociclib-early-breast-cancer,2020-10-09,clinical trial update
Pfizer Announces Positive Phase 3 Top-line Results for Once-Weekly Investigational Long-Acting Human Growth Hormone to Treat Children with Growth Hormone Deficiency,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-announces-positive-phase-3-top-line-results-once,2020-10-08,research
Pfizer and Sangamo Dose First Participant in Phase 3 Study Evaluating Hemophilia A Gene Therapy Treatment,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-sangamo-dose-first-participant-phase-3-study,2020-10-07,clinical trial update
BioNTech and Pfizer Initiate Rolling Submission to European Medicines Agency for SARS-CoV-2 Vaccine Candidate BNT162b2,https://www.pfizer.com/news/press-release/press-release-detail/biontech-and-pfizer-initiate-rolling-submission-european,2020-10-06,clinical trial update
SpringWorks Therapeutics Announces Clinical Collaboration with PfizerInc. to  Evaluate Nirogacestat in Combination with PF‐06863135 in Patients with Relapsed  or Refractory Multiple Myeloma,https://www.pfizer.com/news/press-release/press-release-detail/springworks-therapeutics-announces-clinical-collaboration,2020-10-05,clinical trial update
Pfizer Receives FDA Fast Track Designation for Duchenne Muscular Dystrophy Investigational Gene Therapy,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-receives-fda-fast-track-designation-duchenne,2020-10-01,research
BioNTech and Pfizer Announce Nature Publication of German Phase 1/2 Study Data from mRNA-based Vaccine Candidate BNT162b1 Against SARS-CoV-2,https://www.pfizer.com/news/press-release/press-release-detail/biontech-and-pfizer-announce-nature-publication-german,2020-09-30,clinical trial update
U.S. FDA Approves Pfizer’s XELJANZ® (tofacitinib) for the Treatment of Active Polyarticular Course Juvenile Idiopathic Arthritis,https://www.pfizer.com/news/press-release/press-release-detail/us-fda-approves-pfizers-xeljanzr-tofacitinib-treatment,2020-09-28,regulatory approval
Pfizer Declares Fourth-Quarter 2020 Dividend,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-declares-fourth-quarter-2020-dividend,2020-09-24,financial news
Vivet Therapeutics and Pfizer Inc. Enter into Manufacturing Agreement for Vivet’s  Investigational Gene Therapy for Wilson Disease,https://www.pfizer.com/news/press-release/press-release-detail/vivet-therapeutics-and-pfizer-inc-enter-manufacturing,2020-09-23,research
FDA Accepts Supplemental New Drug Application for Pfizer’s XALKORI® (crizotinib) for the Treatment of Pediatric ALK-positive Anaplastic Large Cell Lymphoma,https://www.pfizer.com/news/press-release/press-release-detail/fda-accepts-supplemental-new-drug-application-pfizers,2020-09-23,regulatory approval
Pfizer Invites Public to View and Listen to Webcast of October 27 Conference Call with Analysts,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-invites-public-view-and-listen-webcast-october-27,2020-09-22,financial news
Javelin Biotech Aims to Develop Industry-Leading “Organ-on-a-Chip” Predictive  Pharmacokinetics Platform in Collaboration with Pfizer Inc.,https://www.pfizer.com/news/press-release/press-release-detail/javelin-biotech-aims-develop-industry-leading-organ-chip,2020-09-22,research
BAVENCIO Pivotal Phase III JAVELIN Bladder 100 Results Published in The New England Journal of Medicine,https://www.pfizer.com/news/press-release/press-release-detail/bavencio-pivotal-phase-iii-javelin-bladder-100-results,2020-09-18,clinical trial update
Pfizer Investor Day Features Significant Number of Pipeline Advances for COVID-19 Programs and Across Numerous Therapeutic Areas,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-investor-day-features-significant-number-pipeline,2020-09-15,research
Pfizer Hosts Virtual Investor Day,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-hosts-virtual-investor-day,2020-09-14,financial news
Pfizer and BioNTech Propose Expansion of Pivotal COVID-19 Vaccine Trial,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-propose-expansion-pivotal-covid-19,2020-09-12,clinical trial update
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-invites-public-listen-webcast-pfizer-discussion-3,2020-09-11,financial news
Pfizer to Present Latest Scientific Advancements from Its Industry-Leading Portfolio at the ESMO Virtual Congress 2020,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-present-latest-scientific-advancements-its-industry,2020-09-10,research
Pfizer and BioNTech Announce Data from Preclinical Studies of mRNA-based Vaccine Candidate Against COVID-19,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-announce-data-preclinical-studies-mrna,2020-09-09,research
Pfizer and BioNTech to Potentially Supply the EU with 200 Million Doses of mRNA-based Vaccine Candidate Against SARS-CoV-2,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-potentially-supply-eu-200-million-doses,2020-09-09,research
Biopharma Leaders Unite To Stand With Science,https://www.pfizer.com/news/press-release/press-release-detail/biopharma-leaders-unite-stand-science,2020-09-08,research
"Pfizer Invites Public to Register for Webcast of Virtual Investor Day on September 14 and 15, 2020",https://www.pfizer.com/news/press-release/press-release-detail/pfizer-invites-public-register-webcast-virtual-investor-day,2020-09-03,financial news
Pfizer and BioNTech Share Positive Early Data on Lead mRNA Vaccine Candidate BNT162b2 Against COVID-19,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-share-positive-early-data-lead-mrna,2020-08-20,clinical trial update
Pfizer Statement on Lyrica (Pregabalin) Patent Infringement  in Japan,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-statement-lyrica-pregabalin-patent-infringement,2020-08-17,medicines
"Pfizer and BioNTech Announce Publication of Peer-Reviewed Data from Ongoing Phase 1/2 study of mRNA-based Vaccine Candidate, BNT162b1, Against SARSCoV-2 in Nature",https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-announce-publication-peer-reviewed-data,2020-08-12,clinical trial update
Pfizer Announces Agreement with Gilead to Manufacture Remdesivir for Treatment of COVID-19,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-announces-agreement-gilead-manufacture-remdesivir,2020-08-07,research
"Pfizer Announces Times for Rescheduled Virtual Investor Day on September 14 and September 15, 2020",https://www.pfizer.com/news/press-release/press-release-detail/pfizer-announces-times-rescheduled-virtual-investor-day,2020-08-06,financial news
Pfizer signs on to The Hispanic Promise further strengthening its ties and commitment to Hispanics in the workplace,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-signs-hispanic-promise-further-strengthening-its,2020-08-06,management update
"The Bristol-Myers Squibb-Pfizer Alliance is pleased with the U.S. District Court decision to uphold both the composition of matter (COM) patent (US 6,967,208) and formulation patent (US 9,326,945) covering Eliquis®.",https://www.pfizer.com/news/press-release/press-release-detail/bristol-myers-squibb-pfizer-alliance-pleased-us-district,2020-08-05,medicines
Pfizer and BioNTech to Supply Canada with their BNT162 mRNA- Based Vaccine Candidate,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-supply-canada-their-bnt162-mrna-based,2020-08-05,research
LORBRENA® (lorlatinib) Significantly Improves Progression-Free Survival in First-Line ALK-Positive Lung Cancer,https://www.pfizer.com/news/press-release/press-release-detail/lorbrenar-lorlatinib-significantly-improves-progression,2020-08-05,clinical trial update
Pfizer and BioNTech to Supply Japan with 120 Million Doses of their BNT162 mRNA-based Vaccine Candidate,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-supply-japan-120-million-doses-their,2020-07-31,research
Pfizer Reports Second-Quarter 2020 Results,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-reports-second-quarter-2020-results,2020-07-28,financial news
Pfizer and BioNTech Choose Lead mRNA Vaccine Candidate Against COVID-19 and Commence Pivotal Phase 2/3 Global Study,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-choose-lead-mrna-vaccine-candidate,2020-07-27,clinical trial update
Pfizer Shares Pre-Clinical Data Updates on COVID-19 Antiviral Research Program,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-shares-pre-clinical-data-updates-covid-19-antiviral,2020-07-22,research
Pfizer and BioNTech Announce an Agreement with U.S. Government for up to 600 Million Doses of mRNA-based Vaccine Candidate Against SARS-CoV-2,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-announce-agreement-us-government-600,2020-07-22,research
"Pfizer and BioNTech Announce Early Positive Update from German Phase 1/2 COVID-19 Vaccine Study, Including First T Cell Response Data",https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-announce-early-positive-update-german,2020-07-20,clinical trial update
Pfizer and BioNTech Announce Agreement with the United Kingdom for 30 Million Doses of mRNA-based Vaccine Candidate against SARS-CoV-2,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-announce-agreement-united-kingdom-30,2020-07-20,research
Pfizer and BioNTech Granted FDA Fast Track Designation for Two Investigational mRNA-based Vaccine Candidates Against SARS-CoV-2,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-granted-fda-fast-track-designation-two,2020-07-13,research
Pfizer Pledges $100 Million to New Industry Fund to Help Fight Growing Threat of Antimicrobial Resistance,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-pledges-100-million-new-industry-fund-help-fight,2020-07-09,research
Pfizer and BioNTech Announce Early Positive Data from an Ongoing Phase 1/2 study of mRNA-based Vaccine Candidate Against SARS-CoV-2,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-announce-early-positive-data-ongoing,2020-07-01,clinical trial update
FDA Approves BAVENCIO as First-Line Maintenance Treatment for Patients with Locally Advanced or Metastatic Urothelial Carcinoma,https://www.pfizer.com/news/press-release/press-release-detail/fda-approves-bavencio-first-line-maintenance-treatment,2020-06-30,regulatory approval
European Commission Approves DAURISMO™ (glasdegib) for Certain Adult Patients with Newly Diagnosed Acute Myeloid Leukemia (AML),https://www.pfizer.com/news/press-release/press-release-detail/european-commission-approves-daurismotm-glasdegib-certain,2020-06-30,regulatory approval
Pfizer Statement on Facebook Advertising Boycott,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-statement-facebook-advertising-boycott,2020-06-29,management update
Pfizer Declares Third-Quarter 2020 Dividend,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-declares-third-quarter-2020-dividend,2020-06-25,financial news
Pfizer and Wellcome Launch Surveillance Program to Combat Growing Threat of Antimicrobial Resistance in Sub-Saharan Africa,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-wellcome-launch-surveillance-program-combat,2020-06-24,clinical trial update
NEW DATA ON THE BURDEN OF EMERGING S. PNEUMONIAE SEROTYPES  PUBLISHED IN ISPPD 2020 ONLINE DIGITAL LIBRARY,https://www.pfizer.com/news/press-release/press-release-detail/new-data-burden-emerging-s-pneumoniae-serotypes-published,2020-06-23,clinical trial update
European Medicines Agency Validates Application for BAVENCIO® (avelumab) for First-Line Maintenance Treatment of Locally Advanced or Metastatic Urothelial Carcinoma,https://www.pfizer.com/news/press-release/press-release-detail/european-medicines-agency-validates-application-bavencior,2020-06-22,regulatory approval
Pfizer Announces Start of Four Phase 3 Clinical Trials for Investigational Vaccines,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-announces-start-four-phase-3-clinical-trials,2020-06-22,clinical trial update
European Medicines Agency Validates Application for BAVENCIO® (avelumab) for First-Line Maintenance Treatment of Locally Advanced or Metastatic Urothelial Carcinoma,https://www.pfizer.com/news/press-release/press-release-detail/european-medicines-agency-validates-application-bavencior-0,2020-06-22,regulatory approval
Pfizer and Sangamo Announce Updated Phase 1/2 Results Showing Sustained Factor VIII Activity Levels and No Bleeding Events or Factor Usage in 3e13 vg/kg Cohort Following giroctocogene fitelparvovec (SB-525) Gene Therapy,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-sangamo-announce-updated-phase-12-results,2020-06-18,clinical trial update
Upjohn Announces Pricing of Senior Notes in Connection with the Proposed Combination of Mylan and Upjohn,https://www.pfizer.com/news/press-release/press-release-detail/upjohn-announces-pricing-senior-notes-connection-proposed,2020-06-18,financial news
Merck and Pfizer’s SGLT2 Inhibitor STEGLATROTM (ertugliflozin) Meets Primary  Endpoint in VERTIS CV Trial for Patients with Type 2 Diabetes and  Atherosclerotic Cardiovascular Disease,https://www.pfizer.com/news/press-release/press-release-detail/merck-and-pfizers-sglt2-inhibitor-steglatrotm-ertugliflozin,2020-06-16,clinical trial update
Pfizer Invites Public to View and Listen to Webcast of July 28 Conference Call with Analysts,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-invites-public-view-and-listen-webcast-july-28,2020-06-16,financial news
Pfizer Invites Public to View and Listen to Webcast of June 18 Conference Call with Analysts to Review Data Presentations at Scientific Conferences during the Week of June 15th,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-invites-public-view-and-listen-webcast-june-18,2020-06-12,financial news
"FDA Approves Pfizer’s Oncology Supportive Care Biosimilar, NYVEPRIA™ (pegfilgrastim-apgf)",https://www.pfizer.com/news/press-release/press-release-detail/fda-approves-pfizers-oncology-supportive-care-biosimilar,2020-06-11,regulatory approval
Pfizer Announces Positive Top-Line Results from JADE TEEN Trial of Abrocitinib in Adolescents with Moderate-to-Severe Atopic Dermatitis,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-announces-positive-top-line-results-jade-teen-trial,2020-06-10,clinical trial update
Complete Results from Second Pivotal Monotherapy Study of Abrocitinib Published in JAMA Dermatology,https://www.pfizer.com/news/press-release/press-release-detail/complete-results-second-pivotal-monotherapy-study,2020-06-03,clinical trial update
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-invites-public-listen-webcast-pfizer-discussion-2,2020-06-02,financial news
Pfizer Establishes New Program to Support Continued Biotechnology Innovation,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-establishes-new-program-support-continued,2020-06-02,management update
"Pfizer Provides Update on Phase 3 PALLAS Trial of IBRANCE® (palbociclib) Plus Endocrine Therapy in HR+, HER2- Early Breast Cancer",https://www.pfizer.com/news/press-release/press-release-detail/pfizer-provides-update-phase-3-pallas-trial-ibrancer,2020-05-29,clinical trial update
Final PROSPER Results Show XTANDI® (enzalutamide) Significantly Extends Overall Survival in Men with Non-Metastatic Castration-Resistant Prostate Cancer,https://www.pfizer.com/news/press-release/press-release-detail/final-prosper-results-show-xtandir-enzalutamide,2020-05-29,clinical trial update
Corning and Pfizer Announce Supply Agreement for Corning Valor® Glass  Packaging,https://www.pfizer.com/news/press-release/press-release-detail/corning-and-pfizer-announce-supply-agreement-corning-0,2020-05-28,management update
Corning and Pfizer Announce Supply Agreement for Corning Valor® Glass Packaging,https://www.pfizer.com/news/press-release/press-release-detail/corning-and-pfizer-announce-supply-agreement-corning-valorr,2020-05-28,management update
"Pfizer Inc. Recommends Rejection of Unsolicited Note Tender Offer by Huguenot Bond Liquidity, LLC",https://www.pfizer.com/news/press-release/press-release-detail/pfizer-inc-recommends-rejection-unsolicited-note-tender,2020-05-22,financial news
"Pfizer Prices $4,000,000,000 Debt Offering",https://www.pfizer.com/news/press-release/press-release-detail/pfizer-prices-4000000000-debt-offering,2020-05-18,financial news
Pfizer’s New Phase 1b Results of Gene Therapy in Ambulatory Boys with Duchenne Muscular Dystrophy (DMD) Support Advancement into Pivotal Phase 3 Study,https://www.pfizer.com/news/press-release/press-release-detail/pfizers-new-phase-1b-results-gene-therapy-ambulatory-boys,2020-05-15,clinical trial update
Pfizer Announces Positive Top-Line Results From Phase 3 Lot Consistency Study of 20-Valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-Naive Adults 18 Through 49 Years of Age,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-announces-positive-top-line-results-phase-3-lot,2020-05-14,clinical trial update
"Save the Date: Pfizer Announces New Date of September 14, 2020 for Rescheduled Investor Day",https://www.pfizer.com/news/press-release/press-release-detail/save-date-pfizer-announces-new-date-september-14-2020,2020-05-13,financial news
New Data from 18 Approved and Investigational Pfizer Medicines to be Showcased at ASCO20 Virtual Scientific Program,https://www.pfizer.com/news/press-release/press-release-detail/new-data-18-approved-and-investigational-pfizer-medicines,2020-05-12,clinical trial update
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-invites-public-listen-webcast-pfizer-discussion-1,2020-05-12,financial news
Pfizer Invites Public to View and Listen to Webcast of May 15 Conference Call with Analysts to Review Duchenne Muscular Dystrophy (DMD) Data Presentation at ASGCT 2020 Annual Meeting,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-invites-public-view-and-listen-webcast-may-15,2020-05-08,financial news
Pfizer and BioNTech Dose First Participants in the U.S. as Part of Global COVID-19 mRNA Vaccine Development Program,https://www.pfizer.com/news/press-release/press-release-detail/pfizer_and_biontech_dose_first-participants_in_the_u_s_as_part_of_global_covid_19_mrna_vaccine_development_program,2020-05-05,clinical trial update
New Data Suggest Burden of Group B Streptococcus (GBS) Infection in U.S. Adults Greater Than Previously Recognized,https://www.pfizer.com/news/press-release/press-release-detail/new-data-suggest-burden-group-b-streptococcus-gbs-infection,2020-05-04,clinical trial update
Pfizer Receives Positive CHMP Opinion for DAURISMO®(glasdegib)for Certain Adult Patients with Newly Diagnosed or Secondary Acute Myeloid Leukemia (AML),https://www.pfizer.com/news/press-release/press-release-detail/pfizer-receives-positive-chmp-opinion-daurismorglasdegibfor,2020-05-01,regulatory approval
Pfizer Receives Positive CHMP Opinion for DAURISMOTM (glasdegib)for  Certain Adult Patients with Newly Diagnosed Acute Myeloid Leukemia  (AML),https://www.pfizer.com/news/press-release/press-release-detail/pfizer-receives-positive-chmp-opinion-daurismotm,2020-05-01,regulatory approval
"Valneva and Pfizer Announce Collaboration to Co-Develop and Commercialize Lyme Disease Vaccine, VLA15",https://www.pfizer.com/news/press-release/press-release-detail/valneva_and_pfizer_announce_collaboration_to_co_develop_and_commercialize_lyme_disease_vaccine_vla15,2020-04-30,clinical trial update
AMRA Medical renews collaboration with Pfizer Inc.  aiming to generate the world’s  largest imaging dataset on body  composition profiling,https://www.pfizer.com/news/press-release/press-release-detail/amra-medical-renews-collaboration-pfizer-inc-aiming,2020-04-30,management update
BioNTech and Pfizer announce completion of dosing for first cohort of Phase 1/2 trial of COVID-19 vaccine candidates in Germany,https://www.pfizer.com/news/press-release/press-release-detail/biontech-and-pfizer-announce-completion-dosing-first-cohort,2020-04-29,clinical trial update
PFIZER REPORTS FIRST-QUARTER 2020 RESULTS,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-reports-first-quarter-2020-results,2020-04-28,financial news
Pfizer Hosts Virtual-Only Annual Meeting of Shareholders,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-hosts-virtual-only-annual-meeting-shareholders,2020-04-23,management update
FoRx Therapeutics AG Raises EUR 10 Million Seed Round to Develop a Pipeline  of Drugs Targeting DNA Replication Stress for Cancer,https://www.pfizer.com/news/press-release/press-release-detail/forx-therapeutics-ag-raises-eur-10-million-seed-round,2020-04-22,management update
BioNTech and Pfizer announce regulatory approval from German authority Paul-Ehrlich-Institut to commence first clinical trial of COVID-19 vaccine candidates,https://www.pfizer.com/news/press-release/press-release-detail/biontech_and_pfizer_announce_regulatory_approval_from_german_authority_paul_ehrlich_institut_to_commence_first_clinical_trial_of_covid_19_vaccine_candidates,2020-04-22,clinical trial update
Valneva Receives FDA Fast Track Designation for its Lyme Disease  Vaccine Candidate VLA15,https://www.pfizer.com/news/press-release/press-release-detail/valneva-receives-fda-fast-track-designation-its-lyme,2020-04-20,regulatory approval
Pfizer and BioNTech Announce Further Details on Collaboration to Accelerate Global COVID-19 Vaccine Development,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-announce-further-details-collaboration,2020-04-09,clinical trial update
Pfizer Advances Battle Against COVID-19 on Multiple Fronts,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-advances-battle-against-covid-19-multiple-fronts,2020-04-09,clinical trial update
EMD Serono and Pfizer Receive US FDA Breakthrough Therapy Designation and Submit Application for BAVENCIO® for First-Line Maintenance Treatment of Locally Advanced or Metastatic Urothelial Carcinoma,https://www.pfizer.com/news/press-release/press-release-detail/emd_serono_and_pfizer_receive_us_fda_breakthrough_therapy_designation_and_submit_application_for_bavencio_for_first_line_maintenance_treatment_of_locally_advanced_or_metastatic_urothelial_carcinoma,2020-04-09,regulatory approval
U.S. FDA Approves BRAFTOVI® (Encorafenib) in Combination with Cetuximab for the Treatment of BRAFV600E-Mutant Metastatic Colorectal Cancer (CRC) After Prior Therapy,https://www.pfizer.com/news/press-release/press-release-detail/us-fda-approves-braftovir-encorafenib-combination-cetuximab,2020-04-08,regulatory approval
Pfizer to Hold Virtual-Only 2020 Annual Meeting of Shareholders,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-hold-virtual-only-2020-annual-meeting-shareholders,2020-04-07,management update
"Pfizer and The Pfizer Foundation Donate $40 Million in Charitable Grants, Expand Product Access and Mobilize Colleagues to Combat COVID-19 Pandemic",https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-pfizer-foundation-donate-40-million-charitable,2020-04-06,management update
"Pfizer Receives European Approval for Oncology Biosimilar, RUXIENCE™ (rituximab)",https://www.pfizer.com/news/press-release/press-release-detail/pfizer-receives-european-approval-oncology-biosimilar,2020-04-02,regulatory approval
Susan Desmond-Hellmann Elected to Pfizer’s Board of Directors,https://www.pfizer.com/news/press-release/press-release-detail/susan-desmond-hellmann-elected-pfizers-board-directors,2020-04-02,management update
"Medical Professionals Across Merck & Co., Inc., Pfizer Inc., and Eli Lilly and Company Activate to Support Health Systems, First Responders and Patients Amid COVID-19 Pandemic",https://www.pfizer.com/news/press-release/press-release-detail/medical-professionals-across-merck-co-inc-pfizer-inc-and,2020-04-01,covid-19
Pfizer Completes $1.25 Billion Sustainability Bond for Social and Environmental Impact,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-completes-125-billion-sustainability-bond-social-and,2020-03-27,social responsibility
Mylan and Pfizer Provide Update Regarding Proposed Combination of Mylan and Upjohn,https://www.pfizer.com/news/press-release/press-release-detail/mylan-and-pfizer-provide-update-regarding-proposed,2020-03-26,financial news
"U.S. FDA Approves Supplemental New Drug Application (sNDA) for Expanded Indication of EUCRISA® (Crisaborole) Ointment, 2%, in Children as Young as 3 Months of Age With Mild-to-Moderate Atopic Dermatitis",https://www.pfizer.com/news/press-release/press-release-detail/us-fda-approves-supplemental-new-drug-application-snda,2020-03-24,regulatory approval
"Pfizer Announces Positive Top-Line Results from Third Phase 3 Trial of Abrocitinib for Moderate to Severe Atopic Dermatitis, Which Showed Improvements in Skin Clearance, Disease Extent and Severity, and Itch",https://www.pfizer.com/news/press-release/press-release-detail/pfizer-announces-positive-top-line-results-third-phase-3,2020-03-18,clinical trial update
Pfizer Announces Top-Line Results from Phase 3 Study of 20-Valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-Naïve Adults Aged 18 Years or Older,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-announces-top-line-results-phase-3-study-20-valent,2020-03-18,clinical trial update
"Pfizer Postpones Investor Day Scheduled for March 31, 2020 Due to Coronavirus Concerns",https://www.pfizer.com/news/press-release/press-release-detail/pfizer_postpones_investor_day_scheduled_for_march_31_2020_due_to_coronavirus_concerns,2020-03-18,financial news
"Pfizer Announces Positive Top-Line Results from Third Phase 3 Trial of Abrocitinib for Moderate to Severe Atopic Dermatitis, Which Showed Improvements in Skin Clearance, Disease Extent and Severity, and Itch",https://www.pfizer.com/news/press-release/press-release-detail/pfizer_announces_positive_top_line_results_from_third_phase_3_trial_of_abrocitinib_for_moderate_to_severe_atopic_dermatitis_which_showed_improvements_in_skin_clearance_disease_extent_and_severity_and_itch,2020-03-18,clinical trial update
Pfizer Invites Public to View and Listen to Webcast of April 28 Conference Call with Analysts,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-invites-public-view-and-listen-webcast-april-28,2020-03-17,financial news
Pfizer and BioNTech to Co-develop Potential COVID-19 Vaccine,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-co-develop-potential-covid-19-vaccine-0,2020-03-17,covid-19
Pfizer and BioNTech to Co-Develop Potential COVID-19 Vaccine,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-co-develop-potential-covid-19-vaccine,2020-03-17,covid-19
Pfizer Outlines Five-Point Plan to Battle COVID-19,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-outlines-five-point-plan-battle-covid-19,2020-03-13,covid-19
EMD Serono and Pfizer Provide Update on Phase III JAVELIN Head and Neck 100 Study,https://www.pfizer.com/news/press-release/press-release-detail/emd_serono-and-pfizer-provide-update-on-phase-iii-javelin-head-and-neck-100-study,2020-03-13,clinical trial update
Susan Hockfield Elected to Pfizer’s Board of Directors,https://www.pfizer.com/news/press-release/press-release-detail/susan-hockfield-elected-pfizers-board-directors,2020-03-04,management update
Pfizer Provides Comment on COVID-19 White House Meeting,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-provides-comment-covid-19-white-house-meeting,2020-03-02,covid-19
"U.S. FDA Accepts Regulatory Submission for Tanezumab, a Potential First-in-Class Treatment for Patients with Chronic Pain Due to Moderate-to-Severe Osteoarthritis",https://www.pfizer.com/news/press-release/press-release-detail/u_s-fda-accepts-regulatory-submission-for-tanezumab-a-potential-first-in-class-treatment-for-patients-with-chronic-pain-due-to-moderate-to-severe-osteoarthritis,2020-03-02,regulatory approval
James Quincey Elected to Pfizer’s Board of Directors,https://www.pfizer.com/news/press-release/press-release-detail/james-quincey-elected-pfizers-board-directors,2020-02-27,management update
Mylan and Pfizer Announce Appointment of Viatris Chief Financial Officer,https://www.pfizer.com/news/press-release/press-release-detail/mylan-and-pfizer-announce-appointment-viatris-chief,2020-02-27,financial news
Mylan and Pfizer Finalize Appointments to Viatris Board of Directors,https://www.pfizer.com/news/press-release/press-release-detail/mylan-and-pfizer-finalize-appointments-viatris-board,2020-02-27,financial news
Mylan and Pfizer Announce Appointment of Viatris Chief Financial Officer,https://www.pfizer.com/news/press-release/press-release-detail/mylan_and_pfizer_announce_appointment_of_viatris_chief_financial_officer,2020-02-27,financial news
Mylan and Pfizer Finalize Appointments to Viatris Board of Directors,https://www.pfizer.com/news/press-release/press-release-detail/mylan_and_pfizer_finalize_appointments_to_viatris_board_of_directors,2020-02-27,financial news
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-invites-public-listen-webcast-pfizer-discussion-26,2020-02-25,financial news
"Montis Biosciences launched with €8,4 million seed financing and a novel  approach to immune-oncology",https://www.pfizer.com/news/press-release/press-release-detail/montis-biosciences-launched-eu84-million-seed-financing-and,2020-02-20,partnerships
"European Commission Approves VYNDAQEL®, the First Treatment in the EU for Transthyretin Amyloid Cardiomyopathy (ATTR-CM)",https://www.pfizer.com/news/press-release/press-release-detail/european-commission-approves-vyndaqelr-first-treatment-eu,2020-02-18,regulatory approval
"European Commission Approves VYNDAQEL®, the First Treatment in the EU for Transthyretin Amyloid Cardiomyopathy (ATTR-CM)",https://www.pfizer.com/news/press-release/press-release-detail/european_commission_approves_vyndaqel_the_first_treatment_in_the_eu_for_transthyretin_amyloid_cardiomyopathy_attr_cm,2020-02-18,regulatory approval
XTANDI® (enzalutamide) Demonstrates Significant Improvement in Overall Survival in Phase 3 PROSPER Trial of Patients with nmCRPC,https://www.pfizer.com/news/press-release/press-release-detail/xtandir-enzalutamide-demonstrates-significant-improvement,2020-02-11,clinical trial update
"Pfizer Receives Positive CHMP Opinion for Oncology Biosimilar, RUXIENCE™ (rituximab)",https://www.pfizer.com/news/press-release/press-release-detail/pfizer-receives-positive-chmp-opinion-oncology-biosimilar,2020-01-31,regulatory approval
PFIZER REPORTS FOURTH-QUARTER AND FULL-YEAR 2019 RESULTS,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-reports-fourth-quarter-and-full-year-2019-results,2020-01-28,financial news
Pfizer Vaccines Launches Global Centers of Excellence Network to Conduct Real-World Research on Vaccine-Preventable Diseases Affecting Adults,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-vaccines-launches-global-centers-excellence-network,2020-01-23,clinical trial update
Pfizer Brings Three New Biosimilars to U.S. Patients at Substantial  Discounts,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-brings-three-new-biosimilars-us-patients-substantial,2020-01-23,commercialized drug update
Pfizer’s Greenstone and Digital Men’s Health Clinic Roman Collaborate to Offer Patients Remote Access to the Only FDA-Approved Authorized Generic Version of Viagra® (sildenafil citrate),https://www.pfizer.com/news/press-release/press-release-detail/pfizers-greenstone-and-digital-mens-health-clinic-roman,2020-01-23,commercialized drug update
Insilico enters into research collaboration with Pfizer Inc. to explore novel data  and artificial intelligence system for potential therapeutic targets,https://www.pfizer.com/news/press-release/press-release-detail/insilico-enters-research-collaboration-pfizer-inc-explore,2020-01-14,partnerships
Biogen to Acquire Novel Clinical Stage Asset with Application in Alzheimer’s Disease  and Parkinson’s Disease from Pfizer Inc.,https://www.pfizer.com/news/press-release/press-release-detail/biogen-acquire-novel-clinical-stage-asset-application,2020-01-13,partnerships
Axsome Therapeutics Enters into Exclusive License Agreement with Pfizer Inc. for Pfizer’s Reboxetine  Clinical and Nonclinical Data and for New Phase 3 Esreboxetine Product Candidate,https://www.pfizer.com/news/press-release/press-release-detail/axsome-therapeutics-enters-exclusive-license-agreement,2020-01-13,partnerships
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-invites-public-listen-webcast-pfizer-discussion-0,2020-01-07,financial news
BAVENCIO Significantly Improved Overall Survival in Patients With Locally Advanced or Metastatic Urothelial Carcinoma,https://www.pfizer.com/news/press-release/press-release-detail/bavencio-significantly-improved-overall-survival-patients,2020-01-06,clinical trial update
"Theravance Biopharma and Pfizer Inc. Enter Global License Agreement for Skin-Targeted, Locally-Acting Pan-Janus Kinase (JAK) Inhibitor Program",https://www.pfizer.com/news/press-release/press-release-detail/theravance_biopharma-and-pfizer-inc-enter-global-license-agreement-for-skin-targeted-locally-acting-pan-janus-kinase-jak-inhibitor-program,2019-12-23,partnerships
BioInvent announces selection of second target and extension of the research  collaboration and license agreement with Pfizer Inc.,https://www.pfizer.com/news/press-release/press-release-detail/bioinvent-announces-selection-second-target-and-extension,2019-12-23,partnerships
U.S. FDA Accepts and Grants Priority Review to sNDA for BRAFTOVI® (encorafenib) in Combination with ERBITUX® (cetuximab) (BRAFTOVI Doublet) for the Treatment of BRAFV600E-Mutant Metastatic Colorectal Cancer After Prior Therapy,https://www.pfizer.com/news/press-release/press-release-detail/u_s-fda-accepts-and-grants-priority-review-to-snda-for-braftovi-encorafenib-in-combination-with-erbitux-cetuximab-braftovi-doublet-for-the-treatment-of-brafv600e-mutant-metastatic-colorectal-cancer-after-prior,2019-12-18,regulatory approval
Pfizer and Mylan Announce Two Future Viatris Board Members,https://www.pfizer.com/news/press-release/press-release-detail/pfizer_and-mylan-announce-two-future-viatris-board-members,2019-12-18,financial news
Pfizer Invites Public to View and Listen to Webcast of January 28 Conference Call with Analysts,https://www.pfizer.com/news/press-release/press-release-detail/pfizer_invites_public_to_view_and_listen_to_webcast_of_january_28_conference_call_with_analysts-0,2019-12-17,financial news
Triplet Therapeutics Launches with $59 Million in Financing to Further its Development of  Transformative Treatments for Triplet Repeat Disorders,https://www.pfizer.com/news/press-release/press-release-detail/triplet-therapeutics-launches-59-million-financing-further,2019-12-17,partnerships
XTANDI® (enzalutamide) Approved by U.S. FDA for the Treatment of Metastatic Castration-Sensitive Prostate Cancer,https://www.pfizer.com/news/press-release/press-release-detail/xtandi_enzalutamide-approved-by-u_s-fda-for-the-treatment-of-metastatic-castration-sensitive-prostate-cancer,2019-12-16,regulatory approval
Pfizer Declares First-Quarter 2020 Dividend and Announces Upcoming Investor Day to Highlight Strength of Innovative R&D Pipeline,https://www.pfizer.com/news/press-release/press-release-detail/pfizer_declares_first-quarter-2020_dividend-and_announces_upcoming_investor_day_to_highlight_strength_of_innovative_r_d_pipeline,2019-12-16,financial news
"Pfizer Receives Positive CHMP Opinion for VYNDAQEL® for Use in Patients with Transthyretin Amyloid Cardiomyopathy, a Rare and Fatal Disease",https://www.pfizer.com/news/press-release/press-release-detail/pfizer_receives_positive_chmp_opinion_for_vyndaqel_for_use_in_patients_with_transthyretin_amyloid_cardiomyopathy_a_rare_and_fatal_disease,2019-12-13,regulatory approval
FDA Approves XELJANZ® XR (tofacitinib) Extended-Release Tablets for the Treatment of Ulcerative Colitis,https://www.pfizer.com/news/press-release/press-release-detail/fda-approves-xeljanz-xr-tofacitinib-extended-release-tablets-for-the-treatment-of-ulcerative-colitis,2019-12-12,regulatory approval
"ImmunOs Therapeutics AG raises CHF 15M in Series A Financing, co-led by Pfizer Ventures and  BioMedPartners, to Advance a Novel Immunotherapy Agent For Cancer Into Human Trials",https://www.pfizer.com/news/press-release/press-release-detail/immunos-therapeutics-ag-raises-chf-15m-series-financing-co,2019-12-10,partnerships
Findings Released from Real-World Data Analysis of Eliquis (apixaban) for the Treatment of Venous Thromboembolism in Patients with Active Cancer,https://www.pfizer.com/news/press-release/press-release-detail/findings_released_from_real_world_data_analysis_of_eliquis_apixaban_for_the_treatment_of_venous_thromboembolism_in_patients_with_active_cancer,2019-12-07,research
Sangamo and Pfizer Announce Updated Phase 1/2 Results Showing Sustained Increased Factor VIII Activity Through 44 Weeks Following SB-525 Gene Therapy Treatment,https://www.pfizer.com/news/press-release/press-release-detail/sangamo_and_pfizer_announce_updated_phase_1_2_results_showing_sustained_increased_factor_viii_activity_through_44_weeks_following_sb_525_gene_therapy_treatment,2019-12-07,research
ImCheck Raises $53 Million Series B to Advance Clinical Pipeline of Novel  Gamma Delta T-Cell-Focused Antibodies for Cancer and Autoimmune Diseases,https://www.pfizer.com/news/press-release/press-release-detail/imcheck-raises-53-million-series-b-advance-clinical,2019-12-04,partnerships
CeMM enters into research collaboration on expanding the druggable proteome  with Pfizer Inc.,https://www.pfizer.com/news/press-release/press-release-detail/cemm-enters-research-collaboration-expanding-druggable,2019-11-22,partnerships
"FDA Approves Pfizer’s Biosimilar, ABRILADA™ (adalimumab-afzb) for Multiple Inflammatory Conditions",https://www.pfizer.com/news/press-release/press-release-detail/fda_approves_pfizer_s_biosimilar_abrilada_adalimumab_afzb_for_multiple_inflammatory_conditions,2019-11-18,regulatory approval
Pfizer Announces CHMP Opinion for XELJANZ® (tofacitinib) in the European Union Related to Ongoing Review of the Product,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-announces-chmp-opinion-xeljanzr-tofacitinib-european,2019-11-15,regulatory approval
"Bristol-Myers Squibb and Pfizer Announce Randomized, Controlled Trial to Evaluate the Effect of Atrial Fibrillation Screening on Health Outcomes in Older Individuals",https://www.pfizer.com/news/press-release/press-release-detail/bristol_myers_squibb_and_pfizer_announce_randomized_controlled_trial_to_evaluate_the_effect_of_atrial_fibrillation_screening_on_health_outcomes_in_older_individuals,2019-11-15,clinical trial update
CENTOGENE Signs Data Access and Collaboration Agreement with Pfizer Inc.,https://www.pfizer.com/news/press-release/press-release-detail/centogene-signs-data-access-and-collaboration-agreement,2019-11-13,partnerships
Mylan and Pfizer Announce Viatris as the New Company Name in the Planned Mylan-Upjohn Combination,https://www.pfizer.com/news/press-release/press-release-detail/mylan_and_pfizer_announce_viatris_as_the_new_company_name_in_the_planned_mylan_upjohn_combination,2019-11-12,finance
Pfizer Announces Results of Phase 3 Study for XELJANZ® (tofacitinib) in Juvenile Idiopathic Arthritis Ahead of Presentation at 2019 American College of Rheumatology/Association of Rheumatology Professionals Annual Meeting,https://www.pfizer.com/news/press-release/press-release-detail/pfizer_announces_results_of_phase_3_study_for_xeljanz_tofacitinib_in_juvenile_idiopathic_arthritis_ahead_of_presentation_at_2019_american_college_of_rheumatology_association_of_rheumatology_professionals_annual,2019-11-12,clinical trial update
EMD Serono and Pfizer Provide Update on Phase III JAVELIN Gastric 100 Trial,https://www.pfizer.com/news/press-release/press-release-detail/emd_serono_and_pfizer_provide_update_on_phase_iii_javelin_gastric_100_trial,2019-11-08,clinical trial update
PFIZER REPORTS THIRD-QUARTER 2019 RESULTS,https://www.pfizer.com/news/press-release/press-release-detail/pfizer_reports_third_quarter_2019_results,2019-10-29,financial news
European Commission Approves BAVENCIO® (avelumab) Plus Axitinib Combination for First-Line Treatment of Patients With Advanced Renal Cell Carcinoma,https://www.pfizer.com/news/press-release/press-release-detail/european_commission_approves_bavencio_avelumab_plus_axitinib_combination_for_first_line_treatment_of_patients_with_advanced_renal_cell_carcinoma,2019-10-28,regulatory approval
"OPKO and Pfizer Announce Positive Phase 3 Top-Line Results for Somatrogon, an Investigational Long-Acting Human Growth Hormone to Treat Children with Growth Hormone Deficiency",https://www.pfizer.com/news/press-release/press-release-detail/opko_and_pfizer_announce_positive_phase_3_top_line_results_for_somatrogon_an_investigational_long_acting_human_growth_hormone_to_treat_children_with_growth_hormone_deficiency,2019-10-21,clinical trial update
"Pfizer Statement on Vincristine Sulfate Injection, USP Supply in the United States",https://www.pfizer.com/news/press-release/press-release-detail/pfizer-statement-vincristine-sulfate-injection-usp-supply,2019-10-18,commercialized drug update
Pfizer Statement on Results of Pay Equity Study and  Opportunity Parity Among Colleagues Worldwide,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-statement-results-pay-equity-study-and-opportunity,2019-10-17,management update
The Bristol-Myers Squibb-Pfizer Alliance and Fitbit Collaborate to Address Gaps in Atrial Fibrillation Detection with the Aim of Accelerating Diagnosis,https://www.pfizer.com/news/press-release/press-release-detail/the_bristol_myers_squibb_pfizer_alliance_and_fitbit_collaborate_to_address_gaps_in_atrial_fibrillation_detection_with_the_aim_of_accelerating_diagnosis,2019-10-17,partnerships
ImaginAb signs multi-party collaboration agreement with three global  pharmaceutical companies to help further develop company’s CD8  ImmunoPET technology,https://www.pfizer.com/news/press-release/press-release-detail/imaginab-signs-multi-party-collaboration-agreement-three,2019-10-14,partnerships
Pfizer Presents Positive Phase 3 Data at the 28th Congress of the European Academy of Dermatology and Venereology for Abrocitinib in Moderate to Severe Atopic Dermatitis,https://www.pfizer.com/news/press-release/press-release-detail/pfizer_presents_positive_phase_3_data_at_the_28th_congress_of_the_european_academy_of_dermatology_and_venereology_for_abrocitinib_in_moderate_to_severe_atopic_dermatitis,2019-10-12,clinical trial update
Akcea and Pfizer Inc. Announce Licensing Agreement for investigative antisense therapy AKCEA-ANGPTL3-LRx,https://www.pfizer.com/news/press-release/press-release-detail/akcea_and_pfizer_inc_announce_licensing_agreement_for_investigative_antisense_therapy_akcea_angptl3_lrx,2019-10-07,partnerships
"Pfizer Presents Interim Analysis Results from Phase 3 BEACON CRC Trial of BRAFTOVI® (Encorafenib), MEKTOVI® (Binimetinib) and Cetuximab for the Treatment of BRAFV600E-Mutant Metastatic Colorectal Cancer",https://www.pfizer.com/news/press-release/press-release-detail/pfizer_presents_interim_analysis_results_from_phase_3_beacon_crc_trial_of_braftovi_encorafenib_mektovi_binimetinib_and_cetuximab_for_the_treatment_of_brafv600e_mutant_metastatic_colorectal_cancer,2019-09-29,clinical trial update
Ian Read to Retire as Executive Chairman of Pfizer’s Board of Directors; Chief Executive Officer Dr. Albert Bourla Named Chairman,https://www.pfizer.com/news/press-release/press-release-detail/ian_read_to_retire_as_executive_chairman_of_pfizer_s_board_of_directors_chief_executive_officer_dr_albert_bourla_named_chairman,2019-09-27,management update
"Pfizer Announces Positive Top-Line Results from Second Pivotal Phase 3 Study of Investigational Oral JAK1 Candidate, Abrocitinib, in Patients Aged 12 and Older with Moderate to Severe Atopic Dermatitis",https://www.pfizer.com/news/press-release/press-release-detail/pfizer_announces_positive_top_line_results_from_second_pivotal_phase_3_study_of_investigational_oral_jak1_candidate_abrocitinib_in_patients_aged_12_and_older_with_moderate_to_severe_atopic_dermatitis,2019-09-27,clinical trial update
New Data for BAVENCIO® (avelumab) for Advanced Cancers to Be Presented at ESMO 2019,https://www.pfizer.com/news/press-release/press-release-detail/new_data_for_bavencio_avelumab_for_advanced_cancers_to_be_presented_at_esmo_2019,2019-09-27,clinical trial update
Pfizer Declares Fourth-Quarter 2019 Dividend,https://www.pfizer.com/news/press-release/press-release-detail/pfizer_declares_fourth_quarter_2019_dividend,2019-09-24,financial news
"Pfizer Presents New Evidence of IBRANCE® (palbociclib) Effectiveness in HR+, HER2- Metastatic Breast Cancer Patients in Four Real-World Studies at ESMO Congress 2019",https://www.pfizer.com/news/press-release/press-release-detail/pfizer_presents_new_evidence_of_ibrance_palbociclib_effectiveness_in_hr_her2_metastatic_breast_cancer_patients_in_four_real_world_studies_at_esmo_congress_2019,2019-09-24,clinical trial update
Pfizer and Flatiron Health Announce Expanded Strategic Collaboration to Unlock Power of Real-World Evidence in Oncology,https://www.pfizer.com/news/press-release/press-release-detail/pfizer_and_flatiron_health_announce_expanded_strategic_collaboration_to_unlock_power_of_real_world_evidence_in_oncology,2019-09-24,partnerships
CHMP Adopts Positive Opinion for BAVENCIO® (avelumab) Plus Axitinib for First-Line Treatment of Patients with Advanced Renal Cell Carcinoma,https://www.pfizer.com/news/press-release/press-release-detail/chmp_adopts_positive_opinion_for_bavencio_avelumab_plus_axitinib_for_first_line_treatment_of_patients_with_advanced_renal_cell_carcinoma,2019-09-20,regulatory approval
Pfizer Presents Scientific Advancements in Cancer Care at the ESMO Congress 2019 Highlighting Expanded Portfolio,https://www.pfizer.com/news/press-release/press-release-detail/pfizer_presents_scientific_advancements_in_cancer_care_at_the_esmo_congress_2019_highlighting_expanded_portfolio,2019-09-19,clinical trial update
TrialSpark and Pfizer collaborating to improve speed and access to clinical trials,https://www.pfizer.com/news/press-release/press-release-detail/trialspark-and-pfizer-collaborating-improve-speed-and,2019-09-17,partnerships
Terry Bradshaw and Pfizer Educate Boomers About the Risks of Pneumococcal Pneumonia and the Importance of Vaccination,https://www.pfizer.com/news/press-release/press-release-detail/terry-bradshaw-and-pfizer-educate-boomers-about-risks,2019-09-17,commercialized drug update
Pfizer Invites Public to View and Listen to Webcast of October 29 Conference Call With Analysts,https://www.pfizer.com/news/press-release/press-release-detail/pfizer_invites_public_to_view_and_listen_to_webcast_of_october_29_conference_call_with_analysts-0,2019-09-17,financial news
Catalia Health and Pfizer collaborate to better understand patient journeys using artificial intelligence and via robot wellness coach,https://www.pfizer.com/news/press-release/press-release-detail/catalia-health-and-pfizer-collaborate-better-understand,2019-09-12,partnerships
Pfizer Announces Positive Preliminary Results from a Proof-of-Concept Phase 2 Study (B7471003) of its 20-Valent Pneumococcal Conjugate Vaccine Candidate Being Investigated for the Prevention of Invasive Disease and Otitis Media in Healthy Infants,https://www.pfizer.com/news/press-release/press-release-detail/pfizer_announces_positive_preliminary_results_from_a_proof_of_concept_phase_2_study_b7471003_of_its_20_valent_pneumococcal_conjugate_vaccine_candidate_being_investigated_for_the_prevention_of_invasive_disease_and,2019-09-09,clinical trial update
"Hospira, Inc., Issues A Voluntary Nationwide Recall for one lot of BACTERIOSTATIC WATER for Injection, USP, due to a Potential Lack of Sterility Assurance",https://www.pfizer.com/news/press-release/press-release-detail/hospira-inc-issues-voluntary-nationwide-recall-one-lot,2019-09-06,commercialized drug update
"Findings Released from NAXOS, a French Real-World Data Analysis and the Largest Real-World  Data Analysis on Oral Anticoagulant Effectiveness and Safety in Europe Among Patients with Non-Valvular Atrial Fibrillation",https://www.pfizer.com/news/press-release/press-release-detail/findings-released-naxos-french-real-world-data-analysis-and,2019-09-01,clinical trial update
U.S. FDA Grants XTANDI® (enzalutamide) Application Priority Review for the Treatment of Men with Metastatic Hormone-Sensitive Prostate Cancer,https://www.pfizer.com/news/press-release/press-release-detail/u_s_fda_grants_xtandi_enzalutamide_application_priority_review_for_the_treatment_of_men_with_metastatic_hormone_sensitive_prostate_cancer,2019-08-21,regulatory approval
"Pfizer Invests Half Billion Dollars to Advance State-of-the-Art Gene Therapy Facility in Sanford, North Carolina",https://www.pfizer.com/news/press-release/press-release-detail/pfizer_invests_half_billion_dollars_to_advance_state_of_the_art_gene_therapy_facility_in_sanford_north_carolina,2019-08-21,finance
The Pfizer Foundation Invests in 20 Organizations Tackling Infectious Diseases and Antimicrobial Resistance,https://www.pfizer.com/news/press-release/press-release-detail/the_pfizer_foundation_invests_in_20_organizations_tackling_infectious_diseases_and_antimicrobial_resistance,2019-08-20,social responsibility
Pfizer Inc. Issues A Voluntary Nationwide Recall For 2 Lots of  RELPAX® (eletriptan hydrobromide) 40 mg Tablets Due to Potential  Microbiological Contamination of Non-Sterile Products,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-inc-issues-voluntary-nationwide-recall-2-lots,2019-08-14,commercialized drug update
Pfizer Announces Phase 3 Top-Line Results for Rivipansel in Patients with Sickle Cell Disease Experiencing a Vaso-Occlusive Crisis,https://www.pfizer.com/news/press-release/press-release-detail/pfizer_announces_phase_3_top_line_results_for_rivipansel_in_patients_with_sickle_cell_disease_experiencing_a_vaso_occlusive_crisis,2019-08-02,clinical trial update
Pfizer Announces Closing of Joint Venture With GlaxoSmithKline to Create a Premier Global Consumer Healthcare Company,https://www.pfizer.com/news/press-release/press-release-detail/pfizer_announces_closing_of_joint_venture_with_glaxosmithkline_to_create_a_premier_global_consumer_healthcare_company,2019-08-01,management update
BioInvent announces selection of first target discovered by BioInvent’s  proprietary F.I.R.S.TTM technology platform under collaboration with Pfizer Inc.,https://www.pfizer.com/news/press-release/press-release-detail/bioinvent-announces-selection-first-target-discovered,2019-07-31,partnerships
Pfizer Completes Acquisition of Array Biopharma,https://www.pfizer.com/news/press-release/press-release-detail/pfizer_completes_acquisition_of_array_biopharma,2019-07-30,finance
"Pfizer Inc. Reschedules Second-Quarter 2019 Earnings Conference Call to July 29, 2019 at 10:30 a.m. EDT",https://www.pfizer.com/news/press-release/press-release-detail/pfizer_inc_reschedules_second_quarter_2019_earnings_conference_call_to_july_29_2019_at_10_30_a_m_edt,2019-07-29,financial news
PFIZER REPORTS SECOND-QUARTER 2019 RESULTS,https://www.pfizer.com/news/press-release/press-release-detail/pfizer_reports_second_quarter_2019_results,2019-07-29,financial news
"Mylan and Upjohn, a Division of Pfizer, to Combine, Creating a New Champion for Global Health Uniquely Positioned to Fulfill the World’s Need for Medicine",https://www.pfizer.com/news/press-release/press-release-detail/mylan_and_upjohn_a_division_of_pfizer_to_combine_creating_a_new_champion_for_global_health_uniquely_positioned_to_fulfill_the_world_s_need_for_medicine,2019-07-29,finance
Pfizer Statement on Update to XELJANZ® (tofacitinib) Prescribing Information in the United States,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-statement-update-xeljanzr-tofacitinib-prescribing,2019-07-26,medicines
"FDA Approves Pfizer’s Biosimilar, RUXIENCE™ (rituximab-pvvr), for Certain Cancers and Autoimmune Conditions",https://www.pfizer.com/news/press-release/press-release-detail/fda_approves_pfizer_s_biosimilar_ruxience_rituximab_pvvr_for_certain_cancers_and_autoimmune_conditions,2019-07-23,medicines
Sangamo and Pfizer Announce Updated Phase 1/2 Results for SB-525 Investigational Hemophilia A Gene Therapy Showing Sustained Increased Factor VIII Levels,https://www.pfizer.com/news/press-release/press-release-detail/sangamo_and_pfizer_announce_updated_phase_1_2_results_for_sb_525_investigational_hemophilia_a_gene_therapy_showing_sustained_increased_factor_viii_levels,2019-07-05,research
Pfizer Completes Acquisition of Therachon,https://www.pfizer.com/news/press-release/press-release-detail/pfizer_completes_acquisition_of_therachon,2019-07-01,finance
"Pfizer Announces Positive Top-Line Results from Phase 4 Study of Crisaborole Ointment, 2%, in Children Aged 3 Months to Less Than 24 Months with Mild to Moderate Atopic Dermatitis",https://www.pfizer.com/news/press-release/press-release-detail/pfizer_announces_positive_top_line_results_from_phase_4_study_of_crisaborole_ointment_2_in_children_aged_3_months_to_less_than_24_months_with_mild_to_moderate_atopic_dermatitis,2019-07-01,research
Pfizer Announces Results from Phase 3 Trial of Revatio® (Sildenafil Citrate) in Newborns with Persistent Pulmonary Hypertension,https://www.pfizer.com/news/press-release/press-release-detail/pfizer_announces_results_from_phase_3_trial_of_revatio_sildenafil_citrate_in_newborns_with_persistent_pulmonary_hypertension,2019-06-28,research
Pfizer Presents Initial Clinical Data on Phase 1b Gene Therapy Study for Duchenne Muscular Dystrophy (DMD),https://www.pfizer.com/news/press-release/press-release-detail/pfizer_presents_initial_clinical_data_on_phase_1b_gene_therapy_study_for_duchenne_muscular_dystrophy_dmd,2019-06-28,research
"Pfizer Receives U.S. FDA Approval for Its Oncology Biosimilar, ZIRABEV™ (bevacizumab-bvzr)",https://www.pfizer.com/news/press-release/press-release-detail/pfizer_receives_u_s_fda_approval_for_its_oncology_biosimilar_zirabev_bevacizumab_bvzr,2019-06-28,medicines
Scott Gottlieb Elected to Pfizer’s Board of Directors,https://www.pfizer.com/news/press-release/press-release-detail/scott_gottlieb_elected_to_pfizer_s_board_of_directors,2019-06-27,management update
Pfizer Declares Third-Quarter 2019 Dividend,https://www.pfizer.com/news/press-release/press-release-detail/pfizer_declares_third_quarter_2019_dividend,2019-06-27,financial news
European Commission Approves TALZENNA® (talazoparib) for Patients with Inherited (Germline) BRCA-Mutated Locally Advanced or Metastatic Breast Cancer,https://www.pfizer.com/news/press-release/press-release-detail/european_commission_approves_talzenna_talazoparib_for_patients_with_inherited_germline_brca_mutated_locally_advanced_or_metastatic_breast_cancer,2019-06-21,medicines
Pfizer Invites Public to View and Listen to Webcast of July 30 Conference Call with Analysts,https://www.pfizer.com/news/press-release/press-release-detail/pfizer_invites_public_to_view_and_listen_to_webcast_of_july_30_conference_call_with_analysts-0,2019-06-18,financial news
Pfizer to Acquire Array BioPharma,https://www.pfizer.com/news/press-release/press-release-detail/pfizer_to_acquire_array_biopharma,2019-06-17,financial news
"Pfizer Announces Results from XELJANZ® XR (tofacitinib) ORAL Shift Study, The First Phase 3b/4 Study to Evaluate Methotrexate Withdrawal with a JAK Inhibitor",https://www.pfizer.com/news/press-release/press-release-detail/pfizer_announces_results_from_xeljanz_xr_tofacitinib_oral_shift_study_the_first_phase_3b_4_study_to_evaluate_methotrexate_withdrawal_with_a_jak_inhibitor,2019-06-12,research
"Jeff Settleman, Ph.D., Joins Pfizer to Lead Oncology Research & Development",https://www.pfizer.com/news/press-release/press-release-detail/jeff_settleman_ph_d_joins_pfizer_to_lead_oncology_research_development,2019-06-05,management update
Pfizer Announces Top-Line Results from Phase 3 Trial of LYRICA® (pregabalin) in Primary Generalized Tonic-Clonic Seizures,https://www.pfizer.com/news/press-release/press-release-detail/pfizer_announces_top_line_results_from_phase_3_trial_of_lyrica_pregabalin_in_primary_generalized_tonic_clonic_seizures,2019-05-24,medicines
Pfizer confirms initiation of EU review of Tofacitinib with interim recommendations,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-confirms-initiation-eu-review-tofacitinib-interim,2019-05-17,medicines
Pfizer Oncology to Showcase New Data from Innovative Science That Address Patient Needs at ASCO 2019 Annual Meeting,https://www.pfizer.com/news/press-release/press-release-detail/pfizer_oncology_to_showcase_new_data_from_innovative_science_that_address_patient_needs_at_asco_2019_annual_meeting,2019-05-15,research
"Pfizer Announces Positive Top-Line Results from Phase 3 Study of Investigational Oral JAK1 Candidate, Abrocitinib (PF-04965842), in Patients Aged 12 and Older with Moderate to Severe Atopic Dermatitis",https://www.pfizer.com/news/press-release/press-release-detail/pfizer_announces_positive_top_line_results_from_phase_3_study_of_investigational_oral_jak1_candidate_abrocitinib_pf_04965842_in_patients_aged_12_and_older_with_moderate_to_severe_atopic_dermatitis,2019-05-15,research
FDA Approves BAVENCIO® (avelumab) Plus INLYTA® (axitinib) Combination for Patients with Advanced Renal Cell Carcinoma,https://www.pfizer.com/news/press-release/press-release-detail/fda_approves_bavencio_avelumab_plus_inlyta_axitinib_combination_for_patients_with_advanced_renal_cell_carcinoma,2019-05-14,medicines
"Pfizer Opens New State-Of-The-Art Biologics Clinical Manufacturing Facility In Andover, Massachusetts",https://www.pfizer.com/news/press-release/press-release-detail/pfizer_opens_new_state_of_the_art_biologics_clinical_manufacturing_facility_in_andover_massachusetts,2019-05-09,financial news
Pfizer Acquires Clinical-Stage Biotech Therachon,https://www.pfizer.com/news/press-release/press-release-detail/pfizer_acquires_clinical_stage_biotech_therachon,2019-05-08,financial news
European Commission Approves LORVIQUA® (lorlatinib) for Certain Adult Patients with Previously-Treated ALK-Positive Advanced Non-Small Cell Lung Cancer,https://www.pfizer.com/news/press-release/press-release-detail/european_commission_approves_lorviqua_lorlatinib_for_certain_adult_patients_with_previously_treated_alk_positive_advanced_non_small_cell_lung_cancer,2019-05-07,medicines
"U.S. FDA Approves VYNDAQEL® and VYNDAMAX™ for Use in Patients with Transthyretin Amyloid Cardiomyopathy, a Rare and Fatal Disease",https://www.pfizer.com/news/press-release/press-release-detail/u_s_fda_approves_vyndaqel_and_vyndamax_for_use_in_patients_with_transthyretin_amyloid_cardiomyopathy_a_rare_and_fatal_disease,2019-05-06,medicines
PFIZER REPORTS FIRST-QUARTER 2019 RESULTS,https://www.pfizer.com/news/press-release/press-release-detail/pfizer_reports_first_quarter_2019_results,2019-04-30,financial news
"Pfizer Inc. Issues A Voluntary Nationwide Consumer Level Recall of One Lot of ThermaCare® Back Pain Therapy HeatWraps, up to 16HR pain relief, Due To Out of Specification Results for  High Cell Temperature",https://www.pfizer.com/news/press-release/press-release-detail/pfizer-inc-issues-voluntary-nationwide-consumer-level-0,2019-04-26,medicines
Pfizer Receives Positive CHMP Opinion for TALZENNA® (talazoparib) for Patients with Inherited (Germline) BRCA-Mutated Locally Advanced or Metastatic Breast Cancer,https://www.pfizer.com/news/press-release/press-release-detail/pfizer_receives_positive_chmp_opinion_for_talzenna_talazoparib_for_patients_with_inherited_germline_brca_mutated_locally_advanced_or_metastatic_breast_cancer,2019-04-26,medicines
Pfizer Hosts Annual Meeting of Shareholders,https://www.pfizer.com/news/press-release/press-release-detail/pfizer_hosts_annual_meeting_of_shareholders-6,2019-04-25,financial news
Pfizer and Lilly Announce Top-Line Results From Long-Term Phase 3 Study of Tanezumab in Patients With Osteoarthritis,https://www.pfizer.com/news/press-release/press-release-detail/pfizer_and_lilly_announce_top_line_results_from_long_term_phase_3_study_of_tanezumab_in_patients_with_osteoarthritis,2019-04-18,research
Pfizer Invites Public to Listen to Webcast of April 25 Annual Meeting of Shareholders,https://www.pfizer.com/news/press-release/press-release-detail/pfizer_invites_public_to_listen_to_webcast_of_april_25_annual_meeting_of_shareholders-0,2019-04-18,financial news
Pfizer Announces Presentation of Data from a Phase 2 Study of its 20-Valent Pneumococcal Conjugate Vaccine Candidate Being Investigated for the Prevention of Invasive Disease and Pneumonia in Adults Aged 18 Years and Older,https://www.pfizer.com/news/press-release/press-release-detail/pfizer_announces_presentation_of_data_from_a_phase_2_study_of_its_20_valent_pneumococcal_conjugate_vaccine_candidate_being_investigated_for_the_prevention_of_invasive_disease_and_pneumonia_in_adults_aged_18_years,2019-04-13,research
"U.S. FDA Approves IBRANCE® (palbociclib) for the Treatment of Men with HR+, HER2- Metastatic Breast Cancer",https://www.pfizer.com/news/press-release/press-release-detail/u_s_fda_approves_ibrance_palbociclib_for_the_treatment_of_men_with_hr_her2_metastatic_breast_cancer,2019-04-04,medicines
VIZIMPRO® (dacomitinib) Receives Marketing Authorization in European Union (EU) for the First-Line Treatment of Adult Patients with EGFR-Mutated Non-Small Cell Lung Cancer,https://www.pfizer.com/news/press-release/press-release-detail/vizimpro_dacomitinib_receives_marketing_authorization_in_european_union_eu_for_the_first_line_treatment_of_adult_patients_with_egfr_mutated_non_small_cell_lung_cancer,2019-04-03,medicines
Sangamo and Pfizer Announce Phase 1/2 Interim Data for Investigational Hemophilia A Gene Therapy,https://www.pfizer.com/news/press-release/press-release-detail/sangamo_and_pfizer_announce_phase_1_2_interim_data_for_investigational_hemophilia_a_gene_therapy,2019-04-02,research
Pfizer Secures Exclusive Option to Acquire Gene Therapy Company Vivet Therapeutics,https://www.pfizer.com/news/press-release/press-release-detail/pfizer_secures_exclusive_option_to_acquire_gene_therapy_company_vivet_therapeutics,2019-03-20,financial news
"Merck KGaA, Darmstadt, Germany, and Pfizer Announce Discontinuation of Phase III JAVELIN Ovarian PARP 100 Trial in Previously Untreated Advanced Ovarian Cancer",https://www.pfizer.com/news/press-release/press-release-detail/merck_kgaa_darmstadt_germany_and_pfizer_announce_discontinuation_of_phase_iii_javelin_ovarian_parp_100_trial_in_previously_untreated_advanced_ovarian_cancer,2019-03-19,research
Pfizer Invites Public to View and Listen to Webcast of April 30 Conference Call with Analysts,https://www.pfizer.com/news/press-release/press-release-detail/pfizer_invites_public_to_view_and_listen_to_webcast_of_april_30_conference_call_with_analysts-0,2019-03-19,financial news
"Hospira, Inc. Issues A Voluntary Nationwide Recall of 8.4% Sodium Bicarbonate Injection, USP Due To The Presence of Particulate  Matter",https://www.pfizer.com/news/press-release/press-release-detail/hospira-inc-issues-voluntary-nationwide-recall-84-sodium,2019-03-18,medicines
AUGUSTUS Demonstrates Favorable Safety Results of Eliquis® Versus Vitamin K Antagonists in Non-Valvular Atrial Fibrillation Patients with Acute Coronary Syndrome and/or Undergoing Percutaneous Coronary Intervention,https://www.pfizer.com/news/press-release/press-release-detail/augustus_demonstrates_favorable_safety_results_of_eliquis_versus_vitamin_k_antagonists_in_non_valvular_atrial_fibrillation_patients_with_acute_coronary_syndrome_and_or_undergoing_percutaneous_coronary_intervention,2019-03-17,research
"U.S. FDA Approves Pfizer’s Oncology Biosimilar TRAZIMERA™ (trastuzumab-qyyp), a Biosimilar to Herceptin®1",https://www.pfizer.com/news/press-release/press-release-detail/u_s_fda_approves_pfizer_s_oncology_biosimilar_trazimera_trastuzumab_qyyp_a_biosimilar_to_herceptin_1,2019-03-11,medicines
European Medicines Agency Validates Application for BAVENCIO® (avelumab) Plus INLYTA® (axitinib) for the Treatment of Advanced Renal Cell Carcinoma,https://www.pfizer.com/news/press-release/press-release-detail/european_medicines_agency_validates_application_for_bavencio_avelumab_plus_inlyta_axitinib_for_the_treatment_of_advanced_renal_cell_carcinoma,2019-03-08,medicines
Pfizer Invites Public to View and Listen to Webcast of Pfizer Presentation at Healthcare Conference,https://www.pfizer.com/news/press-release/press-release-detail/pfizer_invites_public_to_view_and_listen_to_webcast_of_pfizer_presentation_at_healthcare_conference-23,2019-03-05,financial news
"Pfizer Prices $5,000,000,000 Debt Offering",https://www.pfizer.com/news/press-release/press-release-detail/pfizer_prices_5_000_000_000_debt_offering-0,2019-03-04,financial news
Pfizer Receives Positive CHMP Opinion for LORVIQUA® (lorlatinib) for Certain Adult Patients with Previously-Treated ALK-Positive Advanced Non-Small Cell Lung Cancer,https://www.pfizer.com/news/press-release/press-release-detail/pfizer_receives_positive_chmp_opinion_for_lorviqua_lorlatinib_for_certain_adult_patients_with_previously_treated_alk_positive_advanced_non_small_cell_lung_cancer,2019-03-01,medicines
Pfizer Announces Serotypes Included in 20-Valent Pneumococcal Conjugate Vaccine Candidate Being Investigated for the Prevention of Invasive Disease and Pneumonia in Adults Aged 18 Years and Older,https://www.pfizer.com/news/press-release/press-release-detail/pfizer_announces_serotypes_included_in_20_valent_pneumococcal_conjugate_vaccine_candidate_being_investigated_for_the_prevention_of_invasive_disease_and_pneumonia_in_adults_aged_18_years_and_older,2019-02-28,research
Pfizer Announces Modification To Ongoing Tofacitinib FDA Post-Marketing Requirement Study In Patients With Rheumatoid Arthritis,https://www.pfizer.com/news/press-release/press-release-detail/pfizer-announces-modification-ongoing-tofacitinib-fda-post,2019-02-19,medicines
Ochsner Health System and Pfizer Partner to Develop Innovative Models for Clinical Trials,https://www.pfizer.com/news/press-release/press-release-detail/ochsner_health_system_and_pfizer_partner_to_develop_innovative_models_for_clinical_trials,2019-02-19,research
"Pfizer Receives European Approval for ZIRABEV™ (bevacizumab), a Biosimilar to Avastin®*",https://www.pfizer.com/news/press-release/press-release-detail/pfizer_receives_european_approval_for_zirabev_bevacizumab_a_biosimilar_to_avastin,2019-02-19,medicines
Pfizer and Lilly Announce Top-line Results From Phase 3 Study of Tanezumab in Chronic Low Back Pain,https://www.pfizer.com/news/press-release/press-release-detail/pfizer_and_lilly_announce_top_line_results_from_phase_3_study_of_tanezumab_in_chronic_low_back_pain,2019-02-19,clinical trial update
Pivotal Phase III Data for BAVENCIO® (avelumab) Plus INLYTA® (axitinib) in Advanced Renal Cell Carcinoma Published in The New England Journal of Medicine,https://www.pfizer.com/news/press-release/press-release-detail/pivotal_phase_iii_data_for_bavencio_avelumab_plus_inlyta_axitinib_in_advanced_renal_cell_carcinoma_published_in_the_new_england_journal_of_medicine,2019-02-16,clinical trial update
"G-CON Manufacturing Delivers New PCMM POD® With Tablet Coating Capability to Pfizer Inc.’s  Groton, Conn. Site",https://www.pfizer.com/news/press-release/press-release-detail/g-con-manufacturing-delivers-new-pcmm-podr-tablet-coating,2019-02-12,management update
FDA Accepts sBLA and Grants Priority Review for BAVENCIO® (avelumab) Plus INLYTA® (axitinib) for the Treatment of Advanced Renal Cell Carcinoma,https://www.pfizer.com/news/press-release/press-release-detail/fda_accepts_sbla_and_grants_priority_review_for_bavencio_avelumab_plus_inlyta_axitinib_for_the_treatment_of_advanced_renal_cell_carcinoma,2019-02-11,regulatory approval
Phase 3 ARCHES Trial Shows XTANDI® (enzalutamide) Significantly Improved Radiographic Progression-Free Survival in Men with Metastatic Hormone-Sensitive Prostate Cancer,https://www.pfizer.com/news/press-release/press-release-detail/phase_3_arches_trial_shows_xtandi_enzalutamide_significantly_improved_radiographic_progression_free_survival_in_men_with_metastatic_hormone_sensitive_prostate_cancer,2019-02-11,clinical trial update
The Union For International Cancer Control And Pfizer Announce New Phase Of Global Grants Initiative Supporting Metastatic Breast Cancer Patients,https://www.pfizer.com/news/press-release/press-release-detail/the_union_for_international_cancer_control_and_pfizer_announce_new_phase_of_global_grants_initiative_supporting_metastatic_breast_cancer_patients,2019-02-04,management update
Pfizer Receives Positive CHMP Opinion for Vizimpro® (dacomitinib) for the First-line Treatment of Adult Patients with Locally Advanced Or Metastatic Non-Small Cell Lung Cancer with EGFR-Activating Mutations,https://www.pfizer.com/news/press-release/press-release-detail/pfizer_receives_positive_chmp_opinion_for_vizimpro_dacomitinib_for_the_first_line_treatment_of_adult_patients_with_locally_advanced_or_metastatic_non_small_cell_lung_cancer_with_egfr_activating_mutations,2019-02-01,regulatory approval
PFIZER REPORTS FOURTH-QUARTER AND FULL-YEAR 2018 RESULTS,https://www.pfizer.com/news/press-release/press-release-detail/pfizer_reports_fourth_quarter_and_full_year_2018_results,2019-01-29,financial news
Pfizer and Lilly Announce Top-Line Results From Second Phase 3 Study of Tanezumab in Osteoarthritis Pain,https://www.pfizer.com/news/press-release/press-release-detail/pfizer_and_lilly_announce_top_line_results_from_second_phase_3_study_of_tanezumab_in_osteoarthritis_pain,2019-01-29,clinical trial update
US FDA Accepts Regulatory Submissions for Review of Tafamidis to Treat Transthyretin Amyloid Cardiomyopathy,https://www.pfizer.com/news/press-release/press-release-detail/us_fda_accepts_regulatory_submissions_for_review_of_tafamidis_to_treat_transthyretin_amyloid_cardiomyopathy,2019-01-14,regulatory approval
eFFECTOR Enters Into Agreement with Pfizer Inc. to Develop Novel First-inClass Inhibitors of eIF4E to Treat Multiple Cancer Types,https://www.pfizer.com/news/press-release/press-release-detail/effector-enters-agreement-pfizer-inc-develop-novel-first-,2019-01-09,management update
CytoReason Signs Collaboration Agreement with Pfizer Inc. To Utilize CytoReason’s Machine Learning Model  of the Immune System for Drug Discovery,https://www.pfizer.com/news/press-release/press-release-detail/cytoreason-signs-collaboration-agreement-pfizer-inc-utilize,2019-01-07,management update
"Pfizer Initiates Phase 2b/3 Clinical Trial for PF-06651600, an Oral JAK3 Inhibitor, for the Treatment of Patients with Moderate to Severe Alopecia Areata",https://www.pfizer.com/news/press-release/press-release-detail/pfizer_initiates_phase_2b_3_clinical_trial_for_pf_06651600_an_oral_jak3_inhibitor_for_the_treatment_of_patients_with_moderate_to_severe_alopecia_areata,2019-01-03,clinical trial update
